THE MOTHERHOOD CHOICE: DEVELOPMENT AND EVALUATION OF A DECISION AID FOR WOMEN WITH MULTIPLE SCLEROSIS by SPONIAR, MARTINE CLAIRE
THE MOTHERHOOD CHOICE:  
DEVELOPMENT AND EVALUATION OF A  
DECISION AID FOR WOMEN  
WITH MULTIPLE SCLEROSIS 
 
 
 
 
MARTINE CLAIRE SPONIAR 
B.Econ.(Soc.Sci.) 
Grad. Dip. Sci. (Psych.) 
 
 
 
 
A thesis submitted in fulfilment  
of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
School of Psychology 
Faculty of Science 
University of Sydney 
 
September 2007 
 
Acknowledgements 
I am indebted to Associate Professor Louise Sharpe for her supervision of this study 
and thesis. You have been instrumental in the development of my learning in clinical 
health psychology and research. Thank you for your unfailing enthusiasm and 
encouragement, advice, support and commitment in guiding me through my studies. 
Your wisdom and insight continue to inspire me. 
 
I wish to thank my associate supervisors, Professor Phyllis Butow and Dr Gary 
Fulcher for their constructive criticism, expertise and wise counsel. Thank you Phyllis 
for your experienced advice in carrying out qualitative research and Gary, for sharing 
your expertise in MS. 
 
A huge thank you to the women with MS who were participants in my study. Thank 
you for being so generous with your time and for trusting me with your thoughts and 
feelings. There will be many women in the future who will be grateful to you for the 
work we have done together. 
 
To my friends and colleagues in the Doctor of Clinical Psychology course – 
especially Sonia, Jane, Jess, Ainslie, Monica, Rebecca, Sam and Ileana. Thank you 
for your friendship and comic relief over the past four years. Your constant hilarity 
and your encouragement of me to pursue dysfunctional coping habits were much 
needed.  
 
 ii
I am grateful to my parents and the rest of my family for their unfailing interest in my 
work. Thank you especially to Mum and Dad for your enduring emotional (and 
financial) support, patience and encouragement.  
 
And finally to my Chris, for never doubting my ability and for helping me to the 
finish line. Thank you for your support and encouragement and your presence in my 
life. 
 
Martine Sponiar 
September, 2007 
 iii
Presentation of Thesis 
This thesis is presented as a series of published/submitted manuscripts. The first 
chapter contains a review of the literature, introducing the research rationale, aims and 
hypotheses. Chapters two, three, four and five contain the following manuscripts. The 
candidate is the principle author of each of these papers. 
 
• Chapter Two: Sponiar, M.C., Sharpe, L., Butow, P., Fulcher, G. (2007) 
Reproductive Choices of Women with Multiple Sclerosis. International 
Journal of MS Care, 9, 9-12.  
• Chapter Three: Prunty*, M.C., Sharpe, L., Butow, P., Fulcher, G. (in press) 
The Motherhood Choice: Themes Arising in the Decision-Making Process for 
Women with Multiple Sclerosis. Multiple Sclerosis. 
• Chapter Four: Prunty, M.C., Sharpe, L., Butow, P., Fulcher, G. (in press). The 
Motherhood Choice: A Decision Aid for Women with MS. Patient Education 
and Counseling.  
• Chapter Five: The Motherhood Decision Aid: Mechanisms of Treatment. 
(submitted to Patient Education and Counseling August 2007). 
 
The final chapter provides a summary and conclusions of the research findings, 
limitations and suggestions for the direction of future research. 
 
The study presented in this thesis represents research undertaken by the candidate in 
conjunction with other researchers in the Clinical Psychology Unit and the Medical 
Psychology Research Unit at the University of Sydney, and the Multiple Sclerosis 
                                                 
* Candidate’s married name 
 iv
Societies of New South Wales and Victoria. Ethics approval was granted by the 
University of Sydney as well as Multiple Sclerosis Australia. 
 
The candidate was involved in all aspects of the study, and was responsible for 
coordinating the study under the supervision of Associate Professor Louise Sharpe, 
and associate supervision of Professor Phyllis Butow and Dr Gary Fulcher. 
 
The contributions of the candidate include: 
Study design: The candidate was responsible for identifying the topic, recruiting the 
study sample beginning with the large-scale mail-out to 1410 female members of the 
MS Society in New South Wales and Victoria, Australia. The candidate designed the 
initial preliminary decision aid and ran the focus groups in the qualitative study. The 
candidate selected the questionnaire measures and compiled the demographic 
questions and the knowledge questionnaire. 
 
Data collection, entry and analyses: The candidate was responsible for all aspects of 
data collection, entry and analyses. The candidate formulated the hypotheses. All data 
presented in this thesis was analysed by the candidate under the guidance of Associate 
Professor Louise Sharpe. 
 
Manuscripts: The candidate was the principle author and wrote all first drafts of the 
manuscripts presented in this thesis, responsible for the conceptualisation and the 
interpretation of the data, under the supervision of Associate Professor Louise Sharpe 
and Professor Phyllis Butow. 
 v
Abstract 
Multiple sclerosis (MS) is the most common neurological disease affecting young 
adults. MS affects approximately 1 in 1000 people and, like other autoimmune 
diseases, women are more likely to be affected than men. The illness typically onsets 
between the ages of 20 and 40, and hence usually affects women of child-bearing age. 
The course of the MS is often unclear for years after diagnosis and since most women 
are diagnosed in their child-bearing years, they often have to make reproductive 
choices before their prognosis is clear and while the future remains uncertain. 
 
For women with MS, starting a family is an individual choice that needs to balance 
the importance of motherhood for the woman and her partner against the risks that she 
will be unable to care for the infant or child as a result of increasing disability. In 
other areas of medicine where finely balanced decisions are required, there has been a 
recent proliferation of decision aids that aim to inform people of the benefits and risks 
of opposing courses of action. In addition, decision aids help patients to weigh their 
values against the risks and benefits to make an informed decision. Despite the 
existence of over 200 decision aids to help patients consider decisions related to their 
medical conditions, not one exists that deals with the decision of whether or not to 
have a family for women with a chronic disability, such as MS. 
 
This thesis developed and evaluated a decision aid for women with MS to help them 
decide whether to start, forego or enlarge their families. The study utilised the criteria 
set out for the development of decision aids, according to the Cochrane Systematic 
Review of Patient Decision Aids (O'Connor et al., 2003). The first aim was to 
determine the proportion of women who are undecided about the motherhood choice 
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and for whom a decision aid may be relevant. Results found that the motherhood 
choice was relevant to 46% of the women who responded to an initial mail-out. 
 
The second study aimed to establish women’s current concerns and thoughts 
regarding pregnancy and motherhood, and their response to the pilot decision aid. 
Twenty women participated in qualitative interviews and results supported previous 
findings that the mother’s health concerns, coping with parenting and societal 
attitudes are significant concerns when considering this decision. This study further 
identified concerns from different groups that had a direct impact on the decision to 
have children, including the experience of parenting, the child’s well-being and the 
timing and pressure of the decision. 
 
The main study was a randomised controlled trial of the decision aid aiming to 
determine whether the decision aid facilitated decision-making in women with MS. 
The study confirmed that the decision aid presented a balanced view to women, 
increased knowledge, reduced decisional conflict, increased decisional self-efficacy 
and certainty of the decision, and was free from adverse effects on psychopathology.  
 
The final component of the study was a 12 month follow-up which aimed to explore 
the long-term effectiveness of the decision aid and what aspects were valued by the 
women who received it. It was found that over time, women in the intervention group 
did maintain their certainty, but women in the control group also became more certain 
of their choice. At follow-up, the difference in certainty was no longer significant 
between the two groups. However, women did report that the intervention was useful 
in (a) providing access to information previously unavailable or difficult to obtain, (b) 
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facilitating communication between women, their partners and health care 
professionals, (c) aiding them in considering and utilising their networks of support, 
and (d) preparing them for potential difficulties. 
 
In summary, this thesis developed and evaluated a decision aid for women with MS 
who are considering motherhood. The results showed that many women were 
undecided and, in the absence of good information on the topic, many women had 
concerns about pregnancy and parenthood. The decision aid was shown to be 
effective across a range of measures and free from adverse psychological effects. 
Hence, this is evidence-based resource can now be recommended for those women 
with MS who are currently contemplating motherhood. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction and Overview 
Multiple Sclerosis (MS) is a chronic neurological disorder of the central nervous system 
affecting approximately 1 in 1000 people. It is more common among women and its 
onset is typically in the childbearing years of the 20s and 30s (Birk & Kalb, 1992, Cook, 
Troiano, Bansil & Dowling, 1994). Despite advances in the medical treatment of MS, it 
remains a serious illness that is associated with progressive disability for most individuals 
with MS. Due to the progressive and unpredictable nature of MS, coupled with the time 
of onset being one associated with family planning, women with MS are often faced with 
decisional conflict regarding the motherhood decision (Smeltzer, 2002). The already 
physically and emotionally demanding time of pregnancy and childbearing may be 
exacerbated by a potentially disabling illness. However, it has been shown that generally 
the course of MS remains unaffected by pregnancy in the long term and there are no 
higher rates of birth defects or miscarriage (Watkiss & Ward, 2002), although the first 3 
to 6 months postpartum are often a time associated with increased relapse rates (Cook, 
Troiano, Bansil, & Dowling, 1994) as well as being a physically and emotionally 
stressful period. Therefore, the presence of MS means there are additional factors to 
consider in the decision-making process. Only when women are aware and informed of 
the various issues involved can an informed decision be made. 
 
Motherhood is a valued social role for the majority of women. The motherhood decision 
can be defined as the choice to forego, start or enlarge a family (Smeltzer, 2002). For 
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women with MS, there are a number of issues that need to be considered as part of the 
motherhood decision. Four specific factors about which women need to be informed to 
make informed choices have been identified (McNary, 1999), as follows: (a) the neuro-
physical features of MS; (b) the psychological consequences of MS; (c) the culture of 
each individual woman and her family; and (d) the historical context in which women 
with disabilities contemplate motherhood. These themes have been found to influence 
women in their reproductive choices and to determine the ease with which women and 
their partners are able to make this decision. 
 
Although in recent years, there has been an increase in the amount of research on the 
physical consequences of pregnancy and childbirth on the health of women with MS and 
their infants, there is a paucity of research on how women reach their decision. What 
literature is available suggests that women with MS more often choose voluntary 
termination of pregnancy (Mueller, 2002) and are over-represented amongst childless 
women (Damek & Shuster, 1997). Research also suggests that women with MS continue 
to experience negative reactions towards their decision to have a child from society and 
health care professionals and have difficulty accessing good information to allow 
informed decision-making (Grue & Laerum, 2002; Thomas, 1997).  
 
This thesis aims to bridge the gaps in the literature by (a) examining the number of 
women experiencing uncertainty regarding the motherhood choice; (b) understanding the 
reasons why different women choose to have families or to forego them, and (c) 
 2
developing and evaluating a decision aid to provide women with MS with help in making 
informed choices regarding motherhood. 
 
1.2 Physical Characteristics of Multiple Sclerosis 
Symptoms of MS are caused by demyelination in the central nervous system (CNS) and 
include muscle weakness, lack of coordination and balance, numbness and tingling, 
visual disturbance, tremors, spasticity and dysfunction of voiding and bladder. These 
symptoms frequently lead to decreases in quality of life, disturbances in psychological 
functioning and changes in social role functioning (Hart, Fonareva, Merluzzi & Mohr, 
2005). Therefore, MS is associated with functional limitations in self-care and 
independent living. Because MS is characterised by progressive disability which is 
unpredictable, it is difficult to envisage the course and prognosis of the illness medically 
and physically for each individual. As a result it is difficult to feel in control of daily 
living and planning for the future, subsequently compromising the family planning 
process as it is difficult to consider the possibility of significant disability or ongoing 
fatigue problems in the years to come (Birk & Kalb, 1992). 
 
There are a number of courses of MS that have been identified and the course varies 
considerably, with some patients experiencing a progressive course from the outset, and 
others following a more benign course. At present, there are five identified courses of 
MS: 
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1.2(a) Relapse-Remitting MS  
This is the most common course of MS and it is characterised by periods of 
relapse from which the person partially or completely recovers, and illness which 
may be inactive for long periods of time. Approximately 80% of people 
diagnosed with MS begin their course with this pattern of symptoms. Of those 
initially diagnosed with relapse-remitting MS, for 50% the disease course changes 
to secondary-progressive MS within ten years and for 90% of patients within 25 
years (Ferrero, Pretta, & Ragni, 2004). 
 
1.2(b) Secondary-Progressive MS 
As described above, the majority of people with relapse-remitting MS will 
eventually develop secondary-progressive MS. People with secondary-
progressive MS commonly experience an initial period of the relapse-remitting 
course, followed by steady progression of the disease with occasional relapses 
(Lechtenberg, 1995). Patients may experience less recovery from attacks, a 
decline in functioning both during and between attacks and/or fewer attacks with 
progressive disability.  
 
1.2(c) Progressive-Relapsing MS 
In contrast to those with relapse-remitting MS, those with this course of MS 
typically experience continuing disease progression between periods of clear 
acute relapse with or without full recovery. This is the least common course of 
MS with only 5% of people fitting this pattern of the illness at diagnosis. 
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1.2(d) Primary-Progressive MS 
Primary-Progressive MS also has a slow onset, but a continual progression of 
disability either without remissions, or with minor improvements that are only 
temporary. Acute attacks are not generally experienced, rather occasional plateaus 
in disease activity. Ten percent of people with MS begin with this course, 
however diagnosis is usually made after a period of time where progressive 
disability has been ongoing without remission.  
 
1.2(e) Benign MS 
A frequent definition used to define benign MS is where there is “minimal or no 
disability, equivalent to a score on the Expanded Disability Status Scale (EDSS) 
equal to or less than 3.0 (fully ambulatory), at least 10 years after disease onset” 
(Glad, Nyland & Myhr, 2006, p. 55). Prevalence studies have varied in their 
results, with the frequency of benign MS ranging from between 10 and 40%, 
depending on the follow-up time. After 10 years, 40% of people with MS have a 
benign course, however this drops to 20% after 20 years, suggesting that even 
benign MS may be a transient phase (Glad, Nyland, & Myhr, 2006; Hawkins & 
McDonnell, 1999; Weinshenker, Bass, & Rice, 1989). 
 
Half of those diagnosed with MS will need a walking stick for mobility within 15 years 
of diagnosis (Weinshenker, Hader, Carriere, Baskerville, & Ebers, 1989). However, the 
course of the MS is often unclear for years after diagnosis. For example, it can be ten 
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years after diagnosis before a patient can be said with certainty to have a benign course of 
the illness.  
 
Disease progression is typically assessed radiographically via Magnetic Resonance 
Imaging (MRI) highlighting any new lesions, examining changes neurologically and 
electrophysiologically and by assessment of physical and cognitive functioning. It is 
difficult to determine prognosis on an individual basis, but the National MS Society 
Information Sourcebook (2005) states that those who do better tend to have fewer initial 
attacks in the years after diagnosis, longer periods between attacks and complete recovery 
from attacks. Furthermore, attacks of the sensory type, for example being marked by 
symptoms such as numbness or tingling, are associated with better long-term prognosis. 
On the other hand, early tremor, being unco-ordinated and having trouble walking are 
signs that the disease may be more progressive in nature. Progression is also marked by 
more frequent attacks without complete recovery and a higher number of lesions detected 
on MRI. 
 
1.3 Neuropsychological Characteristics of Multiple Sclerosis 
In addition to the physical complications of MS, the disease is often associated with 
neuropsychological deficits. Studies investigating the specific neuropsychological 
profiles among the subtypes of MS have found some significant differences between the 
various courses of the illness. One study investigating the differences in cognitive 
impairment of relapsing remitting, secondary and primary progressive MS (Huijbregts, 
Kalkers, de Sonneville et al., 2004) found that all MS groups had detectable cognitive 
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deficits, but different cognitive profiles. The most severe deficits existed on all tasks in 
those with secondary progressive MS, and significantly more deficient in tasks requiring 
higher-order working memory, except where speed of information processing played an 
important role. Primary progressive patients were the next most impaired, also 
performing poorer than controls on all tasks, and than those with relapse remitting MS 
who only differed from controls on three out of five tasks. People with relapse remitting 
MS were impaired on higher-order working memory tasks and showed relatively poor 
verbal fluency (Huijbregts, Kalkers, Sonneville et al., 2004).   
 
In a sample of 108 patients with relapse-remitting MS, 71 patients with secondary-
progressive MS, 55 patients with primary-progressive MS and 67 healthy controls who 
underwent neuropsychological assessment, they found that deficits were most severe in 
secondary-progressive MS patients, followed by primary-progressive MS and then 
relapse-remitting MS patients. They also found evidence that there is a heterogeneity in 
the picture of cognitive impairment amongst the different courses of MS. Relapse-
remitting MS patients were found to perform significantly better than primary-
progressive MS and secondary-progressive MS patients on tests requiring specific 
working memory operation which also required central processing speed. It is thought 
that the more widespread white matter disease evident in the progressive types of MS 
results in deficient processing speed. On tasks requiring working memory ability with 
less emphasis on processing speed, primary-progressive MS patients performed better 
than those with secondary-progressive MS and relapse-remitting MS, explained by the 
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spatial working memory deficits in secondary-progressive MS and relapse-remitting MS 
(Gaudino, Chiaravalloti, DeLuca, & Diamond, 2001). 
One of the most common complaints among patients with MS is a decline in memory, 
however some aspects of memory are affected more than others. Patients’ ability to 
register and store information has been reported to be intact in MS patients that are not 
experiencing an exacerbation or chronic progressive deterioration, while their ability to 
recall information is significantly reduced (Beatty & Scott, 1993). This significantly 
impaired recall contrasts with normal performance in recognition, suggesting that the 
deficiency lies in the retrieval of information they have learned, rather than the initial 
acquisition of information. This hypothesis is supported by a study investigating the 
acquisition and storage deficits in MS, which reported that patients require more trials to 
learn verbal information, although once acquired, they are able to recall and recognize the 
information to the same extent as healthy controls (De Luca, Gausdino, Diamond, 
Christodoulou & Engel, 1998). The same study found a slightly different pattern with 
visual information whereby MS patients also required more trials to learn visual 
information yet also performed significantly worse than controls at both recall and 
recognition, thus suggesting deficiencies in both acquisition and storage of visual 
information. 
 
Information processing speed is another domain which has been found to be impaired 
among patients with MS. It is an impairment that manifests globally within 
neuropsychological functioning as opposed to being associated with a few tasks or 
specific conditions, and has been likened to the general cognitive slowing that 
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accompanies the ageing process. Moreover, information processing speed has been found 
to influence other cognitive domains such as abstract reasoning and working memory 
(Kail, 1998). Specifically, MS patients have been noted to have a slower response speed 
and tend to process visual information at a reduced rate when compared to healthy 
controls particularly in more complex task conditions (De Sonneville et al., 2002).   
 
Studies measuring attentional ability amongst people with MS have also found deficits in 
various attentional domains. Significantly reduced performance has been found on 
measures of focused, divided and sustained attention, with the performance of patients 
with primary-progressive MS being significantly lower than those with secondary-
progressive MS (Bobholz & Rao, 2003). This manifests in MS patients being more 
susceptible to distraction and irrelevant targets and exhibiting a slowed response speed on 
tasks of attentional flexibility (De Sonneville et al., 2002).  
 
MS is associated with axonal loss in addition to the inflammation and demyelination of 
the CNS. This demyelination and axonal degeneration causes interruption between neural 
connections (Piras, et al., 2003). While some research suggests that cognitive deficits 
become worse as a function of disease duration (Schiffer & Caine, 1991), axonal loss can 
occur early on in the disease and can therefore explain the instance of cognitive 
impairment during these initial stages. It has been demonstrated that despite few physical 
symptoms, decline in cognitive functioning can occur early in the course of the illness 
with impaired performance on tests of executive functioning and working memory 
(Barak, Lavie, & Achiron, 2002). 
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 Fatigue has been acknowledged as a detrimental factor in neuropsychological test 
performance and is also one of the common disabling complaints among patients with 
MS. Studies on the effects of fatigue on cognitive functioning have produced mixed 
results. Early studies reported that fatigue has a negative impact on cognitive functioning 
(Lezak, 1995). However more recent studies differing in experimental design reported 
that fatigued patients with MS have not been found to have impaired performance in 
comparison to healthy controls (Johnson, Lange, De Luca, Korn, & Natelson, 1997). 
Another study concluded that there were no differences in test performance when patients 
were tested during periods of high versus low fatigue (Parmenter, Denney, & Lynch, 
2003), however it has also been purported that MS-related fatigue may have a systematic 
effect on performance, manifesting itself in later tasks (De Sonneville et al., 2002). 
Subjective feelings of fatigue have been found to be a poor indicator of actual cognitive 
ability, with performance either remaining stable from baseline to retest or improving, 
thus illustrating a normal practice effect (Beatty et al., 2003). This study also reported 
that MS patients show greater increase in subjective fatigue over the course of a normal 
day, yet do not exhibit greater cognitive fatigue. However it should also be noted that a 
third of the patients in this study were taking anti-fatigue medications, which can 
alleviate fatigue or improve mood so it is difficult to ascertain how this influenced their 
performance (Beatty et al., 2003).  
 
It has also been suggested that prominent symptoms of depression, for example feelings 
of inferiority and failure, contribute to deficits in information processing speed and 
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executive function linked to working memory, and that negative automatic thoughts 
reduce the individual’s attention and working memory ability (Feinstein, 1999). Although 
there is some disagreement in the literature regarding the exact nature and cause of 
cognitive impairment in MS, studies consistently show that 40-60% of people with MS 
experience clinically significant cognitive impairments (Huijbregts, Kalkers, De 
Sonneville et al., 2004). These are more pronounced amongst those with primary-
progressive MS and tend to become more severe over time. High levels of cognitive 
impairment in patients with MS is likely to result in an inability to maintain employment, 
fewer social support networks and a greater need for support with activities of daily 
living (Mohr & Cox, 2001) and thus the presence of cognitive impairment in MS adds to 
the hardship experienced by these patients. 
 
1.4 Psychological Consequences of Multiple Sclerosis 
Not only is MS associated with physical and neuropsychological consequences, but MS 
has also been associated with a number of symptoms of psychological distress, 
disturbances in personality and increased prevalence of psychiatric disorders (Feinstein, 
1999). The unpredictability of MS is one of the most psychologically challenging aspects 
of MS and patients with the illness commonly experience both anxiety and depression. 
Given the fact that each patient’s outcome remains largely unclear with the threat of 
increased disability, it seems understandable that people with MS experience depression. 
Indeed depression is the most common psychiatric illness amongst people with MS 
(Gorman & Finkel, 2005).  
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Interestingly however, the lesions found in patients with MS occur in a number of brain 
regions associated with depression (Gorman & Finkel, 2005). As a result, there is a 
controversy in the literature concerning whether these disorders are by-products of the 
illness, reactions to medications used to manage the physical symptoms, or psychological 
reactions to the experience of the disease (Minden, 2000). It is possible that MS plaques 
interrupt the neural pathways involved in the regulation of mood. Disruption in white 
matter affecting axonal-neuronal conduction may be linked to a presentation resembling 
vascular depression (Gorman & Finkel, 2005). In a study assessing 95 patients with MS, 
18 met the criteria for major depression and it was found, when comparing the regional 
brain volumes and lesion loads of the depressed and non-depressed, that major depression 
was correlated with right frontal lesion load and right temporal brain volume and that 
severity of symptoms correlated with total temporal volume and right hemisphere volume 
(Zorzon et al, 2001). Of course, this does not exclude the possibility that these people 
with MS had more cognitive impairment and that cognitive impairment is the cause of the 
depression. In a more recent study using MRI to compare 21 depressed MS patients with 
19 non-depressed MS patients, it was found that there were more hyperintense lesions in 
the left inferior medial frontal regions and greater atrophy of left anterior temporal 
regions in the depressed MS patients and that these two regions accounted for 42% of the 
variance in depression (Feinstein, Roy, & Lobaugh, 2004) 
 
On the other hand it is clear that psychosocial factors also contribute to depression. 
Patients often report that their depression is due to the unpredictability of the illness 
(Beatty, 1993). Specifically, that patients’ loss of function is unpredictable and often 
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implacable. Patients with MS who are depressed, typically present as angry, irritable, 
worried and with a sense of hopelessness about the future (Beatty, 1993). In fact, the 
lifetime prevalence of major depressive disorder following a diagnosis of MS is 
approximately 50% and the lifetime rate of suicidal intent in patients with MS is 
considerably higher than that for the general population (Feinstein, 2002). Of concern is 
that despite the common occurrence of suicidal ideation amongst patients with MS, 
depression often goes undetected and untreated (Feinstein, 1999).  
 
Research has suggested that psychosocial factors play a significant role in whether a 
person will develop depression, with coping style and social support receiving the most 
attention (Siegert & Abernethy, 2005). Studies on coping with MS have suggested that 
optimism as well as problem-focused and cognitive coping strategies predict better 
adjustment to the illness (Aikens, Fischer, Namey & Rudick, 1997; de Ridder, Schreurs 
& Bensing, 2000; Pakenham, 1999). These may include positive reframing, finding ways 
of compensating for the disability or maintaining health and goal setting. On the other 
hand, emotion focused coping or avoidance and escape have been associated with higher 
symptom levels (Siegert & Abernethy, 2005). 
 
What has also been found to influence adjustment to MS is the perception the patient has 
of the illness, or their illness representation. Illness representations influence patients’ 
affective psychological adjustment as well as fatigue levels and it has been suggested that 
addressing aspects of illness beliefs may strengthen patients’ ability to adjust to an MS 
diagnosis (Jopson & Moss-Morris, 2003). Further, patients’ individual perceptions of 
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their illness and its variability, as well as how they make sense of the illness’s influence 
on day-to-day tasks have been related to depression and adjustment (Weineman, 1990). 
These findings indicate that psychological factors play at least some role in depression in 
MS and physical explanations alone are unlikely to be sufficient to explain depression in 
MS patients. 
 
In a study exploring the prevalence of psychiatric disorders and measures of 
psychopathology in relapse-remitting MS outpatients, 50 outpatients with relapse-
remitting MS and 50 healthy controls matched for sex, age and educational level, were 
assessed. MS patients reported a higher prevalence of psychiatric disorders as well as 
higher rates of non-mood psychiatric disorders. In a study of 50 MS patients and 50 
healthy controls, it was found that the risk factors for depression amongst people with 
MS were female gender and severity of disability and there were higher rates of 
depressive psychopathology in the MS patients even when they were in the remitting 
phase of their illness (Galeazzi et al., 2005). A correlation was also confirmed between 
disability status and self-perceived depressive symptoms and it has been suggested that 
this supports the view that depression is a psychological reaction to the neurological 
illness (Zorzon et al., 2001). This finding supports a previous study which found that the 
greater the disability, the greater the feelings of uselessness, worthlessness and burden, 
which is a common subjective experience of patients with MS (Mohr et al., 1999). 
 
Depression is highly correlated with anxiety so it has been suggested that there is likely 
to be a high prevalence of anxiety disorders amongst people with MS (Siegert & 
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Abernethy, 2005). There is evidence in the literature to support this notion, however the 
number of studies utilising meticulous methodology is limited in comparison to the 
studies on the prevalence of depression. In one study aiming to determine the prevalence 
of anxiety and depression in 88 patients with MS, it was found that 34% met the criteria 
for probable caseness for anxiety on the Hospital Anxiety and Depression Scale (HADS) 
(Smith & Young, 2000). However it has been suggested that as the sample were patients 
attending an MS clinic it is possible that they would be experiencing higher rates of 
anxiety than would be found in a community based sample of people with MS (Siegert & 
Abernethy, 2005). Further, whether these people with MS had an anxiety disorder is 
unclear. 
 
Other emotional disturbances occasionally found amongst people with MS include 
euphoria, pathological laughing and weeping as well as mania and there has been debate 
over whether these symptoms are a result of brain damage directly or a psychological 
reaction to diagnosis, highlighting the need to distinguish the impact of depression from 
that of the neurological disease itself (Beatty & Scott, 1993). A study aiming to establish 
the prevalence of pathological laughing and crying in MS  and to define the associated 
neurological, emotional and cognitive correlates screened a sample of 152 patients with 
MS for pathological laughing and crying (Feinstein, Feinstein, Gray & O'Connor 1997). 
Pathological laughing and crying was defined by sudden, involuntary displays of 
laughing or crying or both, without associated subjective feelings of depression or 
euphoria. It was found that the prevalence of pathological laughing and crying in MS was 
10% and was not associated with exacerbations of the illness but was associated with 
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more advanced disease. Patients did not differ from controls in levels of depression or 
anxiety but had a significantly lower IQ.  
 
It has also been found that a diagnosis of MS can trigger symptoms of posttraumatic 
stress disorder as a consequence of sudden concerns about the progression of the disease 
and the future of the individual (Chalfant, Bryant & Fulcher, 2004). Recent studies 
support a relationship between stress and disease exacerbation, showing that stress 
increases the likelihood that an individual will experience an exacerbation of their 
symptoms (Ackerman et al., 2002; Sibley, 1997). Sibley (1997) found that stress in 
relation to work and marriage was more likely to be followed by a relapse as opposed to 
negative life events. Ultimately, it should be acknowledged that the experience of an 
exacerbation in MS symptoms provides an additional source of stress for the patient. 
 
1.5 Quality of Life and Health-Related Quality of Life 
It is not surprising given that patients have to cope with the physical, neuropsychological 
and psychological consequences of MS, that MS in its entirety affects quality of life. A 
few studies to this affect then relate to role functioning and the potential for loss of 
important roles which increase the risk of poor quality of life. Quality of life, a term 
relating to an individual’s perception of their general well-being and role fulfillment in 
both physical and psychosocial areas of their lives, has been reported to be negatively 
influenced by the presence of MS (Forbes, While, Mathes & Griffiths, 2006). Further, 
quality of life has been found to be significantly poorer in people diagnosed with MS 
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compared to those diagnosed with other chronic illnesses, such as rheumatoid arthritis, 
diabetes and epilepsy (Hermann et al., 1996).  
 
An MS diagnosis represents a significant adjustment in patients’ lives. When a member 
of a family becomes chronically ill, previously formed ideas about the role of that family 
member, what their future will look like and how they will be able to participate within 
the family are questioned. The psychological consequences (outlined above) that result 
from these considerations, coupled with the uncertainty of the illness and its associated 
physical degeneration, then impacts on their quality of life (Chalfant et al., 2004). In a 
study assessing physical and psychological health, social relationships as well as home 
and community environments, it was found that a lower quality of life is reported 
amongst people with MS than the general population (McCabe & McKern, 2005).  
 
Health-related quality of life is more focused on the effects of disease and treatment on 
physical and psychological functioning as well as overall outlook on life. Assessment of 
health-related quality of life usually includes assessing patients’ mobility, fatigue, pain, 
cognitive function, general health and the impact of these symptoms on their functioning 
(Hart, Fonareva, Merluzzi & Mohr, 2005). Problems associated with MS, such as fatigue, 
pain, employment problems, depression and relationship problems were found to have a 
negative effect on health-related quality of life in a study aiming to explore the 
interrelationship between a number of common MS problems and health-related quality 
of life independent of the effect of physical disease impact (Forbes et al., 2006). Further, 
 17
health-related quality of life was most compromised in patients experiencing multiple 
problems. 
 
1.6 Benefit-Finding 
There is evidence that people with MS tend to search for meaning and that benefit-
finding helps strengthen role function and is therefore associated with better quality of 
life. Finding some positive meaning in illness and other adverse life events has been 
found to enhance coping ability and lessen the risk of depression (Katz, Flasher, 
Cacciapaglia & Nelson, 2005). This process of finding benefit from adversity has been 
termed benefit-finding, whereby existing beliefs are redefined as a form of cognitive 
adaptation to lessen the impact of the situation Using these new found meanings as 
coping mechanisms is known as benefit-reminding (Van Der Wende, 2000). These terms 
were originally developed to apply to response to trauma and have recently been 
broadened to include chronic illness. Benefit-finding has been found to be a psychosocial 
effect of MS as patients tend to experience a deepening of relationships, enhanced 
appreciation of life and an increase in spiritual interests (Mohr et al., 1999). Patients with 
MS have described finding meaning through a deepening of faith and relationships with 
family (Forbes et al., 2006). 
 
Finding meaning in the face of threatening events is suggested to be protective of mental 
health and may also be protective of physical health (Taylor, Kemeny, Reed, Bower & 
Grunewald, 2000). Similarly, benefit finding in the face of illness has been linked to both 
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psychological and physical health, and it appears as a central concept in cognitive models 
of adaptation to threatening circumstances (Katz et al., 2001; Sharpe & Curran, 2006).  
 
1.7 Impact of MS on life planning and child-bearing decisions 
A diagnosis of MS undermines much of the planning that would normally be occurring in 
this stage of a woman’s life (Confavreux, et al, 1998). Since most women are diagnosed 
between 20 and 40, in their child-bearing years, women often have to make reproductive 
choices before their prognosis is clear and while the future remains uncertain. Further, 
since 50% of patients are likely to have serious mobility problems within ten years of 
diagnosis, waiting for clarity in prognosis may mean that increased disability makes 
parenthood more difficult than it might previously have been. This necessitates most 
women with MS making a decision about motherhood during a period of considerable 
uncertainty. 
 
In addition to the uncertainty, the fact that MS onset is in early adulthood, that is after 
maturation, results in additional challenges for the individual as their already developed 
sense of identity may be questioned or doubted (Cole & Cole, 1993). All of these issues 
mean that individuals diagnosed with MS face many psychological barriers as they are 
faced with potential changes in self-image as well as role changes as a spouse and sexual 
partner, parent, and income provider. This can have effects on patients’ quality of life. 
 
Intuitively, it would seem that health-related quality of life indicators, such as diagnosis, 
severity of illness and disability, would impact views on motherhood. For example, 
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women may fear that they will not be able to adequately care for a child during times of a 
disease exacerbation. Further, if people with MS perceive themselves as having poorer 
quality of life, many women may be making decisions about motherhood based on a 
negative view of what their future will look like.  
 
It has however, been reported that the experience of parenthood can lead to an 
improvement in overall quality of life for infertile women (Abbey, Andrews & Halman, 
1994). Relatively little is known about the impacts of voluntary childlessness on the 
quality of life of women with MS. However the instance of childlessness remains higher 
amongst women with MS than the general population (Damek & Shuster, 1997). It is 
possible that voluntary childlessness may be one predictor of lower quality of life. That 
is, women with MS may be deciding to remain childless due to perceived risks or 
negative societal attitudes. If this is the case, then it is possible that women are negatively 
impacted by their choices. Providing this group of women with information as well as 
enhancing their ability to think through their underlying value system may aid them in 
making an informed decision and hence improving their quality of life. The information 
and support provided by health professionals is critical.  It has been stated that the 
relationship between the patient and health care professional is a critical factor that can 
influence attitudes towards motherhood, decisions about contraception, and whether to 
keep or terminate an unplanned pregnancy (Becker & Krumm, 2006). 
 
In summary, a diagnosis of MS marks a significant event in any person’s life with 
marked changes in physical ability. Considerable deficiencies in cognitive function can 
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also occur and patients report a lower quality of life as a consequence of these changes. 
Many patients also suffer from depression and other psychological disorders are 
commonly experienced. Since MS occurs more frequently amongst women, during the 
child-bearing years of their 20s and 30s, intuitively, this poses challenges for women with 
MS with regard to motherhood decision-making. 
 
1.8 Parental Disability 
While there is a relatively small body of literature on MS and pregnancy decision-
making, there is a larger literature on the effect of general disability and motherhood. Past 
research into the reproductive experiences of disabled women has revealed that ‘risk’ is a 
common theme that emerges when making the decision to become a parent (Thomas, 
1997). Generally, common concerns refer to the health of the baby as well as the 
mother’s own health, the fear of passing on the illness or any possible risk due to drug 
treatments. What may result are feelings of guilt and anxiety should the child inherit their 
illness and the interpretation of this as irresponsible and unjust. 
 
It has also been found that disabled women tend to perceive others as judging them to be 
inadequate mothers (Thomas, 1997). As a consequence, many women feel the need to 
demonstrate their competency to the outside world, further adding to feelings of 
insecurity as well as emotional and physical distress. This tends to result from the 
generalist view of disabled individuals as receivers of care as opposed to being capable of 
caring for another (Grue & Laerum, 2002). However, parenting impact is not purely 
influenced by the presence of a chronic illness or disability. Other variables include 
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components of family status, such as single parents and social support, the child status 
itself, which includes variables of age, gender and temperament, and finally, family 
process aspects, including parenting style and communication (Kelley, Sikka & 
Venkatesan, 1997).  
 
While the physical symptoms of MS may affect mothers’ agility and limit the extent of 
physical interaction between a mother and her child, MS has been found not to have a 
significant negative impact on the interaction between mothers and daughters (Crist, 
1993). This highlights the probability that being reared by a parent with a chronic illness, 
with its associated physical disabilities, will not have a harmful effect on the child. 
Furthermore, a substantial body of literature defending the rights of disabled women to 
bear children emphasises love and instilling a strong sense of self-worth in one’s child as 
the basis for being a good mother (Cole & Cole, 1993; Killoran, 1993; Kocher, 1993) and 
argues that the disabled person has grown accustomed to changing the way they carry out 
their daily activities and parenting is no different. Contrary to what evidence has shown, 
women with MS have on occasion been discouraged by health professionals from having 
families and from nursing their babies for fear of further deterioration of their condition 
after childbirth (Poser & Poser, 1983). 
 
1.9 Multiple Sclerosis and Pregnancy 
Historically, in the absence of scientific evidence, women with MS were discouraged 
from becoming pregnant. Prior to 1950, the general consensus was that pregnancy 
accelerated the course of MS and when pregnancy did occur, a termination was often 
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recommended by medical professionals (Cook et al, 1994). The issue of whether 
pregnancy affects the course of MS has been the subject of much research (Cook et al, 
1994; Damek & Shuster, 1997; Hutchinson, 1999; Lorenzi & Ford, 2002; Poser & Poser, 
1983; Watkiss & Ward, 2002) and there is now consensus in the literature, based on 
recent prospective studies, that pregnancy in women with MS neither exacerbates their 
illness nor is a risk to the child (Confravreux, Hutchinson, Hours, Cortinovis-Tourniaire, 
& Moreau, 1998; Confavreux & Vukusic, 2002; Ferrero et al., 2004; Lorenzi & Ford, 
2002; Meuller, 2002; Watkiss & Ward, 2002). The reality is that due to the 
unpredictability of the illness, in the long term the condition may get worse whether or 
not pregnancy occurs.  
 
During pregnancy, the risk of relapse is reduced, but following pregnancy, women are 
more at risk of relapse in the three to six months following their child’s birth (Confavreux 
& Vukusic, 2002; Cook et al., 1994). This is problematic since the first six months post-
natally are stressful for any new mother. The increased risk of a relapse further increases 
stress for the mother and her partner. After this time the relapse rate tends to return back 
to the pre-pregnancy baseline level (Ferrero et al., 2004). MS symptoms that commonly 
worsen during pregnancy, despite the reported reduction in exacerbations, include 
fatigue, bladder and bowel dysfunction, spasticity and difficulty with mobility (Giesser, 
2002) and this may make pregnancy an additional burden for patient who are affected. 
 
Studies have not supported a likely prognosis of long-term disability in MS as a result of 
pregnancy. No significant association has been found between level of disability and 
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number or timing of pregnancies, MS onset and deteriorating MS condition 
(Weinshenker, Hader et al., 1989) and women who become pregnant following an MS 
diagnosis seem to have a reduced risk of developing the chronic progressive course of the 
illness from a previous relapse-remitting course (Runmarker & Anderson, 1995). What 
must be noted, however, is the possibility that women with the severe chronic progressive 
form of MS may avoid pregnancy, or may be unable to become pregnant, so this could 
produce biased results. 
 
A clearer idea of the severity of an individual’s MS and the ensuing disability becomes 
more apparent approximately five years after an MS diagnosis and as a consequence 
women are often advised to delay pregnancy for five years in order to gain a better idea 
of the likely degree of disability support necessary for parenting (Smeltzer & Kelley, 
1997). It is probable however that this request may add further stress to the decision-
making process whereby a possibility of developing the severe chronic, progressive form 
of the illness may mean avoiding pregnancy altogether.  
 
Studies on the effects of maternal MS on infant health and development report that there 
are no adverse consequences for the baby. In one study 37 women with MS, 15 pregnant 
and 22 childless women, were followed up for 3 years (Worthington, Jones, Crawford & 
Forti, 1994). Those in the pregnant group experienced a higher frequency and severity of 
relapses in the first 6 months post partum but were below the rates expected 6-24 months 
post partum. Of note is that babies born were in the normal range with regard to weight 
and head circumference (Worthington et al., 1994).  
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 In a large study investigating the effect of maternal MS on delivery and birth outcome in 
vaginal births, 851 509 intended vaginal births registered in the Medical Birth Registry of 
Norway from 1988 until 2002 were studied (Dahl, Myhr, Daltveit, & Gilhus, 2006). Of 
these, 449 births had noted a diagnosis of MS in the mother leaving 851 060 births as the 
control group. Fifty five MS births and 45 935 control births were excluded because of 
planned Caesarean section. Results showed no difference between the groups for 
complications leading to emergency Caesarean section.  However trends which 
approached significance were evident. Women with MS tended to more often have 
induction of labour, a slower progression to second stage of labour and increased use of 
forceps all approached significance, with these features more apparent in the MS group. 
In comparison to control babies, babies of women with MS had a lower mean birth 
weight and length. However, the frequency of serious complications, such as stillbirths, 
the perinatal mortality rate and the rate of birth defects were not significantly different 
between the groups (Dahl et al., 2006). MS-related disability and fatigue may offer an 
explanation for the higher rate of planned Caesarean sections as well as the higher rate of 
forceps use. The slower progression to second stage of labour may also be explained by 
MS-related symptoms, such as neuromuscular perineal weakness, spasticity, fatigue and 
exhaustion. However, importantly, despite being smaller, the babies of women with MS 
were essentially healthy. 
 
Medications for MS are effective in reducing the length of relapses and improving the 
number of symptoms that people experience (Lechtenberg, 1995). However, a number of 
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the medications used to treat MS are not advised during pregnancy. Many have been 
shown to be harmful to the developing baby, although in other cases the effects are 
simply unknown. Given that the various medications often used in MS can affect the 
unborn child, one of the issues that is important to consider is the risk of going off 
medication while trying to conceive as well as during pregnancy.  
 
Patients with MS are prescribed a number of disease-modifying therapies depending on 
their MS subtype. Immunotherapy drugs such as Avonex, Betaferon, Copaxone and Rebif 
are beneficial for people with relapse-remitting MS and work to reduce disability, the 
frequency of relapses and disease activity (Lechtenberg, 1995). However, it is not known 
from the available studies what the effects of these drugs are on the unborn baby. 
Miscarriages while on treatment with interferons have been reported, however there are 
also cases of healthy babies born to women who continued with their interferons during 
pregnancy (Gilmore, Pennell & Stern, 1998). It is also not yet known if the drugs are 
present in breast milk. Because of the uncertainty it is normally advised to stop taking 
Avonex, Betaferon and Copaxone one month before trying to conceive, during pregnancy 
and while breastfeeding. It is advised to stop taking Rebif three months before trying to 
conceive, during pregnancy and breastfeeding. 
 
Methotrexate is one type of drug that is known not to be safe during pregnancy (Weinreb, 
1994). Studies have shown that methotrexate can cause cranio-facial and limb defects in 
babies and it can also cause central nervous system abnormalities and leads to an increase 
in the likelihood of miscarriage (Ferrero, Pretta, & Ragni, 2004). Methotrexate should be 
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avoided during lactation and should not be taken while a mother is breastfeeding as it has 
been associated with several potential problems, including immune suppression, 
neutropenia, adverse effects on growth, and carcinogenesis (Ferrero et al., 2004). 
 
Steriods and corticosteroids are used to ease inflammation at the affected site, and control 
the severity of relapse. Intravenous steroids are administered only with extreme 
exacerbations and they should be avoided during the first trimester of pregnancy because 
it is thought that the drug can affect the unborn baby (Ferrero et al., 2004). Steroids 
increase risks of congenital abnormalities, and can slow growth while the baby is in the 
uterus. They can be present in breast milk and should be avoided while breastfeeding. 
However, dexamethasone is not associated with congenital defects and it is sometimes 
used to stimulate foetal lung maturation in patients with premature labour (Ferrero, 
Pretta, & Ragni, 2004). Dexamethasone crosses the placenta, though methylprednisolone 
is metabolised before crossing the placenta so is preferred during pregnancy. 
Methylprednisolone also seems to have little effect on the developing foetus (Ferrero et 
al., 2004). 
 
Mitoxantrone, an anticancer drug, is known as Novantrone and is more often used for 
those people with secondary-progressive and progress-relapsing MS. It is an 
immunosuppressant and studies in rats report low foetal birth weight, retarded 
development of the kidney and an increased incidence of premature delivery (Ferrero et 
al., 2004). This drug is known to be present in breast milk and should not be taken while 
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pregnant or breast-feeding. Moreover, the effects of this drug on future fertility remain 
unclear.  
 
1.10 The Motherhood Choice 
Despite evidence showing that pregnancy in MS is neither dangerous to the mother, nor a 
risk for the baby, women continue to view having children in the face of MS as a risky 
decision (Smeltzer, 1994). Additionally, the motherhood choice is complicated further by 
pressure from medical professionals to delay pregnancy for five years. Delaying 
pregnancy for five years not only means the possibility of developing a more chronic type 
of MS, but may introduce problems of conception that are associated with older mothers, 
thus making the motherhood choice even more complicated.  
 
Despite the fact that research now clearly shows that pregnancy is not medically 
contraindicated for women with MS, it has been found that many women with MS have 
avoided pregnancy and parenthood because of perceptions of doubt and disapproval from 
those around them (Wates, 1997). In a population cohort study, pregnancy course, birth 
outcomes, and need for rehospitalization within two years after delivery were compared 
for 198 women with multiple sclerosis and a comparison group of 1584 women without 
MS. Interestingly, demographic results highlighted that a greater proportion of women 
with MS (30%) had a previously induced termination of pregnancy than women in the 
control group (20%) (Mueller, 2002). Moreover, despite the changing advice that is 
recommended for women with MS concerning pregnancy, research shows that there 
continues to be higher rates of termination of pregnancy for women with MS who 
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become pregnant than for the general population (Mueller, 2002). Further, the frequency 
of childlessness in women with MS is greater than in the general population (Damek & 
Shuster, 1997).  
 
1.11 Involuntary Childlessness 
While women with MS are not infertile, there remains a higher number of terminations 
amongst women with MS, as well as a higher frequency of childlessness (Damek & 
Shuster, 1997; Mueller, 2002; Wates, 1997). To date, there is no research on the 
psychological impact of voluntary childlessness amongst women with MS or women 
with other disabilities. However, the effect of childlessness on womens’ psychological 
function has been extensively studied amongst women unable to conceive. While 
speculative, it seems intuitively likely that this group of women, who decide not to have 
children due to their illness, may be experiencing similar psychological effects, such as 
grief, anxiety, depression and a threatened sense of self.  
 
The lifetime prevalence of infertility during childbearing years has been reported to be 
between 17-26% (Schmidt, 2006). Infertility has been identified as one of the most highly 
distressing experiences and fundamentally different from any other stressor (Peterson, 
Newton, Rosen & Schulman, 2006). In fact, 50% of women unable to have children 
report infertility as the most distressing experience of their lives (Freeman, Boxer, 
Rickels, Tureck & Mastroianni, 1985). The experience of infertility brings about a 
number of stressors such as problems with sexual functioning, relationship pressure and 
changes in social and family networks (Newton, Sherrard & Glavac, 1999). Further to 
 29
these, is the emotional impact of the perceived loss of having children and of being able 
to relate to other people with children. Infertility has also been found to pose a unique 
threat to women’s sexual identity and sense of self (Andrews, Abbey & Halman, 1992) 
and anxiety and depression are reported commonly amongst those who experience 
infertility (Jordan & Ferguson, 2006).  
 
Social identity theory suggests that people form their identity via a process of comparison 
to others (Tajfel, 1978). Further, theories have put forward the idea that for women, 
motherhood is the stage of reaching “full womanhood” (Morrell, 1994). It has been 
argued that involuntarily childless women would compare themselves to other women 
and feel a loss of identity as a result of being unable to fill the motherhood role. Infertility 
has also been associated with feelings of failure, anger, shame, confusion and 
helplessness (Letherby, 2002). 
 
Research has most commonly focused on the impact of infertility on the individual, but 
more recently there has been a body of literature exploring how each partner experiences 
the event and how they cope together as a unit (Anderson, Sharpe & Irvine, 2003; 
Peteron, Newton & Rosen, 2003; Peterson et al., 2006; Schmidt, 2006). One study 
assessed couples who were referred for infertility treatment for infertility-related stress, 
adjustment within their relationship and depression. Couple congruence, or a feeling of 
agreement within a couple about how they define stress and their appraisal of the severity 
of a stressful event (McCubbin, Thompson, Thompson & McCubbin, 1993), was found to 
be a significant predictor of depression in infertile women but not men. That is, where 
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there was incongruence in the marital relationship over the need for parenthood, a higher 
number of women (21%) scored in the depressed range in comparison to men (9%) thus 
highlighting that while infertility is a stressful experience for a couple, women perceive it 
as more stressful and are more effected psychologically than are men. Of course, it is 
difficult to extrapolate these findings to women with MS who make a choice not to have 
children. However, this likely depends on whether a woman feels that they are making a 
choice or decision. Intuitively, if women make a considered and informed decision, it is 
less likely that they will regret the decision and experience negative psychological 
impacts. 
 
In recent years, the emphasis in health care has shifted from a focus solely on medical 
indicators to an emphasis on quality of life indicators. It is well documented, across 
different illnesses, that quality of life is only moderately associated with disability and 
other illness characteristics (Sharpe, Sensky & Allard, 2001; Wang, Mayo & Fortin, 
2001). The same is true for the association between disease variables and 
psychopathology. The World Health Organisation (WHO, 1980) has attempted to 
describe the relationship between impairment, disability and patient-perceived handicap. 
According to this system of classification, impairment is defined as the actual damage 
due to an illness. The impairment in MS refers to the demyelination of the central 
nervous system. In contrast, disability refers to the tasks that the person is no longer able 
to perform, such as the inability to walk without a stick. Importantly, patient-perceived 
handicap is determined by the degree to which the person perceives that their disability 
impedes them in achieving their major life goals or continue in their valued social roles. 
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That is, patient-perceived handicap would depend on whether or not the inability to walk 
unaided affected major life roles. Clearly, women’s choices about motherhood would 
affect the degree of patient-perceived handicap. 
 
1.12 Making Decisions About Motherhood 
Even those women who become pregnant express concerns about the effect of MS on 
their pregnancy and vice versa. Indeed, pregnant women with MS continue to view their 
decision to conceive as risky (Smeltzer, 2002). In a study aiming to understand how 
women with MS make decisions about pregnancy and childbearing, 15 pregnant women 
with MS were interviewed about their decisions to become pregnant and asked about the 
various factors that influenced their decision (Smeltzer, 2002). Most women described 
the decision to have a baby as a difficult one, complicated further by a lack of a reliable 
and definitive source of information, uncertainty about the future of their MS, and the 
effect of pregnancy on their MS. Several factors were identified as considerations in this 
decision-making process: a) available information about pregnancy in MS, b) uncertainty 
about the risks of pregnancy in MS, c) availability of support from others in their decision 
making and the prospect of support if needed in the future, d) any potential psychological 
benefits of having a baby, e) the previous course of MS, and f) the paucity of alternatives 
to pregnancy for women with a chronic illness who desired to be a parent. Hence, despite 
evidence to suggest that pregnancy in women with MS is safe, women with MS continue 
to conceive at lower rates than healthy women. Further, those who choose to have a 
family, continue to view their decision as a risk despite good scientific knowledge to the 
contrary. 
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 A small number of qualitative studies have been carried out in order to determine the 
unique themes that arise specifically for women with MS when considering becoming a 
parent (McNary, 1999; Smeltzer, 1994, 2002). Using a descriptive case-study design to 
identify themes arising in the motherhood decision, a sample of four women with MS 
who were pregnant participated in a semi-structured interview covering eight broad topic 
areas: a) childhood aspirations, b) childhood aspiration to motherhood, c) messages about 
motherhood received from family of origin, d) post-diagnosis changes in childhood 
aspirations, e) post-diagnosis changes in childhood aspiration to motherhood, f) post-
diagnosis changes in career aspirations, g) important considerations entering motherhood 
decision, and h) salience of MS among considerations entering motherhood decision 
(McNary, 1999). The 12 most salient themes that arose for all of these women with MS 
included: a) motherhood culture, b) value of motherhood, c) motherhood self-concept, d) 
superwoman, e) career, f) independence, g) MS as a family disease, h) MS as a physical 
concern, i) self-focused anxiety, j) loss, k) social support systems, and l) partner concerns 
(McNary, 1999).  
 
1.12(a) Motherhood culture, value of motherhood, motherhood self-concept 
This theme referred to the motherhood culture in the women’s family of origin 
and the influence that it had on their motherhood self-concept and the value 
placed on motherhood. Women felt that being a mother was special and a blessing 
and women agreed that being a mother is an assumed part of life. Women spoke 
of their mothers staying home to care for them when they were young and how 
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they were in control like, “a finely choreographed ballet” (McNary, 1999, p. 97) 
and then spoke of their own fears of being unable to provide a child with this 
same level of care. These fears centred on deteriorating strength and energy levels 
as well as high levels of stress. 
 
1.12(b) Superwoman, career, independence 
This theme was reflected in statements where women described themselves as 
perfectionists and the belief that MS would not beat them. Typically, women 
likened their independence to stubbornness and this reflected many being adamant 
that they would be able to manage work and parenting and their illness on a full 
time basis. 
 
1.12(c) Social support systems, partner concerns 
Many women spoke about the importance of having a good support network 
around them who would be able to help if they were to experience an 
exacerbation. Some recommended that this is a vital aspect to be sorted out during 
the process of decision-making. Women also spoke about their experience of 
having different ideas about parenting to their husbands and the effect that this 
had on their ability to receive adequate support from their partners.  
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1.12(d) MS as a family disease, MS as a physical concern, self-focused anxiety, 
loss 
These themes specific to MS were reflected in all four participants. There were 
concerns about the impact any visible symptoms would have on their children’s 
relationships with peers at school as well as financial costs for families should 
women become too ill to work or require expensive medical treatment. Women 
also expressed concerns about the possibility that they may deteriorate physically 
and be unable to perform the tasks required to fulfil the role of a mother. These 
tasks included anxiety about an inability to keep children safe as a result of 
slowed reaction time. The theme of loss was relevant in the sense that women felt 
that because of MS they would be unable to fulfil ambitions they had always held. 
 
Other common fears and concerns that women with MS have during the process of 
decision making have been the unpredictability of MS and the effect that pregnancy may 
have on the course of their MS (Smeltzer, 2002). Five categories of concerns have been 
identified as important issues in the decision making process: a) concerns about the 
pregnancy itself, including the decision to become pregnant, b) the effect of MS on future 
child-bearing plans, c) labor and delivery concerns, d) concerns and issues related to 
breastfeeding, and e) concerns about the baby’s well-being and child care (Smeltzer, 
2002). With respect to deciding whether to become pregnant, the contributing factors 
identified as making the decision more difficult included a lack of available and reliable 
information and at times, conflicting advice, uncertainty about the future course of their 
MS and the possible effect that pregnancy may have on that course. What was also 
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identified in this study were the salient factors influencing their final decision, including 
information regarding pregnancy and MS, uncertainty of the risks of pregnancy in MS, 
availability of social support both in terms of the decision making itself, as well as future 
help prospects, potential psychological benefits of having a baby, the individual’s 
previous MS activity and the lack of alternatives to pregnancy available for women 
suffering from chronic illness or disability. All the women interviewed in this study went 
through with their pregnancies and utilised a method of risk-benefit analysis to come to 
their decision, which concerned weighing up the potential risks and benefits involved in 
becoming pregnant. 
 
Despite the reported concerns about pregnancy and the post-natal period, what appears to 
be the greater issue for women with MS is not the pregnancy, but the childrearing. It is 
difficult to predict the likelihood of being physically able to care for a child some years 
ahead and the possibility of childrearing as being impractical in the face of chronic illness 
can be a distressing thought for many women. Fatigue may be particularly worse in the 
postpartum months when the mother may be withstanding the nutritional drain of breast-
feeding and experiencing an irregular schedule, coupled with increased relapse rates 
(Lechtenberg, 1995).  
 
Women with MS considering pregnancy and childrearing would be faced with an 
exaggerated experience of the already stressful concerns associated with bringing a child 
into the world. These concerns include role changes associated with parenthood, the 
wellbeing of the new baby and their confidence in being a good parent (Chalmers, 1982). 
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Additionally, women with MS have to consider a number of issues that are not relevant to 
healthy women. For example, women must consider possible effects of MS on pregnancy 
and the effect of pregnancy and the post-natal period on MS. Many of the medications 
used to treat MS are contra-indicated during pregnancy and women must consider the 
effect on MS of ceasing their medication, sometimes before conception. Practical 
difficulties also present and women worry about whether they will need a caesarean 
section, be able to have epidural anaesthesia during delivery or whether they can 
breastfeed their baby (Ferrero et al., 2004). MS can affect a woman’s ability to care for 
an infant and perform parenting tasks in the short or long term. Finally, women worry 
about the risk of their child inheriting MS (Ferrero et al., 2004; Smeltzer, 1994). 
 
Among mothers with MS it has been reported that lack of emotional, instrumental and 
informational support have been significant issues (Harrison & Stuifbergen, 2002). 
Information pertaining to mothers being able to care for themselves as well as their infant 
in the presence of a disability has not been easily obtained, possibly due to the history of 
those with severe disabilities being discouraged from becoming pregnant. Nonetheless 
the motherhood decision is a significant decision for any woman, whether she has MS, 
any other medical condition or no illness at all and identifying the main concerns for this 
group of women has important implications for health professionals in their treatment of 
women going through this decision-making process. It is important to understand how 
people share decision-making with their healthcare professionals. The following section 
explores medical decision making and interventions to assist the process as it relates to 
the motherhood decision for women with MS.  
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1.13 Shared Decision-Making 
Clearly, motherhood is a decision that requires careful thought in the best of 
circumstances, but the decision is complicated for women with MS who need in addition 
to consider medical risks and physical consequences. Therefore, such decisions need to 
be considered by women and partners in conjunction with physicians who can advise on 
issues or prognosis for the individual woman. The literature highlights four existing 
models of doctor-patient decision-making (Emanuel & Emanuel, 1992). These are the 
Paternalistic, Interpretive Decision-Making, Shared Decision-Making and Informed 
Decision-Making models and it has been suggested that there is much overlap in their 
interpretation (Charles, Gafni & Whelan, 1997, 1999). These models differ in the level of 
participation of the patient in choosing and shaping their ‘treatment’. In the paternalistic 
model, the doctor, as the person with most knowledge of the subject matter, makes all the 
decisions about the patient’s treatment after evaluating the disease, treatment options and 
likelihood of different outcomes. It is assumed that due to their knowledge, the doctor 
will make a decision in the patient’s best interests. The paternalistic model predominated 
until the last few decades, which has seen a shift towards more patient involvement. In 
the interpretative model, the responsibility of choice still lies with the doctor, however, 
the doctor also considers the values and preferences of the patient. The shared decision-
making model emphasises the role of both parties, that is the doctor and the patient. 
Within this model, the two parties reach a decision together after the patient receives all 
necessary information regarding risks and benefits and alternative options available and 
communicates their values and preferences to the doctor. Shared decision making has 
also been associated with terms such as informed decision making, concordance, 
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evidence-based patient choice, enhanced autonomy, and mutual participation (Braddock, 
Edwards, Hasenberg, Laidley & Levinson, 1999; Ford, Schofield & Hope, 2003; Ruland 
& Bakken, 2002). Finally, informed decision-making is described as a model whereby 
the authority lies with the patient in making the final decision after the doctor presents 
them with all available treatment options (Wirtz, Cribb & Barber, 2006). 
 
Of these models, shared decision is now seen by most commentators as the gold standard 
(Butow & Tattersall, 2005). The shared decision-making model evolved from patient-
centred medicine which emphasises that doctors should practice holistically, appreciating 
the patient’s subjective experiences (Weston & Brown, 1995). It is seen as the option 
which respects patient autonomy and contribution, while avoiding over-burdening the 
patient, who often lacks expertise and may be emotionally vulnerable.  
 
Shared decision making occurs via a process of comprehensive communication between 
the doctor and patient and it has a number of key characteristics. Shared decision-making 
must involve both the doctor and the patient, otherwise the process is not shared. 
Additionally, both parties must play an active role in the decision-making process and 
this may require fulfilling a number of roles. Roles might include gathering information, 
recording and interpreting it, advising the patient of treatment options and relaying the 
risks and benefits associated with each option as well as negotiating issues such as timing 
or place of treatment (Charles et al, 1997). Further, the process of sharing information is 
necessary for shared decision-making to occur. Typically, the health professional 
explains all treatment options available, thereby beginning a process of evaluating each 
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option in collaboration with the patient. During the process of shared decision-making, 
patients are informed of the nature of the illness and its prognosis, as well as being given 
a number of options for treatment. Each option is reviewed in collaboration with the 
patient and the pros and cons of each are considered. Pros and cons may include 
weighing up things like risks and benefits, cost and convenience. This provides an 
opportunity for the patient to discuss at length their different perspectives and consider 
their own personal values, concerns, preferences, expectations and ideas. In doing this 
with their doctor, they are provided with an opportunity to hear their physician’s 
recommendations in the context of a particular individual (Charles et al., 1997). A final 
characteristic of shared decision-making is that both parties agree to the final decision 
when it is made.  
 
1.14 Personal Characteristics Influencing Patients’ Ability to Share Decisions 
Shared decision-making, while commonly seen as desirable, is not necessarily an easy 
process for either doctor or patient (Butow & Tattersall, 2005). The likelihood that an 
individual patient will engage in shared decision making depends in part on their degree 
of self-efficacy, or their perception of their ability to make the specified decision 
(Bandura, 1986). The term self-efficacy refers to an individual's own perceived ability to 
perform a specified behavior or set of behaviors (Makoul & Roloff, 1998). Self-efficacy 
is a construct that comes from Social Cognitive Theory, that brings together cognitions, 
behaviour and the environment via reciprocal interaction (Makoul & Clayman, 2006). 
This theory highlights that behaviours are largely determined by the outcome and 
efficacy expectations that patients associate with them. For example, an outcome 
expectation may be that eating less salt will reduce one’s blood pressure, while an 
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efficacy expectation refers to that person’s belief about whether they will be able to eat 
less salt. 
 
Individuals with more confidence, or who perceive themselves to have greater confidence 
with regard to a specific course of action, are more likely to engage in that behaviour. 
Further to this, these people are also more likely to initiate communication 
(Bodenheimer, Lorig, Holman & Grumbach, 2002; Makoul & Roloff, 1998), adjust better 
to illness and treatment (Airlie, Baker, Smith & Young, 2001) comply with treatment 
plans and adhere to health behaviours recommended to them by their health professionals 
(Marcus, Selby, Niaura & Rossi, 1992). Thus people who feel capable of making a 
decision are more likely to engage in shared decision-making. 
 
Self-efficacy is often dependent on the comprehensiveness of an individual’s 
understanding of all the facets that make up a particular decision (Makoul & Roloff, 
1998). These facets may include having a thorough understanding of the facts 
surrounding the decision, including medical facts about the illness and any associated 
side effects, understanding the doctor’s perspective, and the ability to gain further 
clarification if needed. Self-efficacy also includes the patient’s confidence in their ability 
to get the facts about the risks and consequences associated with each of the options 
available, ask questions without feeling incompetent, to ask outside parties for advice and 
also to handle unwanted pressure from others. Research on self-efficacy has highlighted 
the importance of the health professional in checking and clarifying the understanding of 
the patient to help them to be able to make an informed choice (Gazmararian, Williams, 
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Peel & Baker, 2003). With regard to MS and the motherhood decision, the literature as 
outlined previously has shown that the medical outcomes are finely balanced, suggesting 
that discussion around the importance of personal values for each individual is essential. 
Thus the degree to which shared decision-making is preferred is based on the degree to 
which values are primary and medical outcomes are finely balanced (O’Connor, Legare 
& Stacey, 2003). 
 
Of further importance within the shared decision making model, is the issue of follow-up. 
Medical decisions are not always made immediately, but in many cases are decided upon 
gradually over a period of discussion. Shared decision making provides an avenue 
whereby there may be an initial presentation of options on behalf of the health 
professional, after which the patient may take this information home to discuss with their 
significant others or with their healthcare team (Charles, et al., 1997, 1999). Thus, an 
essential component in patient care is to follow up with the patient for further discussion 
whereby any new issues may be raised or questions from the family involved may be 
answered in order to provide them with a clearer picture. This is particularly the case with 
reference to MS and motherhood, where decision-making is ongoing and involves 
multiple people, such as partners and health professionals. 
 
It is important to recognize that, while conceptually, shared decision-making assumes an 
equality or partnership, the decision-making is unlikely to be shared equally. Its emphasis 
lies in the belief that the perspectives of patients as well as health professionals are of 
equal importance, and that they both have a role in decision-making. 
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1.15 Decision-Making about Motherhood in MS 
The motherhood decision is not a once off decision in its entirety, but rather a process of 
decision-making that is often reconsidered many times. Once the initial decision to have a 
child has been made, other family planning issues arise such as how many children to 
have, what size gap to leave between siblings and whether to terminate or continue 
should an unplanned pregnancy occur. When planning a family, there exist many social, 
economic and emotional decisions that must be faced and having to factor in a chronic, 
unpredictable illness exacerbates the complexity of an already complex decision. 
 
Smeltzer (2002) conducted a qualitative study of pregnant women with MS. In describing 
the decision to become pregnant, women likened this to a “risk-benefit analysis” 
(Smeltzer, 2002, p.147). The participants described a lack of available information about 
pregnancy in MS which led them to be uncertain about the risks to them or their child. 
They balanced these fears against the perceived psychological benefits of having a baby 
and the lack of alternatives (e.g. adoption) for women with a progressive neurological 
condition. Further, women specifically referred to lack of available support from others in 
their decision-making. Surprisingly, there is no research on shared decision making in 
this context. Historically, doctors simply advised women against having children, and 
according to women’s accounts, more recently doctors tend to regard the decision as a 
woman’s decision and abstain from advising them.  
 
Decision-making may be defined as a process of making choices between different 
courses of action or inaction. However there are often situations whereby the possible 
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outcomes of different alternatives may not be all positive or even known, and can often 
result in combinations of both negative and positive outcomes. Therefore, the right choice 
for an individual is not clear and they find themselves in a dilemma of uncertainty. This 
situation in which there is uncertainty and conflict over choices where possible results 
may include risk, loss or regret, is known as decisional conflict (O’Connor, Jacobsen & 
Stacey, 2002). As it has been ascertained that an MS diagnosis complicates family 
planning decisions, it would be expected that women and their partners would experience 
much decisional conflict when faced with decisions regarding their family’s future. 
 
1.16 Interventions to Support Decision Making About Motherhood in MS 
In order to provide support for health care decision-making, a number of strategies have 
been identified as helpful. These include providing information about options and 
outcomes to increase knowledge, realigning individual expectations of outcomes to 
ensure they are realistic, clarifying values to decipher what is most important for each 
individual, and increasing individual’s skills in decision making using guidance and 
coaching techniques (O’Connor et al., 2002). Preparing the client and clinician for the 
decision making process and, where appropriate, scheduling follow-up counselling may 
also improve the quality of the choice. Preparation is necessary, especially for those who 
may be experiencing difficulty engaging in decision-making, or who may be vulnerable 
to excessive stress and anxiety as a result of considering and re-considering options. It is 
also useful to prepare clients for communication with the clinician and include follow-up 
counselling for a period following the initial decision. This is an important stage where 
factors such as inadequate knowledge, unrealistic expectations, unclear values, unwanted 
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pressure and inadequate support may be further addressed. Additionally, self help skills 
in handling pressure, seeking social support and managing consequences may be learned.  
 
Providing a structure such as this ensures an individually tailored and supportive decision 
making process which provides appropriate information to ease the stress associated with 
decisional conflict as much as possible. Patients can learn about any likely benefits or 
risks and weigh them with their own personal values. One approach, which tries to utilise 
this structure to facilitate shared decision-making between health professionals and 
patients, is the decision aid.  
 
1.17 Decision Aids 
Decision aids are being increasingly utilised in the medical profession to assist patients in 
making informed decisions regarding choices of treatment, therapy and various types of 
medical tests (Feldman-Stewart et al, 2007). They differ from usual patient information 
handouts and education materials by providing descriptions of various risks and benefits 
involved as well as discussing the likelihood of each outcome occurring. Handouts and 
brochures generally quote statistics that are not easily understood and do not easily allow 
individual patients to judge their own personal likelihood of an outcome occurring 
(O’Connor et al., 1998). Decision aids may be tailored according to a patient’s clinical 
risk profile, while also assessing and utilising their personal values in order to come to a 
conclusion, which is aligned with their own value system. The rationale for decision aids 
is to provide the patient with knowledge that ensures patients are well informed about the 
medical risks involved in their choice, and to lead them to weigh the medical 
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considerations with their own attitudes and values (Deyo, 2001). As a result, the high 
levels of stress and anxiety associated with decisional conflict are reduced so patients can 
play a more active role in decision-making. This process aims to reduce decisional 
conflict and minimise regret over the decision, once made. 
 
Decision aids are of particular benefit for health decisions that are marked by a new 
situation or diagnosis, have uncertain risks and benefits and require more effort in making 
a decision rather than implementing that choice (O’Connor, Rosten & Fiset, 1999). 
Common components of decision aids include information presented in structured format 
to increase patients’ knowledge about the relevant medical issues. Information is tailored 
to consider the risks and benefits in a balanced manner to ensure realistic expectations of 
outcomes. Various issues that are important in considering the decision are discussed and 
supplemented with exercises to help patients clarify their own values relevant to the 
decision the are making. In addition, decision aids often include the experiences of other 
people who have been in a similar situation and describe their retrospective accounts of 
making their decisions (Feldman-Stewart & Brundage, 2004).  
 
Decision aids facilitate the clients’ ability to make possible outcomes tangible and 
functional. They aim to enable clients to better judge the likelihood of different outcomes 
for them personally, thus making each benefit and risk for them somewhat clearer. After 
completing a decision aid, the client has in their possession a visual summary of choices, 
outcomes and probabilities based on accurate, comprehensible and balanced information 
(Lawrence et al., 2000).  
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Most decision aids are related to decisions to have or forego a particular intervention (e.g. 
screening in prostate cancer) or to decide between two treatments (e.g. mastectomy 
versus lumpectomy in early breast cancer). One example is a decision aid for women 
considering hormone therapy after menopause (O’Connor et al., 1998). This decision aid 
uses a self-administered, self-paced booklet and audiotape and is designed to be used by 
women at home in preparation for a follow-up visit to their doctor. The illustrated booklet 
includes general information, worksheets enabling the woman to weigh benefits and 
risks, clarify her values, identify current health practices and preference for her level of 
participation in decision-making and list any questions to ask at the visit. The booklet 
also suggests that the women review the worksheet with their doctors. Ninety-four 
women participated in the trial to validate the decision-aid and they completed 
questionnaires assessing their knowledge, their current predisposition towards taking 
hormone replacement therapy, decisional conflict, personal expectations and importance 
ratings of benefits and risks associated with hormone replacement therapy. Results 
showed that after using the decision-aid, participants’ level of general knowledge about 
hormone replacement therapy had increased, and their personal expectations of the risks 
and benefits were more realistic. Further, women were reported to feel more certain of 
their choice, informed, clear about their values as well as more supported in decision-
making (O’Connor et al.., 1998). 
 
Another example is a cross-cultural consumer-based decision aid for screening 
mammography (Lawrence et al., 2000). In this study, an evidence-based decision aid was 
developed for European American and Mexican American women between the ages of 
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50 and 70, who are at average risk of breast cancer, of varying educational levels and 
who speak either English or Spanish. In its validation, the decision aid was developed and 
evaluated by a multidisciplinary team including oncologists, biostatisticians, social 
scientists, graphics and educational specialists and lay people. Forty-nine European 
Americans and 54 Mexican Americans constituted the sample to test its reliability and 
validity. Results showed that women could comprehend the information, integrate it with 
their own personal value system and they were also able to communicate their 
preferences for screening mammography. 
 
A systematic review of randomised trials of patients’ decision aids in improving decision 
making and outcomes has been reported recently (O’Connor, Stacey, Entwistle, 
Llewellyn-Thomas et al, 2003). Compared with controls, patients receiving decision aids 
had a higher knowledge of options and outcomes, more realistic expectations, less 
difficulty in reaching a decision, more active participation in decision making, and no 
differences in anxiety levels, or satisfaction with decisions or the decision making 
process.   
 
Two types of decisions have been identified (O’Connor, Legare & Stacey, 2003): (a) 
those decisions where there is good medical evidence that one treatment has more 
benefits than harm for a patient; and (b) where there is not strong evidence to favour one 
choice over another and the preference for treatment is related to a person’s values. 
Decision aids are particularly useful to the latter type of decision where the options are 
finely balanced and it is the patient’s values which are important in determining the 
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preferred course of action (O’Connor et al., 2003). This is particularly relevant for the 
motherhood decision in MS. Starting a family is an individual choice that needs to 
balance the importance of motherhood for the woman and her partner against the risks 
that she will be unable to care for the infant or child as a result of increasing disability. 
Surprisingly, despite the fact that motherhood decisions are clearly the type of decision 
ideally suited to the development of a decision aid, no aids exist of this nature for any 
illness group. To date, there is no information available to women with MS who are 
currently considering the motherhood decision. This is despite the fact that MS is an 
illness that predominantly affects women of childbearing age.  
 
1.18 Developing a Decision Aid 
The C.R.E.D.I.B.L.E. criteria were developed by the Cochrane Systematic Review of 
Patient Decision Aids (O’Connor et al., 2003) to guide the development of decision aids. 
These criteria are as follows:  
(C) Competently developed: The decision aid must include the components that promote 
quality decision making and be developed by researchers with appropriate qualifications. 
Further, in the development process it is important to undertake a needs assessment and a 
review of the draft materials both by experts and consumers.  
(R) Recently Up-dated: The data included in the decision-aid should be based on 
evidence available within the past two years. 
(E) Evidence-Based: Statements describing the benefits and harms that are included in 
the decision aid should be based on scientific studies or systematic reviews. 
(DI) Disclosure of conflicts of Interest: Sponsorship or conflicts of interest are disclosed.  
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(BL) Balanced presentation of options, benefits and harms: The decision aid should 
present balanced information and be viewed as balanced by most users.  
(E) Efficacious at improving decision-making: Evaluations should include a randomised 
controlled trial and should demonstrate that the decision aid is effective in improving 
knowledge, is acceptable to users, is free from adverse effects, and shows other benefits, 
such as reduced decisional conflict or increased decisional self-efficacy. 
 
1.19 Aims and Hypotheses 
The aim of this research project is to determine the need for a decision-aid for women 
with MS in New South Wales and Victoria. The second aim is to explore the relevant 
themes associated with motherhood decision-making amongst women at various stages of 
this decision-making process. The primary aim of the project is to develop a decision-
making aid with the function of assisting women with MS in making their decision of 
whether to become a parent. The tool will be evidence-based, and will be designed for 
use in clinical practice to facilitate decision-making amongst women with MS who are 
considering the motherhood decision. Finally, the decision aid will be evaluated as to 
whether is provides information that increases knowledge about pregnancy in MS,  
facilitates decision-making in women with MS who are in the process of deciding 
whether or not to have a child and influences the decision. Finally, the research will 
attempt to determine the long-term impact of the decision-aid on motherhood decision-
making at 12-month follow-up. All ethics documentation for this research project is 
included as Appendix A. 
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This research project is broken up into four phases: 
 
Phase 1 of the study is a needs assessment, which aims to determine the proportion of 
women for whom the motherhood decision is relevant and to identify participants for 
phases 2 and 3. It is anticipated that the motherhood decision will have relevance to a 
large percentage of women with MS between the ages of 20 –40. 
 
Phase 2 of the research is a qualitative study that aims to explore the themes associated 
with motherhood that are relevant for a heterogenous sample of women with differing 
views regarding the motherhood choice. Previously no research has focused on the issues 
relevant to those women who choose to forego motherhood, or those who are yet to make 
a decision. This study will attempt to fill this gap in the literature. This phase will also 
serve as a pilot study to gain feedback from both consumers and physicians on the 
decision aid that has been developed by the authors. Given that phase 2 is qualitative, 
speculative hypotheses will not be made. However, we do expect that by representing the 
views of women who have yet to decide or have decided against having children, new 
themes will emerge that have not previously been documented in the literature. 
 
Phase 3 of this project is a randomised controlled trial of the decision aid. The aims of 
this phase are to determine whether the decision aid (a) increases knowledge; (b) reduces 
decisional conflict; (c) affects a woman’s decision regarding motherhood, (d) increases 
decisional self-efficacy for those who make a decision, and (e) is free from adverse 
effects on psychopathology. For the randomised controlled trial, it is anticipated that the 
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decision aid will increase knowledge about pregnancy and MS, reduce decisional 
conflict, increase decisional self-efficacy and that women will be more certain about their 
choice. It is not expected that the decision aid will push women in one direction or 
another. In terms of the psychological difficulties commonly experienced among people 
with MS, increases in anxiety or depression are not expected in women with MS as a 
result of the decision aid. 
 
The final phase of this study is a follow-up to be conducted at 12 months following 
participants’ initial involvement in the research. The aim of the follow-up study is to 
assess the status of womens’ motherhood decision since post-intervention, using a quasi-
qualitative design, in order to determine the long-term impact of the decision aid and the 
mechanisms through which it operated. It is expected that some women will have become 
pregnant and those women who have become pregnant will be asked about their 
experiences of being pregnant and what impacted on their decision-making process, 
regardless of whether they were in the treatment or control group. Those allocated to the 
intervention group will also be asked about their use of the decision-aid. This aims to 
determine whether the decision aid impacted on the way in which women approached 
their decision and their subsequent experience of pregnancy and/or early motherhood. It 
is anticipated that participating in the study as part of the intervention group will have 
had an impact on the motherhood choice for women with MS and that these women will 
be more certain of their choice as compared to before they began their participation in the 
study. 
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1.20 Significance to MS 
Many women with MS are faced with a decision whether or not to start a family at a time 
where the full impact of the disease on their life is unknown. To date, there is no 
informational resource available to women with MS who are currently considering the 
motherhood decision. This is despite the fact that MS is an illness that predominantly 
affects women of child-bearing age. Further, those who choose to pursue a family have 
numerous concerns about their health and the health of their child. Research suggests 
that, despite strong scientific evidence confirming the safety of pregnancy in MS, doctors 
remain reticent to offer advice on motherhood to women with MS (Smeltzer, 2002). 
Research also shows that the number of women with MS who choose not to have 
children is higher than in the general population or other illness populations (Mueller, 
2002). These data suggest that women may be making uninformed decisions about their 
families.   
 
While there has been an increase in research into the physical outcomes of pregnancy in 
MS with large scale methodologically rigorous studies (Confavreux et al., 1998; Cook et 
al., 1994; Dalmas, Texier, Ducloy-Bouthors & Krivosic-Horber, 2003; Damek & Shuster, 
1997; Deatrick, Brennan & Cameron, 1998; Ferrero et al., 2004; Giesser, 2001, 2003; 
Hutchinson, 1999; Lorenzi & Ford, 2002; Mueller, 2002; Poser & Poser, 1983; 
Runmarker & Anderson, 1995; Verdru, Theys, D’Hooghe & Carton, 1994; Vukusic et al., 
2004; Weinshenker, Hader et al., 1989), the psychological impacts surrounding 
motherhood in MS are largely neglected aside from a few qualitative studies limited to 
pregnant women or those who choose to have children (McNary, 1999; Smeltzer, 1994, 
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2002). We currently have very little information about how many women are undecided, 
why women choose not to have children and whether women are making informed 
decisions. 
 
If the decision aid is demonstrated to be effective in promoting women’s decision 
making, it could be widely applied in routine clinical practice with women with MS. The 
present design will determine whether the decision aid is effective on a range of relevant 
variables. The design will ensure that the decision aid is successful in increasing 
knowledge, reducing decisional conflict and increasing decisional self-efficacy. 
Importantly, the inclusion of measures of psychopathology will ensure that the 
intervention does not have unintended negative consequences for women with MS. 
 CHAPTER 2: REPRODUCTIVE CHOICES OF WOMEN 
WITH MULTIPLE SCLEROSIS 
 
 
2.1 Introduction 
Multiple sclerosis (MS) is the most common neurological disease affecting young adults. 
MS affects ~1 in 1000 people, and, as with other autoimmune diseases, women are more 
likely to be affected than men. Women with MS are typically diagnosed during the 
childbearing years (age 20–40 years) (Smeltzer, 2002). The course of MS varies 
considerably, with some patients experiencing a progressive course from the outset and 
others following a more benign course. However, the disease course is often unclear for 
years after diagnosis. For example, 10 years may pass after diagnosis before a patient is 
certain to have a benign course of the illness (Jopson & Moss-Morris, 2003). Hence, a 
diagnosis of MS is given at a time when women would ordinarily be making decisions 
about motherhood.  
 
Despite the evidence that pregnancy does not accelerate the course of MS, women with 
MS continue to be overrepresented among those who remain childless and who present 
for termination of pregnancy (Wates, 1997). Although qualitative research suggests that 
most women with MS have a strong desire to become mothers, many of them have 
avoided pregnancy and parenthood because of perceptions of doubt and disapproval from 
those around them or their own fears of being unable to cope with the demands of 
pregnancy or parenting (Wates, 1997). 
 
The motherhood choice can be defined as the choice to forego, start, or enlarge a family, 
including facets such as how many children to have and how much time to leave between 
 55
 children. The literature suggests that the decision to become a parent has been 
complicated in recent years because of the career opportunities available to women 
(Meyers, 2001; Sevon, 2005) and increased availability of contraception and abortion 
(Tardy, 2000). Nonetheless, most healthy women report intending to have children. In a 
cohort of the Australian Longitudinal Study on Women’s Health, 91% of young women 
wanted children (Lee et al., 2005).  
 
The decision becomes complicated when health is compromised, as with human 
immunodeficiency virus/autoimmune deficiency syndrome (HIV/AIDS) or sickle-cell 
anemia. For example, a study exploring reproductive decision making in women who 
were healthy carriers of sickle-cell anemia found that the women had difficulty discussing 
their carrier status with their partners, risking rejection and the loss of opportunity to have 
children due to the risk of giving birth to an affected child (Asgharian, Anie, & Berger, 
2003). Little is known about whether these concerns change the reproductive decisions of 
the women. In contrast, the HIV/AIDS Surveillance Report from the US Centers for 
Disease Control and Prevention (2001) stated that 84% of women with HIV and 79% of 
women with AIDS were diagnosed during their reproductive years, yet only 32% of 
women of reproductive age wanted to have children (Heard, Sitta, & Lert, 2007). 
However, both sickle-cell anemia and HIV/AIDS carry potential risks to the unborn child, 
which is not the case for MS. Hence, we cannot generalize from these findings as to 
whether the diagnosis creates ambiguity regarding reproductive choices for women with 
MS.  
 
Because of the progressive and unpredictable nature of MS, coupled with the usual age at 
onset during childbearing years, women with MS are often faced with decisional conflict 
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 regarding the motherhood decision. The presence of a chronic illness would exacerbate 
the already physically and emotionally demanding time of pregnancy and the postnatal 
period. For most women, the presence of MS may necessitate that they consider 
additional factors in the decision-making process. Surprisingly, little research has focused 
on this issue. Studies to date relating to pregnancy and MS have only used small samples 
(n < 15) of women who are either pregnant or already have children, which may not be 
representative of all women with MS. Therefore, whether women are, in fact, undecided 
about motherhood is unknown (McNary, 1999; Smeltzer, 1994, 2002). 
 
 
To our knowledge, this study is the first quantitative research to determine what 
proportion of women with MS are undecided about motherhood. The results offer 
important information about the needs of women with MS.  
 
2.2 Method 
The MS Society of New South Wales (NSW) and Victoria, Australia, maintain a database 
of members who have agreed to be contacted about research that is endorsed by the 
society. The MS Society sent a mailing to all female members between the ages of 20 and 
40 years, constituting a potential sample of 1410 members.  
 
Members were sent a 1-page questionnaire asking them to complete basic demographic 
information (eg, age, marital status, MS type) and to indicate where they were in the 
decision-making process about motherhood. They were asked to return the questionnaire 
to the researchers in a postage-paid envelope. A copy of the questionnaire is included as 
Appendix B. 
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 2.3 Results 
The women in the sample had a mean age of 33 years (SD 4.30 years) and had been 
diagnosed with MS for an average of 6.67 years (SD 4.58 years). Most of the respondents 
had relapsing-remitting MS (80%), 13% were unsure of their type of MS, and smaller 
proportions had primary progressive (2%) or secondary progressive (4%) disease. These 
figures are typical of MS samples with the age and sex inclusion criteria of our sample. 
All statistical output is included as Appendix C. 
 
Of the 461 women who responded to the initial mailing, 212 indicated that they were 
undecided about the motherhood choice (Table 2.1). One hundred and fifty-eight women 
already had children and did not want to have more. Only 52 women indicated that they 
did not want to have children, and 39 indicated that regardless of MS, they want to have 
children. 
 
Table 2.1  
Status of motherhood decision making for women with MS during childbearing years 
Decision status N Percentage
Unsure/considering it  
212 
24.7
Have children/considering more 21.3
Have children/not considering more 158 34.3
Do not want children 52 11.3
Want children 39 8.5
Total  100.0
 
As shown in Table 2.2, 80% of respondents had the relapsing-remitting form of MS. Of 
those, 50% were undecided about motherhood. Thirteen percent of women were unsure of 
their MS type. Of these, 44% were undecided. In contrast, 70% of those with primary 
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 progressive and 81% with secondary progressive MS had decided to either have no 
children or no more children.  
 
Table 2.2  
Reproductive decision status of women with MS during childbearing years, by MS type 
Decision status 
MS type 
TotalRRMS SPMS PPMS
Don't 
know Benign 
Unsure/considering it 91 2 0 12 0 105
Have children/considering more 69 1 3 11 0 84
Have children/not considering 
more 101 8 2 19 0 130
Do not want children 31 5 5 4 1 46
Want children 30 0 0 6 0 36
Total 322 16 10 52 1 401
MS, multiple sclerosis; RRMS, relapsing remitting; SP, secondary progressive; PP, 
primary progressive 
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 Table 2.3 
Results of women who have children vs. women who do not 
 
 N %
No children  
Want 39 19.9
Unsure 105 53.6
Do not want 52 26.5
Total 196 100
Children already  
Unsure 98 38.3
Do not want 158 61.7
Total 256 100
  
Total undecided 212 46
 
 
2.4 Discussion 
We hypothesized that many women with MS would be undecided about their 
reproductive plans. The results show that almost half of the women who responded had 
not yet made their decision. Another third of women reported that they already had 
children and did not want more. Amongst women who did not have children, 26.5% had 
chosen voluntary childlessness (11.3% of the total sample). In the general population, the 
instance of voluntary childlessness amongst healthy women is 9% (Lee & Gramotnev, 
2006).” In the two groups of women who had made their decision to either begin or 
forego starting a family, the motherhood decision would likely have been a necessary 
process, in the past, to reach this conclusion. Unfortunately, the study did not look into 
how many of these women received their diagnosis before starting their families or for 
how many the motherhood choice was affected by MS. However, if the decision was 
relevant only to those currently undecided or yet to decide, half of the women surveyed 
would be represented. Clearly, then, these results support the conclusion that the 
motherhood decision is relevant to women with MS.  
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 The breakdown of women with each type of MS into the various statuses of decision 
making was interesting. Most studies of MS and motherhood have been on women with 
relapsing-remitting disease, because it is the most common type. The situation is the same 
in the current study, with 80% of respondents (n = 322) having relapsing-remitting MS, of 
which half (n = 160) were undecided in their motherhood choice.  
 
Among those with secondary progressive MS (n = 16), most (81%) either decided against 
having children or already had children and did not want to expand their families. 
Secondary progressive MS begins its course as relapsing-remitting MS; therefore, this 
group was older by an average of 3 years and had already made motherhood decisions. 
Nonetheless, a relatively high proportion (31%) of women in this group had decided to 
remain childless. 
 
Similarly, although only 10 women in the sample had primary progressive MS, 5 of them 
had decided against having children, and only 3 had children. Although a small sample, 
these data suggest that more extreme progressive disability has a greater influence on 
future life choices, such as family planning, than less disabling forms of disease. 
 
A smaller proportion (n = 52) of women did not know the course of their MS. We assume 
that their prognosis was unclear to them. A similar proportion of these women (44%) to 
those with relapsing-remitting disease (50%) were considering motherhood. However, 
they were doing so without clear information about their prognosis, which would have 
important implications for informed decision making. For example, women who are not 
informed about their type of MS and its associated prognosis may decide to forego 
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 motherhood because they have assumed that their illness will progress quickly to severe 
disability. 
 
2.5 Limitations 
The study relies on self-report, which may mean that the MS types reported were not 
entirely accurate, particularly in that many women were unsure of the diagnosis. 
Nonetheless, the study shows that women were attempting to make their reproductive 
choices despite lacking this information.  
 
The low response rate of the mailing (33%) may indicate a response bias. Women may 
have failed to return questionnaires for various reasons. However, the possibility that 
those who responded are those for whom this issue was most relevant is likely. Even if 
this is the case, the motherhood decision was so common among those surveyed that it 
was relevant (at the time) to 15% of the possible sample (ie, 212/1410).  
 
How relevant MS was in the reproductive decision-making process of women who 
already had children remains unknown. A high proportion of women reported that they 
already had children and did not want anymore. Knowing whether they were diagnosed 
before having children and, if so, whether MS complicated their decision making would 
have been useful. However, national trends show that women are delaying motherhood, 
this decision will become increasingly influenced by MS for women following diagnosis.  
 
Finally, the study did not have a comparison group, which would help determine whether 
rates of indecision among women with MS are more prevalent than those for women 
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without MS. However, recent data suggest that most healthy women, when asked, 
reported that they want to have children (Lee, et al, 2005). 
 
2.6 Conclusion 
To our knowledge, this is the first study to determine in a large sample of women with 
MS in the childbearing years, what proportion remains undecided about motherhood. The 
study indicated the relevance of this issue for many women with MS. Prior research 
suggested that women face considerable conflict about the motherhood decision 
(Smeltzer, 2002). Further research is necessary to explore the needs of this group.  
 
A follow-up of the women who were undecided, to explore the reasons for their 
indecision and highlight the factors associated with MS that might be increasing their 
uncertainty, would be useful for addressing these issues in clinical practice. The 
development of a decision-making aid may help women access appropriate information 
and consider how their values should be weighed against other relevant information, thus 
allowing for less conflict regarding the decision. 
 CHAPTER 3: THE MOTHERHOOD CHOICE: THEMES 
ARISING IN THE DECISION-MAKING PROCESS FOR 
WOMEN WITH MULTIPLE SCLEROSIS 
    
3.1 Introduction 
MS is the most common chronic neurological disorder among young adults. It most 
often strikes women and its onset is typically in the childbearing years (20s-30s) 
(Confavreux, Hutchinson, Hours, Cortinovis-Tourniaire, & Moreau, 1998). Due to the 
progressive and unpredictable nature of MS, coupled with the time of onset being one 
associated with family planning, women with MS are often faced with decisional 
conflict regarding the motherhood decision as the already physically and emotionally 
demanding time of pregnancy and childbearing may be exacerbated by a potentially 
disabling illness. Therefore, the presence of MS necessitates additional factors to 
consider in the reproductive decision-making process.  
 
Women with MS considering pregnancy and childrearing can be faced with an 
exaggerated experience of the already stressful concerns associated with having a 
child. These may include role changes associated with parenthood, the wellbeing of 
the baby and their confidence in being a good parent (Chalmers, 1982). Additionally, 
women with MS have to consider issues that are not relevant to healthy women. 
Common concerns amongst these women include any possible effects of MS on 
pregnancy and the effect of pregnancy and the post-natal period on MS. Many 
medications used to treat MS are contra-indicated during pregnancy and women must 
consider the impact of ceasing their medication on their MS. Practical difficulties also 
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 present and women worry about whether they will need a caesarean section, be able to 
have epidural anaesthesia during delivery or whether they can breastfeed (Ferrero, 
Pretta, & Ragni, 2004). Symptoms of MS in the post-natal period, during which 
women are at higher risk of relapse, can affect a woman’s ability to care for an infant 
and perform parenting tasks in the short or long term. Finally, women worry about the 
risk of their child inheriting MS (Ferrero, Pretta, & Ragni, 2004; Smeltzer, 1994). 
 
Only three qualitative studies have been carried out to understand the concerns of 
women with MS considering motherhood (McNary, 1999; Smeltzer, 1994, 2002). The 
most salient themes that were identified included ‘independence’, ‘MS as a physical 
concern’, ‘MS as a family disease’, and the importance of the ‘motherhood self-
concept’(McNary, 1999). These themes were added to the usual concerns associated 
with motherhood, such as ‘career’, ‘financial resources’ and ‘partner concerns’. In a 
study of pregnant women, women identified a lack of available and reliable 
information, conflicting advice, uncertainty about the course of their MS  and the 
possible effect that pregnancy may have on the disease as their major concerns 
(Smeltzer, 2002).   
 
Although these prior studies give insights into the experiences of women with MS 
choosing motherhood, this remains an under-researched area. All three available 
studies have relied on interviews with pregnant women (McNary, 1999; Smeltzer, 
1994, 2002). Hence the views of women choosing not to have children have not been 
represented. Similarly, there is no information on how women with MS fare early in 
the post-natal period. Importantly since those studies, there is now good evidence to 
suggest that MS does not adversely affect pregnancy or the infant, nor does pregnancy 
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 adversely impact the long-term course of MS (Confravreux, Hutchinson, Hours, 
Cortinovis-Tourniaire, & Moreau, 1998; Watkiss & Ward, 2002). 
 
The aim of this study is to document the main themes and concerns for women with 
MS considering motherhood. We included the views of women who had decided 
against having a family, as well as those with children and those who were undecided. 
As a result, this qualitative study will offer be the first to document the experiences of 
women with MS who are considering motherhood.  
  
3.2 Method 
As presented in chapter 2, we conducted a large mail-out in January 2005 to 1410 
women, aged between 20 and 40, from the NSW and Victorian MS Societies asking 
them to indicate what stage they were at in the motherhood decision. Women were 
also asked whether they would be interested in taking part in a larger study on this 
topic. 
 
Four-hundred and sixty-one women responded and were divided into four groups: (1) 
those who decided against having children (n=52), (2) those who had children and did 
not want anymore (n=158), (3) those who decided to have children (n=39), and (4) 
those who were undecided about their motherhood choice (n=212). Women from the 
above groups who lived in Sydney and responded within four weeks of the mail-out 
were eligible to participate. From these women, consecutive women were chosen to 
represent the four groups of participants described above. Recruitment continued until 
theoretical saturation (no new themes emerging in two consecutive groups) was 
reached. This occurred after four focus groups and one individual interview. 
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 Women were contacted and invited to attend a focus-group or individual interview in 
February or March 2005.  Women unable to attend a focus group were offered a 
telephone interview. All women contacted agreed to participate. Semi-structured 
questions were used to guide discussion covering womens’ experiences of making this 
decision, including the factors they were weighing up, their experience of accessing 
relevant information from organisations and health professionals and the attitudes of 
those around them with regard to their decision. For women who had made a decision, 
how they reached their decision was discussed, as well as their experience of having a 
child, any challenges of parenting and how they coped in the post-natal period. See 
table 3.1. 
 
Table 3.1 
Interview questions for focus groups 
How has your MS diagnosis affected your decision to have children? 
What sorts of factors were you weighing up in making your decision? 
What was your experience of accessing information about this topic? 
What has been your experience of having a child? 
Have there been any challenges for you in parenting? If so, what were they? 
What was the post-natal period like for you? 
Did you experience different attitudes from those around you towards having a child? 
 
The focus-groups were facilitated by the candidate. Each focus-group or interview 
lasted for approximately 60 minutes, was audio-taped and transcribed (range: 20 mins 
– 76 mins).  
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 This study had ethical approval from the University of Sydney Ethics Committee and 
Multiple Sclerosis Australia. 
 
Audio-taped data was transcribed and analysed qualitatively using the Framework 
method of analysis developed by the National Centre for Social Research, a method in 
which themes are developed both from the research questions and from the accounts 
of research participants, to identify the themes associated with the motherhood 
decision (Towle, Godolphin, Grams & La Marre, 2006). After transcription, the 
transcripts were independently read by the candidate and the Primary Supervisor (LS) 
to identify the major themes and develop a coding framework. The coding framework 
identified semantic content relevant to the subject matter that could be organised into 
meaningful groups (Braun & Clarke, 2006). The different codes were then sorted into 
potential themes and all coded data was collated within the identified themes. The 
researchers then met with the Associate Supervisor (PB) to confirm the themes and 
coding framework. Any disagreements concerning themes were discussed until 
consensus was reached.  
 
3.3 Results 
Twenty women with MS participated, with a mean age of 32 (range 20-40) years and 
diagnosed with MS on average 6.5 years ago (see table 3.2).  Sixty percent of the 
women had relapse-remitting MS, 10% had secondary-progressive MS and 10% had 
primary-progressive MS. Twenty percent did not indicate their MS type. Five 
participants were unsure of whether to start, forego or enlarge their family, five 
definitely wanted children, six had decided not to have children and four already had 
children and did not want more.  
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 Table 3.2 
Demographic information of the participants 
Demographic Information Frequency 
Age (at time of focus group)  
20-25 3 
26-30 5 
31-35 6 
36-40 5 
Not reported 1 
Time since diagnosis  
1-5 years 9 
6-10 years 6 
11-15 years 4 
16-20 years 1 
Type of MS  
Relapse-Remitting 12 
Secondary Progressive 2 
Primary Progressive 2 
Don’t Know 4 
Number of children  
Pregnant 2 
None 12 
One 4  
Two 1 
More than two 1 
Motherhood decision status  
Unsure 5 
Definitely want children 5 
Do not want children 6 
Already have children, don’t want more 4 
 
The following are the main themes that emerged from the qualitative analysis: 
 
3.3(a) Health and well-being 
My health during the post-natal period 
For women who were undecided, a major concern was their future well-being. They 
described fears of the post-natal period, which is typically characterised by increased 
relapses and how this would impact on their ability to care for a new infant.  
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 “It's the 3-6 months after having the baby you are tired and having to get used to 
breastfeeding and getting up every 4 hours, it's going to be difficult and you're more 
likely to relapse”. 
 
Coming off medication 
The uncertainty around how their health would be affected if they discontinued 
medication for conception and pregnancy (and breastfeeding) was also a common 
concern for these women.  
 
“Being able to stay on medication was really important. Being able to manage my 
relapses was like really, really important”. 
 
“I'm really afraid of going off my medication and having a bad exacerbation” 
 
Current health reflective of future health 
Additionally, the current state of women’s MS influenced their self-efficacy in 
decision-making because they viewed their current state as a reflection of how their 
future health would be.   
 
“I've only been diagnosed for a year and I've had 4 relapses in a year so I haven't been 
going great…it may continue to go this way…I think I've got to be a bit better about 
how I'm going with MS, and my husband, before I know which way to go”. 
 
“There's a part of me that would love to have children but there's also a really big part 
of me that questions what effect MS is going to play in their life…it's made a big 
impact in my life so what's it going to do with a child” 
 
 69
 3.3(b) Child’s well-being 
Passing on MS 
Despite the very small objective risk, a large proportion of women worried that they 
would pass MS on to their child. Some spoke of the guilt that they would experience 
if their child inherited MS and the devastation at watching their child suffer. Some 
were unaware how small the chance of passing MS on was (3-5% if one parent has 
the illness) indicating a lack of available information. In contrast, some who knew the 
facts and had children, expressed anger at the insensitivity of people questioning their 
decision to start a family in case they passed on their illness.  
 
“I thought about having kids and it just upset me because I didn't want to pass MS on 
to them”. 
 
“The small percentage of being able to pass it on that would be particularly 
devastating that my child developed it”. 
 
“I would have loved to have had children…but I wouldn't take the risk of them 
getting MS.” 
 
“A lot of people who don't know anything about MS have asked me about my child 
inheriting the illness…it really annoys me”. 
 
“Would it be so bad? Is your life so terrible that you'd rather not have it? Because 
mine isn't. Even when I've been really, really, really sick, I'd still choose to be here. I 
just don't understand where people are coming from when they ask that…”. 
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 Child being a carer for their parent 
Many women who were undecided were concerned that their child may end up caring 
for them as their disease progresses. Numerous women stated that having to care for a 
parent is not a childhood, and that childhood is a precious time which should not be 
taken away from any child. These women reported that they would feel guilty and feel 
like a ‘bad mother’ if this occurred.  
 
“I don't want to bring up a child who is going to have their childhood robbed from 
them by being a carer for their parent”. 
 
“I don't want the child to end up looking after me…for me that's just not a 
childhood”. 
 
Harming the child 
A prominent fear amongst women, particularly those who had decided not to have 
children and those with more progressive illness, was whether they could keep their 
child safe, especially in the early years of the child’s life. Many questioned whether 
they would be sufficiently agile to protect their child from harm or to keep up with a 
child. Due to the uncertainty of their prognosis, women were fearful that future 
progression might affect their ability to care for their child. Women worried about 
dropping their baby or falling over and hurting their child. 
 
“The child running away…putting their finger in a power point…not having the 
reaction time that's going to be fast enough to stop the child from being harmed”. 
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 3.3(c) Coping with parenting 
Fatigue 
All of the women currently deciding whether to begin or enlarge their families 
expressed concern regarding their ability to parent a child in the face of a progressive 
and unpredictable illness. These participants reported that worsening fatigue was a 
source of anxiety as it would make parenting almost impossible. They all explained 
that taking care of themselves was difficult enough and doubted their ability to cope 
with the increased fatigue.  
 
“I don't think we want children but it's just a real sort of factor, I need to be alright to 
be able to look after kids. I'd like to be active with my kids, I want to...do everything 
that everyone wants to.” 
 
“There's no point getting to the point when you're just so tired you can't even cook or 
anything…that's not going to help your baby at all”. 
 
Financial concerns 
Related was the concern that should parenting become compromised, financial 
resources would become strained if partners had to cut back on work to help with 
parenting. This fear was especially difficult to plan for because the uncertain nature of 
MS prognosis for many of these women. 
 
“I worry about financial figures as well. If I'm actually too tired to look after a child 
then my husband will have to stop work and that concerns me, especially it's so 
expensive in Sydney so that worries me.” 
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 “Definitely financial is one. I know that we really want to be financially stable before 
we sort of move in to having kids, just in case…all the what-ifs I get sick”. 
 
Support 
The importance of a good support base revealed itself as a major concern for women 
in all groups. Women who had not yet decided whether they would start a family were 
uncertain about asking for help believing that they should be able to cope as well as 
any able-bodied woman. Some were even unwilling to have children if they were not 
certain that they would be able to cope most of the time. Women who had decided not 
to have children often did not have support nearby and this was noted as an important 
factor in their decision to forego a family. Women who had already had children 
spoke, with the benefit of hindsight, about the importance in asking for help. 
However, many noted that when they first had their babies they were reluctant to do 
so.   
 
“I've got a very supportive family and my partner is very supportive so I know I won't 
be stressing about those things”. 
 
“You've got to start to realise what you can and can't do and it's a hard thing to 
accept.” 
 
“I'd always ring mum and ask her to come and stay with me I need a bit of help and 
she'd be there for a week and I'd be fine after that.” 
 
“I know we've got a great support network…but I personally feel if I can't do it 9 
times out of 10 I don't want to rely on someone else to do it”. 
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 “I just don't think it's fair to rely on someone else to look after it for me. I know in 
times of emergency, yes I could call on someone but I don't want to rely on them all 
the time”. 
 
3.3(d) Societal attitudes and women’s reactions 
Reactions from family, friends and health professionals 
Most women who had previously been through this decision-making process reported 
experiencing negative attitudes from both health professionals and family members 
regarding their future family planning. All women reported that at least some family 
members and friends assumed that these women would not have a family. Even those 
who did not assume that the woman would remain childless, assumed that there would 
be difficulties with pregnancy or labour, such as the need for a Caesarian or the 
inability to breastfeed.  
 
“I remember my neurologist saying, ‘you'll probably never have children’. I'm very 
much like, ‘don't tell me what to do’ because I like to make my own decisions”. 
 
“I went to see the GP…to check results of whether I was pregnant…she said, ‘Oh yes 
you're pregnant’ she looked in the file - I have MS. She said oh you shouldn't be 
having children!” 
 
“The whole way through my pregnancy I'd hear, ‘so I guess you'll be having a 
Caesarian?’ I'm like, ‘no way’.” 
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 Not letting MS beat you 
Despite this, there was a strong union amongst all the women with children that, 
despite their illness, they valued their lives and would still choose to be alive even if 
they were forewarned about developing MS. In addition to this, the women who 
already had children all reported that they went through a stage of defiance where 
they would not let anyone try and influence their decision. They said they would do 
the opposite when it was recommended that they slow down and ignored any offers of 
advice, whether helpful or unhelpful. 
 
“I didn't go around asking people because I didn't really care what they said.” 
 
“I can do whatever I want and I'll do it. And whatever you say is not going to 
impact.” 
 
Experience of parenting 
Women who had children described the challenges they had faced with their 
pregnancy or parenting. None reported regret over their decision to start a family and 
all spoke of the joy of motherhood and the importance it held for them in their lives. 
Interestingly, every woman in the sample who had children described a period of 
post-natal depression, which they attributed to their reluctance to readily ask for help 
from others and the pressure of coping with their new infant as well as their MS. 
 
“You've got to realise what you can and can't do…it's a hard thing to accept…when 
every other parent in the neighbourhood pops their kid in the pram and goes down to 
feed the ducks”. 
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  “I lost my mother 10 years ago from cancer so I've always wanted to have kids and 
be a mother. I wanted to have that bond I never had when I was an adolescent, so it's 
important at one point but it's just making a careful decision now.” 
 
“I would just bounce back from whatever was thrown in my way…I had postnatal 
depression but refused to let anyone know. I put on a false bravado in front of 
everybody…and then I crumble because no one offers me help.” 
 
“I was superhuman. I could do anything and everything and no one could stop me. If 
they dared to get in the way I would try even harder and then I would crumble when 
no one else could see me.” 
 
Timing and pressure of the decision 
In contrast to previous research where women reported that they were often advised to 
wait 5 years to decide, the women in this study reported common advice from health 
professionals was that to start a family happen before the age of 30 and before their 
MS progressed. Hearing this made many women, who were in the process of making 
this decision, anxious as to the timing of their decision. Women, particularly those in 
their 20s, commonly reported that they felt it was necessary to rush their decision. 
This put pressure on their relationships, as they were often not at a stage where they 
might otherwise have been ready to have children. Women spoke about how 
unhelpful, unnecessary and even untrue they found some of the advice they had 
received.  
 
“I don't want to be older and like…secondary progressive…I wouldn't want to be at 
that stage and for it to be too late for me to start thinking more about having kids if I 
hadn't had kids.” 
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 “Part of my brain is geared around where I do have MS and in the last 11 years and 
especially the last 5 it has impacted me…I'm in a wheelchair…I don't have the energy 
to get around…if I'm considering having a child now or in another 10 years, can I still 
do it at the age of 40”. 
 
“My neurologist saying you've got to do it before you're 30, that nearly broke my 
husband and I up”. 
 
“I've always wanted to have kids…you might say I've made a decision, younger 
rather than wait older before things get worse…cause I probably would have waited 5 
years or more”. 
 
“I took my partner to my neurologist early in our relationship to discuss this issue. 
We, as a couple, were not ready at the time to have children and now I feel I am too 
old. Information on this earlier would have helped make the decision and opened up 
discussion.” 
 
3.4 Discussion 
The aim of this study was to provide a qualitative investigation of the views of women 
with MS about the issues relevant to their motherhood decision. Prior research has 
only encapsulated the views of women who have decided to have children. Our results 
supported those findings (Smeltzer, 1994) identifying similar themes such as mother’s 
health concerns, coping with parenting and societal attitudes. This study further 
identified concerns from different groups that had a direct impact on the decision to 
have children amongst those who had already decided, including the experience of 
parenting, the child’s well-being and timing and pressure of the decision.  
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 Those women who had not yet decided to have children as well as those who had 
decided not to have children reported different concerns from those with children 
already. Those who did not have any children held fears about the possibility of their 
children inheriting their MS. Of concern is that this fear was, for a number of women, 
disproportionate to the level of risk. For example, the risk of inheriting MS when one 
parent has MS is 3-5%, a similar risk to juvenile diabetes (2.9%) (Sandler, 1990) and 
yet a few women reported deciding against a family largely because of the fear that 
this unlikely outcome would occur. 
 
Women who were unsure of their decision had more concerns around their ability to 
cope on a number of levels. They questioned their own stamina during labour and 
were concerned they would be unable to be as functional during the post-natal period 
when relapses tend to increase (Cook, Troiano, Bansil, & Dowling, 1994). They 
worried about having to come off medication in order to conceive safely and were 
fearful of the permanency of any exacerbations occurring while off medication. The 
ability to parent with the level of fatigue that can occur amongst those with MS was 
questioned by these women. They also felt that having children would make them 
financially unstable, particularly during times of relapse when role changes would 
need to occur in the household and income could not be guaranteed. Women who had 
decided not to have children held the same concerns though were surer that they 
would not be able to cope with these possibilities. 
 
Those women who had decided to go ahead and have families reported that, in 
retrospect, they shared the same concerns before making their final decision. Of 
interest was that, in reaching their decisions, they had developed a defiant attitude. 
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 They tended to do the opposite of what people would recommend with regard to their 
general health and ignored signs from their bodies that they needed to rest. Indeed, 
this may account for the very high rates of reported post-natal depression amongst 
those women in this group. While it is not clear that they would have met formal 
criteria for post-natal depression, the fact that these women identified their defiant 
attitude as a source of stress is important because this may be an unintended 
consequence of uninformed and unhelpful attitudes from society and health 
professionals. Over time this group had come to learn to realise when they need to 
slow down and had become more comfortable with asking for help from their support 
base. Despite their acknowledged difficult experiences during the post-natal period, 
this group of women nonetheless found meaning in their role of a mother and 
cherished the bond they have formed with their children. 
 
Those whose illnesses had exacerbated recently, and who did not yet have children, 
were also worried about their current state of health and being uncertain of the rate of 
progression of their MS. Being unwell as a new parent was a major concern because 
of the impact that this would have on the rest of the household as well as other family 
members. Most women felt that asking for help and for their child to grow up having 
had to care for their mother at various times rendered them a “bad mother” and were 
unwilling to become parents while this possibility for their future remained. They had 
adamant views on what childhood should and should not entail and were of the 
opinion that having to care for a sick parent is an experience children should not have 
to endure.  
 
 79
 There are several limitations to the study that must be addressed. Firstly, the women 
recruited for this study were all members of the MS Society and were willing to attend 
an allocated focus group or interview session. It is possible that those who are 
members of the MS Society are more likely to seek out and read information 
regarding their own health and therefore be more interested and aware of what their 
fears and concerns are. Further to this, it is likely that these women were more able to 
discuss their concerns than non-responders. Secondly, women were contacted as 
responses were returned and hence, there may be a bias in the early responders 
relative to late responders. Additionally, demographic information, such as marital 
status, level of education and occupation was not collected so it is unknown whether 
these factors have influenced or biased the sample in any way. Finally, given the 
qualitative design and the small sample size, these data should be considered 
hypothesis generating. 
 
These limitations notwithstanding, this is the first study to investigate the concerns of 
women with MS who are at all the different stages of the motherhood choice. The 
results supported previous research suggesting that womens’ concerns are currently 
not being addressed adequately. Women themselves reported misunderstandings 
about information, such as the rate of heritability. Further, they also discussed 
unhelpful attitudes of well-meaning health care providers which in some instances had 
unintended negative consequences.  
 
These results indicate that there is a need for access to more information about the 
effect of MS on pregnancy and child-rearing and the effect of pregnancy on MS and 
its progression. It seems that such information would be valuable to women in the 
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midst of this decision-making process. Moreover, it seems that educating health care 
professionals and the wider community in these issues may also have positive 
consequences for women with MS who do chose to pursue motherhood. 
  82
CHAPTER 4: THE MOTHERHOOD CHOICE: A DECISION 
AID FOR WOMEN WITH MULTIPLE SCLEROSIS 
 
4.1 Introduction 
The motherhood decision is defined as the choice to forego, start or enlarge a family. For 
women with chronic illnesses or disabilities, this is not an easy decision (Asgharian, Anie, 
& Berger, 2003; Grue & Laerum, 2002). The issue of reproductive choices amongst women 
with disabilities is an important area that has received a lot of attention (Grue & Laerum, 
2002; Heard, Sitta, & Lert, 2007; Killoran, 1993). Despite the principles of normalization 
having been adopted in Westernized societies for more than two decades, women with 
disabilities continue to remain over-represented amongst those who remain childless 
(Killoran, 1993).  Such women often view motherhood as ‘risky’ (Thomas, 1997). Common 
concerns relate to the ongoing health of both baby and mother, fear of the baby inheriting 
the illness and risks associated with drugs taken during and after pregnancy to manage the 
illness (Birk & Kalb, 1992). Operating within a medical discourse which emphasizes 
minimization of risk can intensify these concerns. Women with chronic illnesses or 
disability and their partners are sometimes made to feel that having children is irresponsible 
(Grue & Laerum, 2002; Killoran, 1993). Hence, this is an area in which health care 
professionals are inadvertently communicating in a way that women experience as 
unhelpful. 
 
MS is a progressive, unpredictable neurological disorder of the central nervous system and 
its onset is more common amongst women of child-bearing age (Birk & Kalb, 1992; Cook, 
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Troiano, Bansil, & Dowling, 1994). The likely activity of the disease for any individual is 
often unclear for at least five years after diagnosis so women often have to make 
reproductive choices while their future remains uncertain. Since 50% of patients are likely 
to have mobility problems within ten years of diagnosis, waiting for clarity in prognosis 
may mean that increased disability makes parenthood more difficult than it might 
previously have been (Ferrero, Pretta, & Ragni, 2004). Because the onset of MS occurs in 
early adulthood, it may challenge a woman’s self image, including their present and future 
images of themselves as spouses, sexual partners, parents and income providers.  
 
Prior to 1950, the general consensus was that pregnancy accelerated the course of MS and 
women were discouraged from becoming pregnant (Cook, Troiano, Bansil, & Dowling, 
1994). When pregnancy did occur, a termination was often recommended. Women with MS 
were on occasion discouraged by health professionals from nursing their babies for fear of 
further deterioration of their condition (Poser & Poser, 1983). While most women possess a 
strong desire to become a mother, many women with MS have avoided pregnancy and 
parenthood because of perceptions of doubt and disapproval from those around them 
(Wates, 1997). 
 
The issue of whether pregnancy affects the course of MS has been the subject of much 
research (Cook, Troiano, Bansil, & Dowling, 1994; Damek & Shuster, 1997; Hutchinson, 
1999; Lorenzi & Ford, 2002; Poser & Poser, 1983; Watkiss & Ward, 2002) and there is now 
consensus in the literature, based on large prospective studies, that pregnancy in women 
with MS neither exacerbates their illness nor is a risk to the child (Confavreux, Hutchinson, 
Hours, Cortinovis-Tourniaire, & Moreau, 1998; Confavreux & Vukusic, 2002; Ferrero, 
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Pretta, & Ragni, 2004; Lorenzi & Ford, 2002; Mueller, 2002; Watkiss & Ward, 2002). In 
the long term the condition may get worse whether or not pregnancy occurs. Despite this 
changing evidence concerning pregnancy and MS, higher rates of pregnancy termination 
(Mueller, 2002)  and childlessness (Damek & Shuster, 1997) persist in women with MS 
than for the general population, and pregnant women with MS continue to view their 
decision to conceive as risky (Smeltzer, 2002).  
 
The presence of MS complicates the motherhood decision, and there are a number of issues 
which women need to understand before an informed decision can be made (Mueller, 
2002). Four specific factors which women need to consider have been identified (McNary, 
1999), as follows: (a) the neuro-physical features of MS; (b) the psychological 
consequences of MS; (c) the culture of each individual woman and her family; and (d) the 
historical context in which women with disabilities contemplate motherhood. These themes 
have been found to influence women in their reproductive choices and to determine the ease 
with which women and their partners are able to make this decision. However, to date, there 
are no available patient resources to assist women who are contemplating a decision or the 
health professionals who are counseling them in their decision. 
 
Decision-making may be defined as a process of making choices between different courses 
of action or inaction. Many decisions involve weighing up uncertain positive and negative 
outcomes, leading to uncertainty and vacillation (decisional conflict) (O'Connor, Jacobsen, 
& Stacey, 2002). The motherhood decision is not a once off decision, but rather a process of 
decision-making over time. Once the initial decision to have a child has been made, other 
family planning issues arise such as how many children to have, what size gap to leave 
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between siblings and whether to terminate or continue should an unplanned pregnancy 
occur. When planning a family, there exist many social, economical and emotional factors 
that must be considered (Feldman-Stewart et al., 2007), and having to factor in a chronic, 
unpredictable illness exacerbates the complexity of an already stressful situation (Smeltzer, 
2002). 
 
A number of strategies have been identified as helpful to facilitate decision-making about 
health care. These include providing information about options and outcomes to increase 
knowledge, realigning individual expectations of outcomes to ensure they are realistic, 
clarifying values to determine what is most important for each individual, and increasing 
individuals’ skills in decision making using guidance and coaching techniques (O'Connor, 
Jacobsen, & Stacey, 2002). Such strategies are commonly employed in decision aids.  
 
Decision aids have been defined as interventions designed to help people make specific and 
deliberate choices among options, including the status quo, by providing at the minimum 
information on the options and outcomes relevant to a patient’s health (O’Connor, Roston, 
& Fiset, 1999). They aim “to facilitate patient involvement in decisions about their health 
care, with the goal that each person’s decision be informed and consistent with his/her 
values” p.47 (Feldman-Stewart et al., 2007). They typically contain relevant evidence-based 
information presented in a simple, clear, graphical form, and lead patients through a process 
of clarifying their values and weighing the pros and cons of the options prior to decision-
making.  A recent systematic review showed that, compared with controls, patients 
receiving decision aids had a higher knowledge of options and outcomes, more realistic 
expectations, less difficulty in reaching a decision, more active participation in decision 
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making, and no differences in anxiety levels, or satisfaction with decisions or the decision 
making process (Elwyn et al., 2006).   
 
Decision aids are being increasingly utilised in medicine to assist patients in making 
informed decisions regarding choices of treatment, therapy and medical tests (Elwyn et al., 
2006; Volk & Spann, 2000). They are of particular benefit for health decisions made in the 
context of a new situation or diagnosis, in which there are certain risks and benefits 
(O'Connor et al., 1998), such as the motherhood decision in MS. To date, there is no 
information available to women with MS who are currently considering motherhood. 
Hence, there are few educational resources that health professionals can recommend or use 
to initiate discussion with women with MS faced by this decision. If the decision aid is 
demonstrated to be effective in promoting women’s decision making, it could be applied by 
a range of health care professionals in routine practice with women with MS.  
 
This study aims to evaluate a decision aid with the function of assisting women with MS to 
decide whether or not to start or enlarge their families. Specifically, we hypothesize that the 
decision aid will increase knowledge about pregnancy in MS; reduce decisional conflict; 
increase decisional self-efficacy and make women more certain of their decision. We did 
not expect that the decision aid would affect anxiety, depression or the direction of their 
decision. 
 
4.2 Method 
Eligible women were women diagnosed with MS, aged between 20 and 40 at the time of 
recruitment, were currently unsure about the decision to start or enlarge their families and 
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who could read and write English sufficiently to complete questionnaires. The MS Societies 
of New South Wales and Victoria have databases of members who agree to participate in 
research endorsed by the Society. The MS Societies sent mail-outs to all women between 20 
and 40 years (n=1410) between March and November 2005 inviting them to participate in 
the study by returning a one-page questionnaire about their motherhood decision-making, 
the results of which were reported in chapter 2. Women were also asked to indicate if they 
would agree to be involved in a randomized controlled trial of a decision aid.  
 
Women who consented were then sent baseline questionnaires with a reply-paid envelope. 
A list of random numbers corresponding to intervention vs control were generated using the 
Excel Bernoulli function and linked to participant identification numbers. The random 
sequence was concealed electronically until the point of allocation. Women were randomly 
allocated after being sent their baseline questionnaires. Women in the intervention group 
were sent the decision aid which they were asked to read within two weeks. They were 
telephoned two weeks later to ensure they had read and understood the decision aid, to 
answer any questions and to screen for distress. Telephone conversations did not exceed 20 
minutes and confirmed that all women had read the decision aid. After the telephone 
conversation or at the corresponding time for control women, the post-intervention 
questionnaires were sent to participants to be returned by mail.  
 
This study had ethics approval from the University of Sydney Ethics Committee and 
Multiple Sclerosis Australia. 
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A draft of the decision aid was developed by the authors following a literature search of the 
databases PSYCHINFO, MEDLINE and SCIENCEDIRECT, using the search terms 
PREGNANCY, MOTHERHOOD, PARENTING both individually and combined with 
MULTIPLE SCLEROSIS from June until November, 2004. Publication dates of literature 
retrieval ranged from 1961 to 2004. The format for the decision aid was based on the 
Ottawa Decision Support Framework and followed the C.R.E.D.I.B.L.E. criteria, developed 
by the Cochrane Systematic Review of Patient Decision Aids (O'Connor et al., 2003). The 
criteria stipulates that decision aids must be Competently developed, incorporating 
components promoting quality decision-making. The researchers developing the decision 
aid should possess appropriate qualifications. The decision aid should be Recently updated, 
and include information based on evidence available within the last two years. It must also 
be Evidence-based, such that the information presented is based on scientific studies 
following a thorough literature search. There should be no Conflicts of Interest, and the 
decision aid should be Balanced. Finally, the decision aid must be Efficacious at improving 
decision-making and be free from adverse effects.  
 
The decision aid provided general background information about MS, different types of MS 
and the likely prognosis associated with each type. Following was a section on the 
psychosocial impacts of MS on lifestyle factors relevant to decisions about parenting, 
including financial burden, changes in relationships, psychological disturbances and social 
role changes within the family.  
 
Data about the effect of MS on child-rearing was described. Research confirming that 
pregnancy does not alter the course of MS was presented and that MS does not interfere 
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with fertility or miscarriage rates. The documented effects of MS on pregnancy, labour and 
delivery, were described, including the fact that 70% of women experience a remission 
during pregnancy. There was a section that described the best evidence about the safety of 
different medications during conception and pregnancy. The decision aid also discussed the 
effect of MS during the post-natal period in terms of increased relapse rates and fatigue. 
There was a section that addressed breastfeeding issues, such as needing to decide whether 
to breastfeed if medications were counter-indicated during lactation. There was also a 
section on commonly asked questions by women who are making this decision, such as 
fertility, the contraceptive pill and the risk of the child inheriting MS.  
 
There was a section on the issues that may arise in parenting with MS. This section 
described the concerns that mothers with MS have reported. This included worries of their 
ability to provide physical affection to their child during relapse. The need for good support 
post-natally and the meaning associated with motherhood. To present a balanced view, the 
decision aid included patient stories, of one woman who chose to have and one who chose 
to forego children. The stories included the factors that influenced their decisions. These 
stories were developed on the basis of the qualitative interviews reported in chapter 3. The 
decision aid then included a number of options that women may consider, such as having a 
smaller family, having no children, leaving a larger gap between siblings etc. The choices 
were followed by exercises to help women consider their personal values and those of their 
partners. Women were encouraged to list important factors for and against each option and 
rate the importance of each factor. Women were also encouraged to consider what support 
they would have if they had children and how support people could help them.  
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The decision aid was piloted with 20 women with MS (those who took part in the 
qualitative interviews described in chapter 3), who commented on its readability, balance 
and usefulness and gave feedback on the content. The feedback was generally positive, 
however, some exercises were simplified on the basis of their comments. Fifteen 
neurologists, who specialise in MS, were also sent the decision aid by mail and given an 
opportunity to comment on the accuracy of the information. Eight neurologists wrote back 
with positive feedback and a further seven phone calls were made to the remaining 
neurologists. There were no factual errors identified. Feedback on the decision from women 
is included as Appendix D. The decision aid is included as Appendix E.  
 
4.2.1 Measures 
Primary outcomes for this analysis were decisional conflict, decisional self-efficacy, 
knowledge and certainty of decision-making. Secondary outcomes were depression and 
anxiety. This analysis was conducted on an intention to treat basis. 
 
The following questionnaires were administered and can be found in Appendix F: 
4.2.1(a) A demographic questionnaire elicited age, duration and type of MS and 
time since last exacerbation. Participants indicated whether they wanted to have 
children before receiving their MS diagnosis, whether they currently have children 
and whether their diagnosis complicated their decision to have children by ticking 
yes or no. Women were asked to rate their certainty about having children on a 
continuum where –5 meant they would definitely not have children now or in the 
future, 0 meant they were unsure, and +5 meant they definitely would have children 
at some stage. In addition to the score from -5 to +5 which indicated the direction of 
  91
a person’s choice, we calculated a score from 0-5, to indicate certainty of choice 
regardless of direction. For example, both -5 and +5 were scored as 5 to indicate 
women were certain of their decision. 
 
4.2.1(b) As there is no questionnaire which specifically addresses the issue of 
pregnancy in MS, a knowledge questionnaire was developed based on the 
information provided in the decision aid. Participants were asked to answer 10 
questions relating to pregnancy and child-rearing in people with MS. Scores were 
derived by adding the number of correct answers given. 
 
4.2.1(c) The Decision Conflict Scale 4th Edition (A. O'Connor, 1999) : The 
Decisional Conflict Scale is a 16-item Likert scale that has been widely used to 
evaluate patients’ decisions regarding a range of healthcare decisions. The scale 
consists of five subscales: uncertainty; feeling uninformed; feeling unclear about 
one’s values; feeling unsupported in decision-making; and the perception of the 
effectiveness of the decision-making once it has been made. Items in each subscale 
are scored on a 5-point scale from 1 (strongly agree) to 5 (strongly disagree), with 
reverse scoring for 5 negative statements. Item scores are summed and divided by 
the total number of items to yield the average item score, with total scores ranging 
from 1 (low decisional conflict) to 5 (high decisional conflict). A 2-week test–retest 
reliability coefficient of 0.80 has been reported, and the internal consistency for the 
total scale has ranged from 0.78 to 0.92 when the scale was applied to a variety of 
groups, including patients with cardiac or respiratory disorders who made decisions 
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about influenza immunization and women aged 50–69 years who made decisions 
about being screened for breast cancer (O’Connor, 1995). 
 
4.2.1(d) Decision Self-Efficacy Scale (A. O'Connor, 1995): The Decision Self-
Efficacy Scale has been used with patients confronting a range of decisions. This 
measure is an 11-item Likert scale, which was administered to determine the level of 
self-confidence and belief that participants had in their own ability to make this 
decision. Respondents obtain a score between 0 (extremely low self-efficacy) to 100 
(extremely high self-efficacy). It has an internal consistency coefficient of 0.92.  
 
4.2.1(e) Center for Epidemiologic Studies Depression Scale (CESD) (Radloff, 1977): 
The CESD is a short 20-item, self-report scale intended to measure depressive 
symptoms in the general population. Scores are obtained by the sum of the 20 item 
weights. It has an internal consistency coefficient of 0.89. A score of 16 or greater is 
considered depressed. Research has confirmed the reliability and validity of this 
measure within the MS population (Verdier-Taillefer, Gourlet, Fuhrer, & 
Alpérovitch, 2001). This measure was preferred for this population over the Beck 
Depression Inventory (BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) due 
to the overlap between the somatic items in the BDI and medical symptoms in MS 
patients (Mohr et al., 1997).  
 
4.2.1(f) State-Trait Anxiety Inventory (STAI) (Spielberger, 1983): The STAI is an 
extensively used self-administered inventory comprising self-report scales for 
measuring state and trait anxiety. The state anxiety form was used in this study to 
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compare any changes in anxiety over time. The scale consists of 20 items and 
respondents rate how well statements reflect how they feel on a 4-point scale. 
Reliability coefficients exceed .90, the inventory has good construct validity and it is 
used with MS populations (Tsivgoulis et al., 2007). 
 
4.2.2 Analyses 
Baseline differences between the intervention and control group were assessed using 
parametric (for continuous variables) and non-parametric (for dichotomous variables) t-tests 
to identify covariates. A series of (group: intervention; no intervention) x 2 (time: pre; post) 
mixed model ANCOVAs were performed, using SPSS 15 for Windows, to determine the 
effectiveness of the intervention.  
 
According to the Cochrane systematic review, decision aids, on average, increased 
knowledge by 19 pts, improved realistic perceptions by 40%, reduced decisional conflict by 
9 pts, reduced passive decision-making by 30% and reduced the proportion of undecided 
people after counselling by 57% (O'Connor, Legare, & Stacey, 2003). A sample of 150 is 
sufficient to detect each of these differences with at least 80% power at a 0.05 level of 
significance.  
 
4.3 Results 
4.3.1 Demographic variables 
As reported in chapter 2, 461 women responded to the MS Society invitation to participate, 
of whom 212 were eligible. Of these, five participated in the qualitative study reported in 
chapter 3 and pilot phase to review the decision aid. The eligible participants were 
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randomized to receive the decision aid or no intervention. One-hundred and fifty-two 
women (78%) completed pre-treatment questionnaires. Forty-two women did not complete 
measures because they did not respond (n=19), became pregnant (n=13) or withdrew 
(n=10). At post-treatment, 13 participants failed to return questionnaires due to withdrawal 
(n=3) or non-response (n=10). 
 
The mean age for the intervention group was 31.95 (SD=3.79) and 31.10 (SD=5.64) in the 
control group (see Table 4.1). There were no significant differences between the 
intervention and control groups for age (t(1,149)=-1.093,p = 0.276) or any of the 
demographic or outcome measures (see Table 4.2), with the exception of whether the 
diagnosis of MS had complicated their decision of whether to have children 
(t(1,149)=1.998,p=0.046). Women in the intervention group were more likely to feel that 
MS had complicated their decision. Therefore all ANCOVAs were conducted controlling 
for this variable. 
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Table 4.1 
Demographic Variables 
Measures Decision-Aid Group (n=78) Control Group (n=61) 
  Mean (SD)  Mean (SD) 
Age  31.95 (3.79)  31.10 (5.64) 
Time since Dx  5.15 (3.45)  6.22 (4.19) 
  N   N 
Have children Yes 
No 
45 (54%) 
39 (46%) 
Yes 
No 
29 (43%) 
39 (57%) 
MS type Relapse Remitting 
Secondary Progressive 
Primary Progressive 
Don’t Know 
75 (89%) 
2 (2%) 
1 (1%) 
6 (7%) 
Relapse Remitting 
Secondary Progressive 
Primary Progressive 
Don’t Know 
63 (92%) 
0 
0 
5 (8%) 
Wanted kids 
before Dx? 
Yes 
No 
Unsure 
69 (82%) 
6 (7%) 
9 (11%) 
Yes 
No 
Unsure 
52 (76%) 
1 (1%) 
15 (22%) 
Dx  complicate 
decision 
Yes 
No 
64 (77%) 
19 (23%) 
Yes 
No 
42 (62%) 
26 (38%) 
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Table 4.2 
Outcome Measures 
 Decision-Aid Group Control Group Effect Size 
 PRE 
mean (SD) 
POST 
mean (SD) 
PRE 
mean (SD) 
POST 
mean (SD) 
 
Knowledge 4.12 (1.81) 6.30 (2.18) 4.19 (1.93) 4.63 (1.86) 0.89 
Decisional 
Conflict 
2.48 (0.69) 2.07 (0.55) 2.34 (0.65) 2.29 (0.64) 0.72 
Decision Self-
Efficacy 
77.69 (17.56) 86.09 (12.51) 82.23 (16.21) 82.56 (18.36) 0.51 
Certainty 2.47 (2.04) 3.34 (1.85) 2.66 (1.84) 3.00 (1.81) 0.28 
Balance  1.19 (2.98) 1.08 (3.68) 2.13 (2.44) 1.79 (3.03)  
Depression 14.74 (11.21) 13.09 (9.25) 13.95 (11.61) 12.48 (10.17)  
Anxiety 35.82 (11.98) 36.17 (12.03) 34.69 (11.59) 35.34 (11.35)  
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4.3.2 Intervention Effects  
The statistical analyses for this chapter are included as Appendix G. For certainty of the 
decision, there was a main effect for time at post-treatment, indicating that the passage of 
time significantly improved the certainty of all subjects, regardless of which group they 
were in (F(1,135)=8.739;p=0.004;η²=0.061). There was no main effect for group 
(F(1,135)=0.493;p=0.484;η²=0.004). However, there was a significant interaction effect, such 
that those in the intervention group shifted towards a more certain choice with regard to 
either choosing to have or not to have children, while the control group tended to remain 
relatively less sure (F(1,135)=2.854;p=0.047;η²=0.021) (See Figure 4.1). Although women 
became more certain of their decision, the decision aid did not systematically change 
women towards wanting or not wanting a child. That is, for the raw score on this 
continuum, there were no main or interaction effects (F(1,135)=0.079;p=0.779;η²=0.001).  
Figure 4.1 
Continuum (absolute value) 
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For decision self-efficacy, the main effects for time (F(1,135)=2.486;p=0.117;η²=0.018) and 
group (F(1,135)= 0.006;p=0.936;η²=0.001) were not significant. However there was a 
significant interaction effect (F(1,135)= 8.375;p=0.002;η²=0.058) suggesting that women in 
the intervention group became more confident in their decision over time (See Figure 4.2).  
Figure 4.2 
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Between the pre and post assessments, decisional conflict reduced significantly in both 
groups (main effect for time: F(1,133)=11.997;p=0.001;η²=0.083). There was also an 
interaction between group and time indicating that decisional conflict was improved more 
over time in the decision aid group  (F(1,133)=10.820;p=0.001;η²=0.075) (see figure 4.3). 
There was no main effect for group (F(1,135)=1.211;p=0.273;η²=0.009).  
 
Figure 4.3 
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At post-treatment, both groups showed a significant improvement in their knowledge 
regarding pregnancy in MS (F(1,133)=8.215;p=0.005;η²=0.058). There was also a main effect 
for group (F(1,133)=6.774;p=0.010;η²=0.048). Importantly the group x time interaction was 
also significant (F(1,133)=19.883;p<0.001;η²=0.130). That is, prior to treatment there was a 
small non-significant difference between the groups. Over time, both groups improved in 
knowledge, but this change was significantly greater in the group who received the decision 
aid (See Figure 4.4). 
 
Figure 4.4 
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Levels of depression were not effected by the passage of time 
(F(1,133)=1.744;p=0.189;η²=0.013) nor were they different between the groups 
(F(1,133)=0.003;p=0.954;η²=0.001) and there was no significant interaction effect 
(F(1,133)=0.001;p=0.973;η²=0.001). A similar pattern resulted in levels of anxiety, with 
anxiety remaining unaffected by time (F(1,133)=0.291;p=0.590;η²=0.002) or group 
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(F(1,133)=0.019;p=0.890;η²=0.001). As hypothesised, the interaction between time and group 
was also not significant (F(1,133)=0.001;p=0.991;η²=0.001). 
 
4.3.3 Clinical significance 
In addition to these analyses, it was also important to determine whether significant changes 
are of clinical significance. For this reason, scores on the Decisional Self-Efficacy Scale 
were reanalysed using a cut-off difference of 25% as indicative of a significant change in 
self-efficacy. For example, a participant who obtained a score of 50 at pre-intervention 
would have to score either below 25 or above 75 to indicate a clinically significant change 
in decisional self-efficacy. Scores on the Decisional Conflict Scale were similarly 
reanalyzed such that a change in score of 1, that is 20%, or more indicated a significant shift 
in decisional conflict. With regard to assessing the clinical significance of knowledge, 
conceptually is seemed that a score of 7 out of 10 reflected adequate knowledge about the 
subject matter to make a relatively informed choice. This cut-off score was decided a priori. 
With this in mind, both pre and post treatment knowledge scores were reanalysed to 
indicate whether subjects had adequate or inadequate levels of knowledge regarding the 
subject matter. 
 
For self-efficacy, analyses indicated that there was no clinically significant change between 
the decision-aid intervention group and the control group (X²=4.475; df=2; p=0.107). For 
decisional conflict, analyses revealed a clinically significant difference between the groups 
(X²=6.467; df=2; p<0.05). Examination of the resulting proportions in each category 
indicates that whereas 7% of the control group became more conflicted over time, this was 
not true for anyone in the intervention group. In both groups, 87% remained the same and 
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only 7% in the control group became less conflicted, whereas 13% of the intervention group 
became less conflicted with regard to this decision. Therefore there are differences between 
the groups although clinical differences occurred in only a minority of women, but small, 
statistically significant changes were evident. With regard to subjects’ levels of knowledge 
about MS and pregnancy, results revealed that at pre-intervention there was no significant 
difference between the groups, with 91% of the control group and 90% of the intervention 
group scoring less than 7 out of 10 on the knowledge measure (X²=0.123; df=2; p=0.940). 
However, at post-intervention a clinically significant difference was revealed between the 
two groups with 47% of the intervention group having adequate knowledge about  MS and 
pregnancy, as compared to only 20% in the control group (X²=11.147; df=1; p<0.001).  
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Figure 4.5 
Flow diagram 
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4.4 Discussion 
The aim of this study was to evaluate a decision aid for women with MS in making the 
motherhood decision. We hypothesised that the decision aid would result in increased 
knowledge, self-efficacy and certainty and a reduction in decisional conflict. We also 
hypothesised that there would be no effect of the decision aid on anxiety or depression. 
These hypotheses were all supported. Similarly, there was no evidence of a difference in the 
direction of the decision, suggesting that the decision aid was balanced. 
 
Despite careful attention to the study design and methodology there remain a number of 
limitations that need to be acknowledged in interpreting the results. Firstly, the study had 
substantial reliance on self-report. The demographic questionnaire, in particular, required 
women to report details such as the number of years since their diagnosis, their type of MS 
and whether they had wanted to have children before receiving their MS diagnosis. A 
number of women were not sure of their type of MS, which is concerning because it 
suggests that they are going through the process of making their motherhood decision with 
an absence of information about their individual illness and prognosis. The decision aid was 
also self-administered. The fact that the decision aid was effective with minimal face-to-
face contact suggests that as an informational resource it is useful. It is more likely that in 
practice a tool such as this would be discussed face-to-face between health professional and 
patient. Its efficacy when administered in this manner has not been tested. However, 
research has consistently found that women with MS contemplating motherhood report no 
available information to help make an informed decision (McNary, 1999; Smeltzer, 1994, 
2002). Hence, the provision of information in and of itself is likely to be important. 
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Although we had a high rate of recruitment and retention in this phase of the research, this 
was of those who initially responded to the mail-out, where a considerably lower response 
rate was achieved (33%). Therefore, it is possible that these women were more interested in 
this topic than other women with MS and may not be representative of this population. 
Nonetheless, presumably it is these women who would request supplementary information 
regarding MS and motherhood and therefore, those most likely to receive the intervention in 
clinical practice.  
 
The final limitation is that while there were no differences between groups on any of the 
outcome variables or demographic variables, there was a difference between the groups in 
one question: whether MS had complicated their choice to have a family. In all other 
respects, randomization was effective and the groups were well matched. Further, in our 
analyses, we controlled for this variable. To ensure that these results were robust with and 
without this covariate, we analysed the data using ANOVA also and the pattern of results 
remained unchanged. 
 
Women who had experienced a miscarriage during the treatment period were confused 
about where to place themselves with regard to the decision continuum at the post-
intervention. While these women had made the decision to have children, they felt the 
likelihood of carrying a pregnancy to term was low. This highlights the issue that for some, 
the decision is taken out of their hands by physical realities. 
 
These limitations notwithstanding, this study also has a number of strengths. Firstly, we 
developed a decision aid according to the C.R.E.D.I.B.L.E. criteria, developed by the 
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Cochrane Systematic Review of Patient Decision Aids (O'Connor et al., 2003). 
Additionally, we consulted the Patient Decision Aid Checklist of the new International 
Patient Decision Aid Standards (Elwyn et al., 2006). The decision aid provides information 
about the positive and negative outcomes associated with each option to allow effective 
decision-making. It presents information in an unbiased, understandable way, using 
diagrams. The decision aid has methods for clarifying patient values and includes 
worksheets and questions that facilitate communication with health professionals and family 
members. The decision aid was systematically developed by researchers with appropriate 
credentials, and the area was thoroughly researched to determine needs (chapter 2). It was 
reviewed by potential users and experts and field tested with users (chapter 3). The decision 
aid was acceptable, balanced and understood by users. The decision aid was up-to-date with 
scientific evidence that was cited in a reference section and it used patient stories 
representing different choices. Finally the decision aid was shown to be effective in 
facilitating decision-making (chapter 4). These results are much more compelling indicating 
that nearly half the women versus less than a quarter are well informed after reading the 
pamphlet three weeks prior. 
 
Importantly, women have consistently indicated that they have been unable to access an up-
to-date informational resource about MS and pregnancy to facilitate appropriate decisions 
about their families (McNary, 1999; Smeltzer, 1994, 2002). This is problematic since 
women report that health professionals often have negative attitudes towards pregnancy and 
MS and hence there is considerable scope for the dissemination of misinformation. This 
decision aid is a first step towards the provision of an up-to-date resource that women can 
use with their partners and health professionals to facilitate decision-making.  
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Since this study, the MS Society of NSW has been using it as a resource for members of 
their society. The decision aid has been re-branded by the MS Society, advertised in their 
newsletter and made publicly available. Hence, there is a direct clinical benefit to patient 
care. As this is the first application of a decision aid to what is primarily a lifestyle choice, 
rather than a decision to have or forego a treatment or to determine between two treatment 
options, the question arises as to who would be an appropriate health care professional to 
administer the decision aid. Given that a number reported taking the decision aid to their 
general practitioners or neurologists, it would seem that they would be appropriate health 
care providers to introduce patients to this resource. However, MS Societies internationally 
employ a range of psychologists, social workers, nurses and other health professionals who 
provide counseling and support to women with MS and these practitioners may also find it 
helpful in initiating discussions about these issues.  
 
Secondly, this decision aid could provide an important template for broadening the use of 
decision aids to other groups of women whose reproductive choices are affected by a 
medical illness. Such groups may include women with Systemic Lupus Erythematosis 
(SLE), infertility or who are HIV positive. Health professionals and researchers working 
with these women would need to adapt and evaluate the educational component in the 
pamphlet, however, many of the values exercises would remain similar. Indeed, health 
professionals working in these areas, where decision aids are yet to be available, could use 
these exercises to structure counseling sessions that focused on the motherhood choice. 
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Most decision aids are related to decisions to have or forego a particular intervention (e.g. 
screening in prostate cancer), or to decide between two treatments (e.g. mastectomy versus 
lumpectomy in early breast cancer) (Volk & Spann, 2000s). However, the motherhood 
choice, while being similar to the latter type of choice, relates more to a lifestyle choice that 
is complicated by a medical illness. While this study has developed an evidence-based 
decision-aid for women with MS that can be directly translated into practice, it also has the 
potential for wider applicability. It provides a direct model for other conditions where 
reproductive choices may be complicated by illness (eg SLE, infertility, HIV etc). Future 
research is needed to test the efficacy of decision-aids in other areas. 
 
There is a need for future research to explore the relationship between stated preferences 
and actual behaviour to determine the effects of the decision aid in the longer term. A 
follow-up study would be useful to discover whether these women go on to have children or 
not, and experience less anxiety about risk during pregnancy and child-rearing. 
 
In summary, we have developed a decision-aid to help women with MS consider issues 
relevant to their decision whether or not to have a family. The decision-aid was developed 
according to the gold standard CREDIBLE criteria and was acceptable to women in the 
study. The decision-aid was efficacious in improving women’s certainty of their decision, 
their decisional self-efficacy and reducing their decisional conflict and there were no 
negative effects in terms of psychopathology. Hence, this decision aid can be readily used 
with women with MS contemplating motherhood. 
 
 
 
 
CHAPTER 5: THE MOTHERHOOD DECISION AID: 
MECHANISMS OF TREATMENT 
 
5.1 Introduction 
Motherhood is arguably a decision that requires careful thought. Once the initial 
decision to have a child has been made, other family planning issues arise such as 
how many children to have, what size gap to leave between siblings and whether to 
terminate or continue should an unplanned pregnancy occur. When planning a family, 
there are many social, economic and emotional decisions that must be considered 
(Sevon, 2005)and having to factor in a chronic, unpredictable illness increases the 
complexity of the decision.  
 
Multiple Sclerosis (MS) is the most common chronic neurological disorder among 
young adults. MS is largely progressive and unpredictable in nature, occurring more 
often in women in their reproductive years (Confavreux, Hutchinson, Hours, 
Cortinovis-Tourniaire, & Moreau, 1998). Women with MS are often faced with 
decisional conflict regarding the motherhood decision as the already physically and 
emotionally demanding time of pregnancy and childbearing may be exacerbated by a 
potentially disabling illness. For many women, the decision is not simple, and 
decisional conflict may be significant. Their choice must balance their family 
aspirations and career goals, and are further complicated by an illness characterised by 
uncertainty.  
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Women with MS considering pregnancy and childrearing need to consider not only 
the normal stressors associated with parenthood, the wellbeing of the baby and their 
confidence in being a good parent (Chalmers, 1982) but any possible effects of MS on 
pregnancy and the effect of pregnancy and the post-natal period on MS (Smeltzer, 
1994). However, the majority of the research, to date, has focused on women who 
have already decided to have children. (e.g. (McNary, 1999; Smeltzer, 1994). Hence, 
the issues that are relevant to women who are currently considering this decision have 
not been adequately addressed.  
 
In chapter 3, we interviewed 20 women with MS from various stages in the decision-
making process. We confirmed the importance of previously identified themes. For 
example, some women had experienced negative attitudes from health-care providers 
or family and friends towards having children when they have a chronic, progressive 
illness. Women also voiced concerns about their own health and well-being as well as 
the well-being of their child. Another source of anxiety that affected the decision-
making particularly of women who were undecided or who had decided not to have 
children was their ability to cope with the demands of parenting due to their MS. This 
related not only to whether to have children but also to when they should have 
children. That is, women reported the pressure to have children while they are less 
disabled although their longer term prognosis was unclear. This was because they 
feared that they would become too disabled to have a child later on. However, this 
pressure to bring forward child-bearing also had negative impacts on them, such as 
creating a stressful impact on their relationships as well as their own psychological 
well-being. Finally, women who had not had children were worried about the 
possibility of the child inheriting MS, despite the fact that this outcome was very 
 107
unlikely. However, for women who had already had children, these fears were 
outweighed by their experiences of being a mother, the meaning they have found in 
their role and the bond they have formed with their child. Finally and importantly, 
most of the women in the study agreed that currently their concerns were not being 
addressed adequately through the health care system. 
 
The fact that women do not consider that they can easily get information about 
pregnancy and childrearing in MS is important because there are a lot of medical 
information that they need to facilitate informed decision-making. For example, many 
medications used to treat MS are contra-indicated during pregnancy and it is 
recommended that some should be stopped well in advance of conception. Hence, 
women must consider the impact of ceasing their medication on their MS. Practical 
difficulties also present and women worry about whether they will need a caesarean 
section, be able to have epidural anaesthesia during delivery or whether they can 
breastfeed (Ferrero, Pretta, & Ragni, 2004). Symptoms of MS in the post-natal period, 
during which women are at higher risk of relapse, can affect a woman’s ability to care 
for an infant and perform parenting tasks in the short or long term. Finally, women 
worry about the risk of their child inheriting MS (Ferrero, Pretta, & Ragni, 2004). 
 
Research suggests that, despite strong scientific evidence confirming the safety of 
pregnancy in MS, doctors remain reticent to offer advice on motherhood to women 
with MS (Smeltzer, 2002). Research also shows higher rates of termination of 
pregnancy amongst women with MS and that the number of women with MS who 
choose not to have children is higher than in the general population or other illness 
populations (Mueller, 2002). It has also been found that many women with MS have 
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avoided pregnancy and parenthood because of perceptions of doubt and disapproval 
from those around them (Wates, 1997). In chapter 2, the only large scale study 
assessing reproductive choices in women with MS to date, we found that 46% of a 
group of 461 women with MS aged between 20 and 40 were currently unsure about 
whether or not to have children. These results, taken together, confirm that the 
motherhood choice is not a straightforward decision for women with MS but that 
women do not feel that they are given sufficient access to accurate information to help 
them in their decision-making. In chapter 4, we conducted a randomised controlled 
trial of a decision aid, developed according to the CREDIBLE criteria (O'Connor et 
al., 2003) with 194 women with MS who were currently unsure whether or not they 
wanted children. They completed questionnaires measuring their decisional-conflict, 
self-efficacy, knowledge about MS and pregnancy, depression and anxiety as well as 
their motherhood choice at pre and post intervention. It was found that the decision-
aid reduced women’s decisional-conflict and increased their self-efficacy and 
knowledge of MS and pregnancy. The decision aid also resulted in a more certain 
choice that was not biased in either direction, and did not increase depression or 
anxiety. 
 
As medicine has steered away from traditional paternalistic models towards models of 
shared decision-making, decision aids have been developed to support patients and 
their physicians in decision-making. They differ from usual patient information 
handouts and education materials by providing descriptions of various risks and 
benefits involved as well as discussing the likelihood of each outcome occurring 
(O'Connor et al., 1998). Decision aids have been shown to reduce uncertainty and 
decisional conflict in patients, increase their knowledge of the illness and the relevant 
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issues, provide more realistic expectations of outcomes and more consistency between 
patients’ choices and values (Deyo, 2001). Shared decision-making assumes that the 
effectiveness of decision aids is because it allows patients to get relevant information 
and promotes communication between relevant parties (e.g. doctors and patients) 
regarding patient values and individual prognosis. However, while there is 
considerable evidence for the efficacy of decision aids (O’Connor, Roston, & Fiset, 
1999), there is less information about the mechanisms through which patients find 
them helpful. 
 
The aim of this study is to assess the long-term impact of a decision aid that was 
developed to help women with MS with their reproductive decision-making, using a 
quasi-qualitative framework. That is, we aim to determine whether the decision aid 
impacted on the way in which women approached their decision. It is expected that 
some women in both groups will have become pregnant and we aim to understand the 
way in which the decision aid may have changed their experience of pregnancy and/or 
early parenting. We predict that participating in the study as part of the intervention 
group will have had an impact on the motherhood choice for women with MS and that 
these women will be more certain of their choice as compared to the control group. 
 
5.2 Method 
5.2.1 Participants 
The MS Societies of New South Wales and Victoria (Australia) maintain a data-base 
of members who have agreed to be contacted about research that is endorsed by the 
Society. The participants in this study were initially recruited (as described in chapter 
2), via a large-scale mail-out to all women with MS aged 20 to 40 (n=1410), from this 
 110
database in January 2005. Four-hundred and sixty-one women responded (33% 
response rate), of whom 212 were currently undecided about whether or not to have a 
family. All women who were indecided (except 8 who took part in the qualitative 
phase reported in chapter 3) were invited to enter the RCT, 194 (recruitment rate = 
92%) agreed (see chapter 4). These women were followed-up at 12 months for the 
current study. Unfortunately, only 106 women (55%) completed the follow-up (61 in 
the intervention group and 45 in the control group). Those remaining women who did 
not complete the study, failed to do so due to changed contact details or non-response 
after four failed attempts to make contact. Every woman with whom contact was 
made agreed to participate. 
 
5.2.2 Procedure 
We developed and evaluated in a randomised controlled trial, a decision aid with the 
aim of facilitating an informed choice that is in line with women’s own personal 
values (O’Connor, 1995). In chapter 2, we completed a needs assessment which found 
that a decision aid would be useful for women with MS in making decisions about 
motherhood. In chapters 3 and 4, a preliminary version of the motherhood decision-
aid was piloted amongst 20 women with MS from different stages of decision-
making. These women attended focus groups after receiving a copy of the preliminary 
decision-aid and their feedback was sought. Women found the decision-aid to be 
comprehensive and reported that it covered most of the issues they would find 
relevant. Additional information women thought relevant was incorporated into the 
decision aid at this stage and it was then sent to 15 neurologists who commented on 
its accuracy. The details of the development of the decision aid are presented in 
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chapters 3 and 4. It was developed in accordance with the CREDIBLE criteria 
(O'Connor et al., 2003). 
 
Women allocated to both the control and intervention groups in the randomised 
controlled trial, were telephoned 12 months after their initial participation in the study 
and completed a semi-structured interview over the phone which lasted approximately 
5-20 minutes. Interviews began in July 2006 and finished in March 2007. All women 
were initially asked three questions: (1) whether their participation in the study had 
any effect on their decision; (2) if they had fallen pregnant since participating in the 
study; and (3) to indicate their current position on the motherhood choice continuum 
(outlined below). Interviews with women who had not fallen pregnant were 
terminated at this point, and those who had fallen pregnant (n=22) were asked further 
questions such as what factors influenced their decision, their use of the motherhood 
decision-aid in reading a decision, whether they had any difficulties with their 
pregnancy and the post-natal period, their experiences as a result of having made a 
decision about motherhood, and the support they now require. These interviews lasted 
between 5 and 15 minutes. See Table 5.1 for the full list of questions asked during the 
interviews. The interviews were audio-taped and transcribed. 
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Table 5.1  
Questions asked at follow-up 
1. You may remember when you last participated in this study, you were asked 
to place yourself on a continuum from –5 to 5 where –5 meant you definitely 
will not have children now or in the future and 5 meant you definitely will 
have children now or in the future and 0 meant you were unsure.  Where do 
you see yourself in terms of this decision now? 
2. Did your participation in this study have any effect on your decision? 
3.   Since you began participating in this study have you fallen pregnant? 
4. I wonder whether you could tell me a bit about the factors that influenced your 
decision, those that you weighed up in considering whether or not to have a 
family. 
5. [If in the decision aid group] Did you use the decision aid at all in reaching a 
decision? Do you think that the decision aid might have alerted you to some 
issues that you might not otherwise have considered? 
6. Did you have any difficulties with your pregnancy? Do you think that these 
were related to your MS? 
7. Have there been positive experiences that you have had as a result of deciding 
to start a family? 
8. What sort of support did you need when coming to your decision? Who did 
you talk with about the decision? Was anyone unsupportive of your choice? 
9. What kind of support do you require now as a new mother? Do you think that 
you would need this support regardless of whether you had MS? Is there any 
specific help that you need that you believe that you wouldn’t need if you did 
not have MS? 
10. When you look back now at your decision to become pregnant, is there any 
issue that you would think about differently in making that decision now that 
you have experienced pregnancy and/or motherhood? Are you pleased with 
the decision that you made? Have you had any regrets? 
11. Some women find that the post-natal period is a difficult one for them? What 
was most difficult for you in managing the post-natal period? Do you think 
that it was made more difficulty by the fact that you had MS? In what way? 
Many women find that their mood can be very low at times when trying to 
manage a newborn infant, did you experience any symptoms of post-natal 
depression? What were they? 
12. Have you and your partner thought about whether or not you might have more 
children?  
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5.2.3 Measures 
As part of the follow-up questionnaire, women were asked to rate their certainty about 
having children on a continuum where –5 meant they would definitely not have 
children now or in the future, 0 meant they were unsure, and +5 meant they definitely 
would have children at some stage. Two scores were derived. Firstly, a score from -5 
to +5 was given indicating the degree to which they definitely did want children. In 
addition, we calculated a score from 0-5, to indicate certainty of choice regardless of 
direction. For example, both -5/+5 was scored as 5 to indicate women were certain of 
their decision and 0 meant women were undecided. 
 
5.2.4 Analysis 
We compared completers and drop-outs using independent t-tests to determine 
whether there were any differences between the groups. Regarding the preliminary 
three questions administered to all participants, differences between the intervention 
and control group were assessed using parametric (for continuous variables) and non-
parametric (for dichotomous variables) tests. Two (group: intervention; no 
intervention) x 3 (time: pre; post; follow-up) mixed model ANCOVAs were 
performed on the continuum measures, using SPSS 15 for Windows, to determine the 
effectiveness of the decision aid after 12 months. 
 
Interviews with women in the intervention group were recorded and analysed 
qualitatively in order to identify the main issues. We analysed the dad using Thematic 
analysis which is a method for analysing and reporting themes within data (Braun & 
Clarke, 2006). The process involved a number of phases. Firstly, the interpreters 
familiarized themselves with the depth and breadth of the content via a process of 
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rereading the data. Initial codes were then generated by identifying features of the 
data that could be assessed in a meaningful way. The data was then collated into a 
number of themes.  
 
This study had ethics approval from the University of Sydney Ethics Committee and 
Multiple Sclerosis Australia. 
 
5.3 Results 
5.3.1 Demographics 
One hundred and six women with MS, between the ages of 20 and 40 agreed to 
participate in the study. The mean age of women in the intervention group was 33.22 
(SD=3.69) and 32.93 (SD=4.38) in the control group. The mean age of the women 
who completed the study (to 12-month follow-up) was 31.98 (SD=3.99). There was 
no significant difference in age between the women who completed the study and 
those who did not (F=0.297), p=0.586). Women in the intervention group had been 
diagnosed, on average, 5.55 years ago (SD=3.39) and 6.43 (SD=4.29) in the control 
group. Out of the women who completed the follow-up, the mean time since diagnosis 
was 5.93 years (SD=3.82) and there was no significant difference in time since 
diagnosis between the women who completed the study to follow-up and those who 
did not (F=2.279, p=0.133). Ninety-three percent of women in this study had relapse-
remitting MS, 1% had secondary-progressive MS, another 1% had primary-
progressive MS and 5% were unsure of their MS type.  
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5.3.2 Quantitative Results 
All statistical analyses for this chapter are included as Appendix H. For women’s 
certainty over their motherhood decision, there was a main effect for time at follow-
up, indicating that the passage of time since post-treatment significantly improved the 
certainty of all subjects, regardless of which group they were in 
(F(1,102)=6.464;p=0.013;η²=0.060). There was no main effect for group 
(F(1,102)=1.041;p=0.310;η²=0.010) and no interaction effect (F(1,102)=0.851;p=0.358; 
η²=0.008). With regard to the raw score on the decisional continuum, there was a 
main effect for time since post-treatment, indicating that with time, both groups 
wanted children less (F(1,102)=4.101;p=0.045;η²=0.039). There were no group or 
interaction effects. 
 
At follow-up, significantly more women in the decision aid intervention group 
indicated that their participation in the motherhood choice study had an effect on their 
decision (χ²=14.662, df=1, p=0.000).  
 
Women were also asked whether they had fallen pregnant since participating in the 
study. Seven women in the control group had fallen pregnant and 15 in the 
intervention group. Results indicated that there was no significant difference between 
the groups in the number of women who fell pregnant during the study (χ²=1.410, 
df=1, p=0.235). Those women who had fallen pregnant since first participating in the 
study were asked whether they had experienced any difficulties with their pregnancy 
and if so, whether these were due to their MS. Only eight women had experienced 
difficulties out of 22, including four women who had miscarriages. Three (3/7; 43%) 
of these women who had miscarriages were in the control group, with one woman in 
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the intervention group (1/14; 7%) reporting her third miscarriage since participating in 
the study. The number of miscarriages occurring between the two groups (χ²=3.86, 
df=1, p=0.055) failed to reach significance, although, closely approached significance 
and was in the direction of fewer miscarriages in the intervention groups. Other 
difficulties experienced included extreme fatigue, morning sickness and swelling in 
the hands and feet. With regard to MS-specific difficulties, one woman reported two 
relapses and another took longer than usual to achieve full remission from an attack.  
 
5.3.3 Qualitative Interview 
The qualitative interview highlighted a number of mechanisms of change in decision-
making, which the participants identified as being helpful. The following are the main 
themes that emerged as facilitating decision-making from the qualitative analysis: 
 
5.3.3(a) Provision of Comprehensive Information 
A common response amongst those who used the decision aid was the amount 
of information about pregnancy in MS that it provided, which these women 
had previously found difficult to access. Women reported that previously they 
had tried to seek information from a number of sources but were unaware of 
the sorts of information that they needed and hence were unable to request it. 
Thus the decision aid served as a resource where relevant information could be 
found in a single place. 
 
“It did give me better information about having a baby in MS and I know MS 
won’t be effected in the long term and I will always have the decision aid to 
refer to if I decide to have another child”. 
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“My husband and I are very into researching MS anyway but it was good to 
clarify things. It gave us extra information we hadn’t been able to access 
anywhere. It clarified nothing is for certain, but it was reassuring”. 
 
“The decision aid enhanced my knowledge and I got information that I hadn’t 
thought of. It pointed out medical facts that I’d have to think about or be 
prepared for”. 
 
5.3.3(b) Communication 
An additional effect of the decision aid that women highlighted was the 
facilitation of communication between these women and their partners and 
healthcare professionals. In fact, some women sought information and support 
from other sources where they could discuss options with other women who 
had been in the same situation. 
 
“It helped me to talk to doctors and the case studies were helpful because I 
didn’t know anyone with MS who had kids. I have now spoken and met other 
women with MS and kids and I’ve gone to the MS Society and my doctor so 
it helped me seek out more information”. 
 
“The study prompted me to speak to the MS Society who put me in touch 
with someone else going through the same thing”. 
 
“It was also good for my husband to read and my family because they were 
all worried that I was going to relapse”. 
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5.3.3(c) Utilising support 
Women who had become pregnant highlighted the importance of identifying 
sources of support. All women identified their husbands as their main support. 
Most women also named their close family members, such as their parents or 
siblings, and friends as important figures. Some women spoke of the 
disapproval they had received from some friends or family members. 
 
“My husband had to be happy with the decision. I looked at who would be 
around to help. My parents-in-law are close by and so are friends”. 
 
“My husband, how he will help me, and how me getting sick will impact the 
family”. 
 
“I see a psychologist regularly. My partner and I did research together and 
now he understands and helps me more. My mum has MS also and was very 
unsupportive, so was my grandmother, so we don’t speak now”. 
 
5.3.3(d) Planning for potential difficulties 
The decision aid outlined potentially difficult times, such as the post-natal 
period, which women reported enabled them to prepare and plan for problems. 
Some women had experienced post-natal depression (PND) with previous 
pregnancies and were aware of the risk of this occurring again. They sought 
the help of their healthcare providers and support network in planning how to 
proceed if they developed a relapse of PND. Other sources of potential stress 
were being unable to breastfeed if going straight back on medication was 
necessary and working out a strategy for night time feeds if fatigue became a 
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problem for the mother. This awareness empowered women to feel prepared 
for potential difficulties increased their self-efficacy in being able to cope. 
 
“Since my first pregnancy was more difficult, I had morning sickness 3 times 
a week for 20 weeks, but this time I have begun exercise with a physio to 
help prevent pelvic instability and short term osteoperosis.” 
 
“We have a lot of friends and family on standby and my husband is taking off 
one day per week for the rest of the year.” 
 
“I had PND with my second child and I'm worried it will happen again, it has 
been suggested I go straight onto antidepressants once the baby is born.” 
 
“Every new mum needs support, I go to mother's group and it's not only for 
people with MS. I also had PND after my first two children so I'm aware of 
the counsellor and doctor.” 
 
“I had PND with my first two kids, so I'll seek counselling and go to the GP 
at the hospital if necessary.” 
 
5.3.4 Impact of reaching a decision 
Most women spoke of the gladness and excitement they felt at making a decision to 
start a family. Other positive experiences also included feeling less stressed once the 
process of deciding was over, and more in control. Women also described how the 
process of deciding to start a family had brought them closer to partners and family. 
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“Having the baby has been huge. We’ve had lots of support and happiness from 
others around us”. 
 
“No betaferons for a year! Being a ‘normal’ person, and live a normal life for a 
while”. 
 
“Less stress once the process of deciding is over. It was the only thing talked about 
for three months”. 
 
“I have a stronger bond with my partner, we’re expanding our family and starting a 
new phase of life”. 
 
5.4 Discussion 
The aim of this study was to determine the qualitative impact of the motherhood 
decision-aid twelve months later and to determine the likely mechanisms of change. 
We hypothesised that women in the intervention group would be more certain of their 
choice compared to the control group. As predicted, women in the intervention group 
reported that participating in the study impacted their decision-making process more 
than women in the control group. The short-term results presented in chapter 4 found 
that women in the intervention group did become more certain as compared to the 
control group at post-treatment, however, at 12 month follow-up we found that this 
difference was no longer significant. Rather, after 12 months, both groups had become 
more certain of their choice. Interestingly, however, 12 months later women in both 
groups were less likely to want children. 
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This study also gathered qualitative data from women, who have been participants in 
the motherhood study since January 2005, regarding their experience of going through 
the decision-making process and the impact this study has had on the choices they 
have made regarding motherhood. Women in the intervention group reported the 
benefits of using a motherhood decision aid. They identified that the decision aid gave 
them information they had difficulty accessing and also prompted them to seek out 
more information from their health-care providers. This is important, because, the 
information in the decision aid is targeted towards population level statistics and not 
the individual prognosis and characteristics of the woman. Clearly, if the aid is helpful 
in prompting women to (a) understand what information they need to know; and (b) to 
gain this information through medical resources, then they will be able to access 
individually tailored information. Women also reported that it improved their 
communication with their partners by allowing them to use the decision aid to clarify 
the values of their partner. Again, since child-rearing is a decision that involves both 
parents, the fact that the decision aid is reported to have prompted discussions 
between couples is very encouraging. 
 
In addition to allowing women to gain more information from their immediate 
environment, a number of women sought out opportunities to meet others in similar 
situations in order to gain additional support. Women reported feeling less isolated as 
a result. They reported that it was helpful knowing that there were other women in the 
same position as them. Women who had become pregnant described their personal 
experiences of having decided to have children and how important this has been to 
them and their own value system. Additionally, they were able to express their 
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difficulties, either with parenting or the pregnancy, and to share their insight into how 
this impacted on them personally. 
 
Despite careful attention to the study design and methodology there remain a number 
of limitations that need to be acknowledged in interpreting the results. Firstly, the 
women recruited for this study were all members of the MS Society. It is possible that 
these would be people who are more likely to seek out information regarding their 
health and therefore would be more interested in a decision aid. This may mean that 
this group of women value the decision aid more than other women. 
 
A second limitation is the drop-out rate. At 12-month follow-up only 55% of the 
sample who participated in the randomised controlled trial could be contacted due to 
change of contact details or being unavailable for a phone interview. This may 
indicate a response bias. The women who were unavailable for phone interview may 
have been unavailable for a number of reasons. It is possible that those who dropped 
out of the study were those who felt the study was no longer relevant for them. 
However, there did not appear to be any systematic difference between those who 
completed and those who did not. Further, every single woman who could be 
contacted agreed to participate in the study, suggesting that the women remained 
motivated and interested in the study. Nonetheless, although our initial randomized 
controlled trial was well powered, due to drop-out, power was reduced in the present 
study.  
 
It is possible that some analyses that rely on low base rates are particularly affected by 
the limitations to power. For example, 23% (14/61) of women in the control group 
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became pregnant as compared with 16% in the intervention group (7/45). This 
difference was not significant. Perhaps more importantly, the number of women who 
miscarried in the total sample was very low since there were only 22 pregnancies (ie. 
4 women), however three of these were in the control group (3/7), compared to only 
one (1/14) in the intervention group. This result was unexpected and narrowly failed 
to reach significance on two-tailed tests (p = 0.055). However, this may indicate a 
difference between groups which, if confirmed, would be important. The only 
plausible reason for a difference between groups would be due to the effect of 
medications in the pre-conception or early pregnancy period. That is, it is possible that 
women in the control group did not realise that some medications needed to be 
stopped prior to conception and this may have affected their ability to carry the 
pregnancy to term. While this is speculative and the finding did not reach significance  
and hence may be due to chance, future research should investigate the effects of MS 
medications on early pregnancy and pre-conception health. 
 
In the long-term, women from both the intervention and control groups became less 
conflicted in their decision over time, however, those in the intervention group 
became more certain more quickly. Further, those in the intervention group 
maintained their certainty in the longer term. Since all women in the study 
volunteered, it remains a possibility that participation in a study about motherhood in 
MS triggered women to begin thinking about their options and seek out information, 
regardless of which group they were allocated to. Therefore it is likely that this 
process may, at least partially, explain why women in the control group became more 
certain over time of their choices also. 
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These limitations not withstanding, this is the first study to develop and validate, 
according to the C.R.E.D.I.B.L.E. criteria (O’Connor et al, 2003), a decision-aid to 
help women with MS make family-planning choices. This follow-up study provides 
additional support for the value of a decision-making tool to assist women with MS in 
making decisions about motherhood. Specifically, women found the decision aid to be 
useful in providing information, facilitating communication, helping to foster support 
in their environments and to plan for difficult periods. This decision-aid is currently 
being utilised by MS Australia and is distributed to women who have questions about 
child-bearing and child-rearing. Thus the motherhood decision-aid provides a 
relatively simple, potentially low cost intervention that can enhance women’s ability 
to make informed decisions about motherhood in the face of a chronic illness, such as 
MS. Moreover, it seems that educating health-care professionals in these issues may 
also have positive consequences for women with MS who are making family-planning 
choices. This also represents a tool that could be adapted to suit other medical 
conditions where reproductive decision-making may be complicated, such as Lupus, 
HIV or whether to go through or continue IVF. Our results suggest that this would be 
an important direction for future research to take.  
 
 
 
CHAPTER 6: SUMMARY AND CONCLUSIONS 
 
6.1 Summary 
The aim of this thesis was to develop and evaluate a decision aid for women with MS 
in making decisions about motherhood. The study was guided by the 
C.R.E.D.I.B.L.E. criteria, developed by the Cochrane Systematic Review of Patient 
Decision Aids (O’Connor et al, 2003) and consisted of four, related studies.  
 
The first study was a needs assessment, which aimed to determine the need for a 
decision-aid for women with MS in New South Wales and Victoria. It was 
hypothesised that the motherhood decision would have relevance to a large percentage 
of women with MS between the ages of 20 – 40 and this was confirmed in chapter 2.  
 
The second study was a qualitative study that sought to explore the themes associated 
with motherhood that are relevant for a heterogenous sample of women with differing 
views regarding the motherhood choice. It was expected that by representing the 
views of women who have yet to decide or have decided against having children, new 
themes would emerge in addition to themes already represented in the literature from 
pregnant women with MS. It was found that there were some notable differences in 
women’s concerns depending on their stage of decision-making (see chapter 3). At 
this point, a review of the draft materials was also conducted by both experts and 
consumers (reported in chapter 4). The preliminary decision aid was found to be 
clearly written, accessible, balanced and relevant by potential consumers and accurate 
by experts.  
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Minor additions were made to the decision aid based on feedback and individualised 
personal stories based on the experiences of group members were included. A 
randomised controlled trial was carried out to test the efficacy of the final decision 
aid. It was hypothesised that the decision aid would increase knowledge about 
pregnancy and child rearing in MS, reduce decisional conflict and increase decisional 
self-efficacy. This trial also aimed to ensure that the decision aid was free from any 
adverse effects on psychopathology. Increases in anxiety or depression were not 
expected in women with MS as a result of the decision aid. All hypotheses were 
confirmed (see chapter 4). 
 
The final study was a follow-up phase conducted 12 months after participants’ initial 
involvement in the research. The aim of this final phase was to assess the status of 
women’s motherhood decisions since post-intervention and to determine whether the 
decision aid impacted on the way in which women approached their decision. It was 
also expected that some women would have become pregnant and those women who 
became pregnant were asked about what impacted on their decision-making process 
and their experiences of being pregnant, regardless of whether they were in the 
treatment or control group. It was also anticipated that receiving the decision aid may 
have had an impact on the motherhood choice for women with MS and that women 
would remain more certain of their choice compared to women in the control group. 
The results showed that over time, women in the intervention group did maintain their 
certainty, but women in the control group also became more certain of their choice. At 
follow-up the difference in certainty was no longer significant between the two 
groups. However, women did report that the intervention was useful in (a) providing 
access to information previously unavailable, (b) facilitating communication between 
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women, their partners and health care professionals, (c) aiding them in considering 
and utilising their networks of support, and (d) preparing them for potential 
difficulties. 
 
6.2 Methodological Problems 
Despite careful attention to the design and methodology of the study, there were some 
limitations that should be borne in mind in interpreting these findings. Firstly, the 
generalizability of the results may be limited. The initial recruitment process of the 
study consisted of a mail-out to all female members of the MS Society of NSW and 
VIC who were aged between 20 and 40 (1410 women). The initial recruitment rate 
was modest (33%) and may potentially indicate a response bias. That is, that this issue 
was more prominent for those women who did respond and therefore, participants 
may not be representative of the population as a whole. In subsequent studies this 
response rate could be improved by sending a reminder letter or conducting a 
telephone reminder (Silva, Smith & Bammer, 2002). However, since ethical 
requirements mean that the MS Societies had to send the information and we were 
unable to access names due to privacy laws, we were unable to organize to follow up 
these participants in order to increase the response rate. This is most problematic in 
chapter 2, which aimed to document the need for such a decision aid and as a result 
the need may be over-estimated. However, 46% of the sample did feel currently 
undecided and hence the motherhood decision was still relevant to at least 15% of the 
possible sample, that is 212/1410 representing a significant need. With regard to the 
qualitative study presented in chapter 3, generalizability is not an issue since it is the 
depth of the individual’s experience that is important to capture in qualitative 
research. Further, clearly in clinical practice one would administer the decision aid 
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only to those who were currently considering motherhood. Therefore it would be 
these women who would be expected to receive the intervention in clinical practice, 
as they would be most likely to seek information about pregnancy in MS and other 
supplementary material regarding MS and motherhood. As such it is likely that 
women similar to those who took part in the study will be offered the decision aid in 
the future Hence, we can be reasonably confident that the decision aid will be 
effective for those women requesting information regarding MS and pregnancy based 
on the results of chapers 4 and 5. 
 
A second limitation was the failure of randomization to equalize the groups on all 
potential confounders in the randomized controlled trial. The intervention and control 
groups were significantly different on one measure, that being whether their decision 
to have children was complicated by the diagnosis of MS. Results showed that 
significantly more women in the intervention group found their MS diagnosis 
complicated their decision of whether to have children than women in the control 
group. However, in all other respects, randomization was effective and the groups had 
no significant differences on any of the demographic variables. That is, there were no 
differences for age, gender, type of MS, illness duration, and whether they wanted to 
have children before their diagnosis or any of the outcome variables. Given the 
number of outcomes where differences were not observed in a study that had good 
power to detect even small differences between groups, this suggests that the groups 
were nonetheless relatively well matched and the one difference observed would have 
been expected solely due to chance. Nonetheless, in order to be conservative in the 
analyses in chapter 4, whether MS was felt to complicate the decision was controlled 
for. To ensure that these results were robust with and without this covariate, the data 
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was analysed using ANOVA also and there were no changes in the pattern of 
responses. Hence, it is unlikely that this difference effected results.  
 
The intervention comprised of the decision aid as well as a follow-up telephone call to 
ensure that participants had read the decision aid, understood it and were not upset by 
it. However, this also provided the opportunity to clarify any issues that women had 
after reading the decision aid. This raises the question of whether the significant 
results achieved in the randomised controlled trial of the decision aid, were from the 
decision aid itself, or from the discussion with an intern clinical psychologist 
following receipt of the decision aid. This procedure was chosen because the decision 
aid should be given in combination with a personal discussion with a health 
professional and it was the intent of the research team to mirror how the decision aid 
would best be used in clinical practice. Further, it should be noted that during the 
telephone discussions, none of the women reported feeling any distress as a result of 
receiving the decision aid. Thus, there was no need for the intern clinical psychologist 
to utilise any therapeutic techniques that may have influenced the participants in any 
way. Women tended to discuss their thoughts regarding the decision aid and how it 
alerted them to issues they may not have otherwise considered. They also spoke about 
their own situations and how they felt the information presented in the booklet was 
relevant to them. The length of the discussions was relatively short (5-20 minutes), 
which likely reflects a similar time that would be available in a medical consultation. 
Nonetheless, the fact that the discussion contributes to the efficacy of the decision aid 
cannot be excluded. 
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While results in the randomised controlled trial indicated that there were no adverse 
effects of the decision aid on depression or anxiety, this does not rule out the 
possibility that some individuals may have responded adversely. The outcome for 
people who failed to complete post-assessment measures remains unknown. However, 
women were provided with a phone number to contact if they felt distressed at any 
point from their participation in the study and no one accessed this number. 
 
The maintenance of the gains achieved from the decision aid remains in question. 
Although women reported the decision aid to be useful, there was not a significant 
difference on the only measure re-administered. Ideally, all the measures administered 
in chapter 4 could have been re-administered at follow-up. While this may have 
confirmed the long-term efficacy of the decision aid more clearly, we decided against 
this for two main reasons. Firstly, the drop-out rate was already relatively high and it 
was feared that with greater demands, an increased attrition might be expected. 
Secondly, we wanted to explore outcomes in a qualitative fashion because we were 
particularly interested in the mechanisms of the decision aid, which was more suited 
to a qualitative methodology. However, as a result we cannot conclude that the 
decision aid has long term effects. This raises the issue of the timing of intervention or 
when would be most effective to provide women with the decision aid. However, with 
regard to ecological validity, this study was an efficacy study and not an effectiveness 
study and further research is needed to determine the decision aid’s effectiveness in 
clinical practice. 
 
Another possible issue may be that it appeared as though the decision aid was directed 
at women only. Obviously it is ideal to have both the mother and father involved in 
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the preparation for childbearing and for the childrearing itself. Therefore, particularly 
where there is the presence of a chronic illness such as MS, it would seem that it is 
even more necessary for partners of these women to be aware of the relevant issues so 
that they may be involved in the decision-making process. The decision aid was 
designed in such a way as to present information about the physical changes that 
occur with MS and when pregnancy occurs in a woman with MS. It also presented 
information about what women may experience psychologically, from pre-conception 
to the post-natal period. This included considering those people around them, such as 
partners and other family members and there were exercises in the decision aid to 
guide women through this process. Further, during the conversations with women in 
the randomized controlled trial, as well as at follow-up, women commented on how 
the decision aid actually helped them in discussing the relevant issues with their 
partners. 
 
Secondly, some women were not in a relationship at the time of the study, but for 
them the decision aid was still helpful in enabling them to understand the facts so that 
when they are ready to have children they have a resource available and know how to 
approach health professionals for advice. The decision aid, therefore, is a tool for use 
by both parents in helping them become aware of the relevant facts, as well as helping 
them plan for any difficult times that may arise from MS. It also serves as a useful 
source of information for any woman with MS when learning about their illness 
generally, in preparation for future family-planning. Nevertheless, future research 
should explore the information needs of partners of women with MS, and ways in 
which the decision aid might be modified to include them more.  
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6.3 Strengths 
Despite these limitations this study also has a number of strengths. The decision aid 
was developed according to the already well-established C.R.E.D.I.B.L.E. criteria, 
developed by the Cochrane Systematic Review of Patient Decision Aids (O’Connor et 
al, 2003) and the new International Patient Decision Aid Standards (Elwyn et al, 
2006). Following the CREDIBLE criteria, the decision aid was Competently 
developed with the inclusion of components that promote quality decision-making 
and was developed by researchers with appropriate qualifications. Further, a needs 
assessment was conducted to determine whether this would be a useful resource. Once 
established that a decision-making took would be useful to women with MS for the 
motherhood decision, a draft was written and a pilot study undertaken to gather 
further information to improve the decision aid and gain feedback from the potential 
users. The draft was also sent to neurologists who were given an opportunity to write 
back with their feedback on its accuracy. The data in the decision aid is Recently 
updated, such that it includes information that is based on evidence available within 
the past two years. Of course the decision would need to be updated every two years 
in order to remain accurate. The decision aid is Evidence-based in that the information 
provided is based on scientific studies following a thorough literature search. There 
were no conflicts of Interest and the decision aid had Balanced presentation of 
options, benefits and harms and this was confirmed by women during the pilot study 
and the results of the RCT where women in the decision-aid group were not pushed in 
one or another direction. The final criteria is that the decision aid is Efficacious at 
improving decision-making. This criteria was met as its evaluation included a large 
randomised controlled trial which demonstrated that the decision aid is effective in 
improving knowledge, reducing decisional conflict and increasing decisional self-
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efficacy. Further, it was found to be free of adverse effects, such as depression and 
anxiety. 
 
The decision aid developed in this study is unique in that it involves a lifestyle choice 
that is complicated by a medical illness, rather than a choice to either have or forego a 
particular intervention (e.g. screening in prostate cancer) (Volk & Spann, 2000), or a 
choice between two particular treatments (e.g. mastectomy versus lumpectomy in 
early breast cancer). This study has shown that decision aids may be useful for 
lifestyle choices, and thus other decision aids may be developed to empower people 
with the ability to get information for other lifestyle choices, such as in vitro 
fertilisation (IVF). A final strength of this study is that the MS Society of NSW is 
now using the developed decision aid as an evidence-based tool, thus it has been 
directly translated into practice. 
 
6.4 Importance of the Motherhood Decision in Women with MS 
The first study in this thesis was a needs assessment aiming to determine the 
proportion of women with MS in New South Wales and Victoria for whom the 
motherhood decision was relevant. The Cochrane Systematic Review of Patient 
Decision Aids (O’Connor et al, 2003) developed the C.R.E.D.I.B.L.E. criteria to 
guide the development of decision aids and advises that a needs assessment be 
undertaken in order for the decision aid to be competently developed. A second aim of 
this study was to identify subjects for the later stages of this research project. The 
main findings are summarized below. 
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The majority of women (80%) in this study had been diagnosed with relapse-remitting 
MS, and of these, 50% were undecided about their motherhood choice. In contrast, 
only 4% of women had been diagnosed with secondary-progressive MS and of these, 
19% were undecided about their motherhood choice. This result is not surprising 
given that secondary-progressive MS begins its course with a relapse-remitting 
pattern and as this study targeted women between the ages of 20 and 40, intuitively it 
would seem that women with secondary-progressive MS would represent an older 
sample of women, and hence been excluded at the initial mail-out stage. This 
assumption was confirmed in this study, as the women with secondary-progressive 
MS were older than those with relapse-remitting MS by an average of three years. 
Further, in chapter 5, it was confirmed that even over a period of only one year 
women do become less inclined to want children. 
 
Results showed that out of the 1410 women who were sent the initial mail-out inviting 
them to take part in the study, 461 (33%) women responded and of those, 212 (46%) 
were currently undecided about their motherhood choice. Another 158 (34%) women 
indicated that they already had their children and did not want to have anymore. It is 
unknown whether women in this group received their MS diagnosis before or after 
they had their children, however it is likely that a significant proportion of these 
women were making their decisions about motherhood after having received their 
diagnosis. Thus, the motherhood decision would have been a significant process that 
they had previously been through.  
 
According to Access Economics (2005), which draws on data from the Australian MS 
Longitudinal Study (AMSLS), over 16 000 people in Australia have MS. It also 
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indicates that of this number, 74%, (ie 11, 200) are women. The National MS Society 
Sourcebook (2005) estimates that in the United States of America, approximately 400 
000 people have been diagnoses with MS, and as in Australia, women are two to three 
times more likely to be affected than men. Therefore there are 280 000 women in the 
US and 11 200 women in Australia with MS. Even if we were to assume that the 
motherhood decision was irrelevant to those 949 (67%) women who did not respond 
to the initial mail-out and only to the 15% of the total sample who endorsed 
uncertainty currently, the DA would still be relevant to 4200 women in the US and 
1680 women in Australia. These numbers are likely to be an underestimate since there 
are likely to be many reasons for the 949 women who failed to respond, not all of 
which are due to the irrelevance of the topic.  
 
6.5 Issues Relating to Women in Decision-Making 
The second study in this thesis was a pilot phase where a preliminary decision aid was 
drafted and sent to 20 women with MS in the four stages of the motherhood decision. 
These stages were those who had no children, those who had children and were 
unsure about having more, those who already had children and did not want to have 
anymore, and those who had decided against having children. Focus groups were run 
with an aim to capture the main concerns of women in each group, and those women 
who had already been through this decision-making process were able to share their 
experiences and insight with those who had not. These results were presented in 
chapter 2. 
 
For women who were undecided about their choice of whether to start or enlarge their 
families, there were common concerns about their own health and well-being. A new 
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theme that emerged was that women were hesitant about having children at a time 
when their own illness was giving them trouble and that many women did not want to 
have children until they had experienced a period of stability in their illness. Their 
rationale was that they needed to be as sure as they could that they would be able to 
cope with the demands of looking after a baby, especially given that the post-natal 
period has been shown to be a time of increased relapse rates (Cook, Troiano, Bansil, 
& Dowling, 1994).  
 
Another common concern found in this study amongst women who were undecided 
was the well-being of the child. Women who had no children were particularly 
concerned that the child may end up having to care for their mother and they were 
adamant that they did not want to have children if this would occur due to their beliefs 
that this would be an unfair situation for any child. Worries about coping with 
parenting itself were very strong amongst women in this group also. Many felt that it 
would be wrong to have to rely on other people, even if only in times of an 
exacerbation, and that if they could not handle the task for the majority of the time 
then they should not be taking it on at all.  
 
Women from all groups commented that they felt increased pressure when it came to 
the timing of this decision. Some women who had had children spoke in retrospect of 
the advice they had been given that they should have children sooner rather than later 
and this sometimes posed dilemmas in relationships that perhaps were not ready for 
children. Women who had no children were worried that they were getting older and 
that it may be more difficult in the future to fall pregnant, which made them feel 
stressed that they should be having children now. Finally, women spoke about not 
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wanting to miss the experience of parenting, and this was supported by those who had 
had children, in the sense that having children brought a sense of meaning to them and 
they valued their roles as mothers. 
 
During this phase, the decision aid was also sent to 15 neurologists who were given an 
opportunity to respond with their feedback on the decision aid’s accuracy. The 
decision aid was very well received by the neurologists, and positive feedback was 
gained. They reported that it was an easy to read resource that contained the most 
relevant information for women with MS and that it would be a valuable tool to use in 
conjunction with their consultation. Indeed, we were approached by one neurologist 
prior to completing the study to see whether he could get a copy to use with his 
patients. Additionally, the women in the focus groups gave feedback on the 
preliminary decision aid. They reported that they found the resource very accessible 
and helpful in that it collated information in one place. Many women who had had 
children already spoke about how difficult it was to access this kind of information 
when they were going through their motherhood choice, and that a booklet such as 
this would have been a valuable thing to have had at the time. 
 
The results of this phase are significant because they indicate that women with MS are 
not only unsure of the relevant issues when making family-planning choices, but that 
they have difficulty accessing this sort of information. Further, communication 
between health care professionals and these patients was highlighted as an area that 
needs improvement. Women in this pilot study found the preliminary decision aid to 
be a valuable resource because it collated the information that they would need to 
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seek out for themselves and for many it was useful as a tool to guide discussions 
between themselves and their health care professionals and partners. 
 
6.6 Intervention 
The third study in this thesis aimed to test the efficacy of the motherhood decision aid, 
by determining if it increased knowledge about pregnancy in MS, increased decisional 
self-efficacy, decreased decisional conflict, and made women more certain of their 
choice. It also aimed to ensure that the decision aid was unbiased towards any 
particular view and that it did not increase depression or anxiety amongst women 
allocated to either condition. The main findings are summarised below. 
 
Women in the decision aid intervention group were significantly more certain of their 
choice than those in the control group at post intervention. Furthermore, there was no 
systematic change with regard to wanting a child or not wanting a child in either of 
the two groups, thus indicating that the decision aid did, indeed provide women with 
an unbiased view of all the relevant information. It was also confirmed that the 
decision aid increased decisional self-efficacy amongst women in the intervention 
group, and reduced decisional conflict. Both groups had a significant increase in their 
knowledge about pregnancy in MS at the post-intervention stage; however the 
increase in the intervention group was significantly greater than the change in the 
control group. Finally, levels of anxiety and depression remained unaffected with no 
significant main or interaction effects. 
 
Knowledge about pregnancy in MS increased amongst women in the intervention 
group as compared to the control group. It is highly likely that merely participating in 
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the study itself may have triggered questions amongst participants motivating them to 
seek information about the issues involved in their motherhood decision. However, 
despite this likelihood, the interaction effect between group and time was highly 
significant. 
  
6.7 Follow-Up 
The mechanisms for change within the decision aid lie in several areas that would 
account for the significant improvement in decisional conflict and self-efficacy in the 
intervention group. Firstly, support has been identified as a key consideration for 
women with MS when making this choice (McNary, 1999; Smeltzer, 1994, 2002) and 
this decision aid required women to consider their sources of support should they fall 
pregnant. They were specifically asked to consider what each person could do to 
support them not just after the arrival of a new baby, but also in making the decision 
as well as in the future. Rather than making assumptions, women were able to gain a 
clear picture of what constituted support for each person whom they considered 
supportive.   
 
Secondly, in participating in the decision aid intervention, a large proportion of this 
group of women ended up sharing decision-making with their health team. In 
accordance with the shared decision-making model, the patient received all necessary 
information regarding risks and benefits and alternative options available (Braddock, 
Edwards, Hasenberg, Laidley, & Levinson, 1999; Ford, Schofield, & Hope, 2003; 
Ruland & Bakken, 2002). The patient then also had the opportunity to communicate 
their values and preferences to their healthcare professional. In this case, 
communication between the individual and her partner or significant others as well as 
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family was encouraged. Additionally, shortly after receiving the decision aid, each 
woman was contacted by an intern clinical psychologist and given the opportunity to 
discuss any concerns or issues raised. The motherhood decision aid was designed with 
the intent of being used in conjunction with open communication between the 
individual with MS and her healthcare team. When women were contacted for 
discussion, many reported that they had read the information and subsequently 
decided to discuss their options further with their neurologist or GP. 
 
Thirdly, the motherhood decision covers a range of issues, such as how many children 
to have and how much time to leave between children. Some people do not consider 
the additional decisions that are incorporated within the motherhood choice and the 
decision aid brings attention to these decisions as an additional way of enabling 
participants to plan for their futures. Women were asked to list the pros and cons of 
not having children, having a smaller family than they had originally planned, leaving 
a larger gap between children and proceeding as they had always intended, regardless 
of their medical condition. This method allowed women to consider their own 
personal values associated with each pro and con and rate how important this was to 
them.  
 
A major concern for women was the possibility of passing on their MS to their baby. 
Despite research showing the small chance of this occurring, and the advice given to 
women who seek information about this possibility from their neurologists, it remains 
one of the main concerns in women with MS considering motherhood. The decision 
aid addressed by issue by means of a visual aid enabling the participants to compare 
the probability of inheriting MS if neither, one or both parents has it. Research has 
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suggested that the use of visual aids facilitates communication and assists with 
information-processing (Ahmed & Boisvert, 2003). Therefore this method directly 
addressed this concern for women and highlighted the realistic likelihood of this 
outcome in such a way that is easily comprehended. 
 
6.8 Future Research 
There is a need for future research to explore the relationship between stated 
preferences and actual behaviour to determine the effects of the decision aid in the 
longer term. Most decision aids refer to decisions that are taken immediately (Elwyn 
et al, 2006). Such decisions are usually one-off and when a decision is made, the 
treatment is pursued. Hence, there are few follow-up studies of decision aids, since 
the decision aid aims to affect the current decision. However, the motherhood choice 
is ongoing and can be visited on numerous occasions. A number of follow-up studies, 
for example at two, five and ten years, would be useful for the purpose of discovering 
whether these women go on to have children or not. However, given the difficulty in 
accessing women in this study, drop-out is likely to be a problem. 
 
In this study, women were asked during the pilot phase, the telephone conversations 
in the randomized controlled trial and at follow-up, about their hesitations in having 
children and what their associated concerns were. At follow-up, many women 
reported that they no longer saw their decision to have children as risky, and that the 
decision aid helped them to gain perspective. This idea of perceived risk is an 
important issue as it illustrates the importance of people having an accurate 
understanding of the issues related to their illness and highlights the need for 
consultation with health professionals about the relevant issues relating to specific 
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lifestyle choices. It would be useful for future research to look into the issue of 
perceived risk to determine if, after using the decision aid, women still attach the 
same level of risk to going through with pregnancy and child-rearing. 
 
While this study has developed an evidence-based decision aid for women with MS 
that has been directly translated into practice, it also has wider applicability. Future 
research is needed to test the efficacy of decision aids in other areas. Systemic Lupus 
Erythematosus (SLE or Lupus) is another chronic autoimmune disease that is more 
prevalent in women than men (9:1 ratio) (Goodman, Morrissey, Graham & 
Bossingham, 2005). Like MS, it too is progressive in nature and treated 
symptomatically with corticosteroids and immunisuppressants, though it is more 
likely than MS to be associated with early mortality. Research has found that patients 
with Lupus experience similar psychological symptoms to those with MS, such as 
depression, anxiety and adjustment problems and also experience feelings of 
uncertainty and fear of death (Goodman, Morrissey, Graham, & Bossingham, 2005). 
Lupus also tends to onset prior to age 40 when child-bearing decisions are usually 
made. Since there is an established need for a decision aid for women with MS in 
making family-planning choices, it would seem likely that a similar need would exist 
for other chronic illnesses that onset relatively early in women, such as Lupus, where 
family-planning choices are likely to be compromised.  
 
Another example is infertility, which is a medical condition that affects the ability of 
some couples to conceive (Peterson, Newton, Rosen & Schulman, 2006). One 
treatment option is in vitro fertilization (IVF) (Hjelmstedt, Widstrom & Collins, 
2006). However, IVF is not without side-effects and disappointments and up to 40% 
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of couples fail to conceive (Eugster & Vingerhoets, 1999). The results of this study 
suggest that such complicated lifestyle choices can be adequately addressed in a 
decision aid and future research could develop a resource for couples contemplating 
IVF.  
 
This decision aid provides a direct model for other conditions where reproductive 
choices may be complicated (e.g. Lupus, infertility, HIV, etc). Clearly, the 
educational components of the decision aid will be different, but the sections that 
relate to values and different options could form the basis of future applications. 
Clearly, information will need to be targeted to the particular illness. For example in 
Lupus the risk of miscarriage is greater than in healthy people. However, the issues of 
values and expectations are similar across illnesses. Obviously the efficacy of 
modified versions would need to be assessed. 
 
There also exist broader implications for the development of the motherhood decision 
aid. For example, it represents a tool that may be adapted to suit other illnesses, for 
example HIV/AIDS or Sickle Cell Disease. With these illnesses there is a higher risk 
of genetic transmission (Asgharian, Anie, & Berger, 2003; Heard, Sitta, & Lert, 2007) 
than with MS so while we cannot generalize from these findings as to whether the 
diagnosis creates ambiguity regarding reproductive choices, it is likely that providing 
these patients with information to enable informed decision-making, as well as to 
facilitate communication between patients, their carers and their treating team would 
be of significant benefit.  
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6.9 Clinical Implications 
The development of a decision aid for women with MS in helping them to make 
decisions about motherhood, raises several considerations for its use clinically. 
Firstly, there is the question of when the right time is to administer the decision aid. 
Given that the majority of women are diagnosed with MS between the ages of 20 and 
40, it may be valuable to provide this resource to women when they are newly 
diagnosed, allowing them to be already equipped with information when they come to 
making family-planning choices. However, given that a diagnosis of MS has been 
found to be associated with depression, anxiety and symptoms of post-traumatic stress 
disorder (Beatty, 1993; Chalfant, Bryant, & Fulcher, 2004; Feinstein, 2002), raising 
the issue of motherhood may, in reality, be an additional stressor for women at this 
already distressing time. It could, for example, increase women’s perception that this 
is a decision with a pressure of time.  
 
Further, this study has assessed efficacy and not effectiveness, therefore whether 
health care professionals would need additional training to administer it is an 
empirical question. Linked to this issue is the question of who would be an 
appropriate health care professional to administer the decision aid. Given that a large 
number of women in this study took the decision aid to their general practitioners or 
neurologists, it would seem that they would be appropriate health care providers to 
introduce patients to this resource. What may be even more helpful would be for 
general practitioners and neurologists to liaise with clinical psychologists and clinical 
nurse consultants who could support the patient with some of the more emotional 
aspects of the decision, such as who they would be able to turn to for support, as well 
as for facilitating discussions between these women and their partners and families. 
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An issue of relevance raised in this study is the pressure women have felt, either from 
their health care providers, partners or themselves, in coming to a decision. This is 
particularly significant given the current trend of delaying motherhood by having 
babies later and the related issue of conception sometimes taking up to a year 
(Chapman, Driscoll, & Jones, 2006). For example, at age 40, it takes on average 9-10 
months for a couple to conceive in comparison to 4 months for women at age 30 
(Sydney IVF, 2007). This is particularly difficult for women with MS needing to be 
without medication while contemplating pregnancy, that is, trying to conceive. 
Intuitively it would be stressful for any woman trying to establish their career and 
financial security to receive a diagnosis of an illness which may cause them to feel 
like they must have children sooner than they would prefer out of fear of it being 
more difficult later or because of the possibility of increased disability. This decision 
aid would be helpful in this instance because it could help to create realistic 
expectations of outcomes regarding future disability as well as assisting women to 
plan with their partners for times of difficulty. Additionally, providing information to 
women that educates them about the impacts of MS on pregnancy and vice versa 
should also ease some distress because it allows them to have a clearer picture of what 
to expect. 
 
6.10 Conclusion 
In conclusion, this thesis has developed and evaluated a decision aid for women with 
MS to help them make decisions about motherhood. This study found that a decision 
aid is needed for these women, and when it was trialed, it was found to be effective 
without adverse effects. That is, the decision aid reduced decisional conflict, increased 
decisional self-efficacy and knowledge, made women more certain of their choice and 
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did not bias them towards a particular choice. Further, the decision aid did not cause 
increased levels of anxiety or depression. This decision aid therefore, represents a 
useful tool that not only helps women obtain relevant information but also equips 
them with a resource that guides discussions with their health care providers and aids 
communication with their partners. While evidence of the long term impact is not 
conclusive, the motherhood decision aid has been put into practice as an available 
resource used by the MS Society of New South Wales, Australia. It is the first 
decision aid of this kind, and may be easily adapted by other countries.  
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APPENDIX A: 
ETHICAL APPROVAL 
 
Department of Psychology 
The University of Sydney, N.S.W. 2006 
  
 
PARTICIPANT INFORMATION SHEET 
“The Motherhood Decision: Designing a Decision Aid for Women with MS” 
 
This information sheet has been prepared to provide you with information about 
the study you have been asked to take part in. This study aims to develop a 
decision-making aid with the function of assisting women with MS in making their 
decision of whether to become a parent. 
 
Researchers at the University of Sydney are interested in how the use of a 
decision aid will provide information that increases knowledge about pregnancy 
in MS as well as facilitating decision-making in women with MS who are in the 
process of deciding whether or not to have a child. Research suggests that 
women with MS are often faced with decisional conflict regarding the motherhood 
decision as the already physically and emotionally demanding time of pregnancy 
and childbearing may be exacerbated by a potentially disabling illness. Women 
with MS considering pregnancy and childrearing are faced with an exaggerated 
experience of the already stressful concerns associated with bringing a child into the 
world. However at this time little is known about how such distress and conflict 
may be alleviated with the provision of an aid to assist woman in engaging in the 
decision making process.  
 
If you agree to take part in this study, you will be asked to attend a one hour 
focus group at the MS Society in order to give feedback on the decision aid and 
provide some information on your experiences. We are interested in the views of 
women who have already contemplated this decision, regardless of whether they 
chose to have children or not, and of women who are currently making this 
decision.. We have developed a decision aid to help women currently making this 
decision and will ask you to read through the decision aid and complete a brief 
questionnaire giving us your opinion about it, which will take approximately five 
minutes. We will also ask you some questions in the group about your own 
experiences of this decision and ask you to share any other information that you 
think might be helpful to women in this situation. All information collected during 
this study is strictly confidential, except as required by law. The information will 
not be stored with your name, but will be stored against a number. Only the 
investigators for this project will have access to this information.  
 
We hope that you will agree to take part in this study, but you do not have to. 
Your participation is completely voluntary. If you do agree to take part, but later 
change your mind you may withdraw at any time. Whatever you decide about the 
study, your decision will not in any way affect you or your future treatment at the 
MS Society, which will continue exactly as before. We will provide you with a 
copy of this information sheet if you agree to take part. 
 
If you have any questions about the study, please do not hesitate to ask Ms. 
Martine Sponiar, the intern clinical psychologist collecting information from 
participants. She can be contacted on (02) 9351 5952. For further information, 
you can contact Dr. Louise Sharpe on (02) 9351 4558 who is the chief 
investigator for this project.  
 
 
 
Department of Psychology 
The University of Sydney, N.S.W. 2006 
  
 
 
CONSENT FORM 
 
 
“The Motherhood Decision: Developing a Decision Aid for Women with MS” 
 
 
 
 
I, ……………………………………………………, have been told about this study and 
have been allowed the opportunity to ask questions about it. I understand what is 
involved in taking part and I agree to do so. 
 
 
Signed: ……………………………………………  Date:        /      / 
 Name: …………………………………………… 
 
 
Witness: …………………………………………  Date:      /      / 
Name: ……………………………………………   
 
If you have any concerns or complaints about your involvement in the 
study, please contact the Manager of the Human Research Ethics 
Committee, University of Sydney on (02) 9351 4811. 
 
Department of Psychology 
The University of Sydney, N.S.W. 2006 
  
 
PARTICIPANT INFORMATION SHEET 
“The Motherhood Decision: Designing a Decision Aid for Women with MS” 
 
This information sheet has been prepared to provide you with information about 
the study you have been asked to take part in. This study aims to develop a 
decision-making aid with the function of assisting women with MS in making their 
decision of whether to become a parent. 
 
Researchers at the University of Sydney are interested in how the use of a 
decision aid will provide information that increases knowledge about pregnancy 
in MS as well as facilitating decision-making in women with MS who are in the 
process of deciding whether or not to have a child. Research suggests that 
women with MS are often faced with decisional conflict regarding the motherhood 
decision as the already physically and emotionally demanding time of pregnancy 
and childbearing may be exacerbated by a potentially disabling illness. Women 
with MS considering pregnancy and childrearing are faced with an exaggerated 
experience of the already stressful concerns associated with bringing a child into 
the world. However at this time little is known about how such distress and 
conflict may be alleviated with the provision of an aid to assist woman in 
engaging in the decision making process.  
 
If you agree to take part in this study, you will be asked to fill out a number of 
questionnaires related to your own feelings and beliefs, which will take 
approximately forty minutes. You will be asked to complete these same 
questionnaires again after one month and twelve months. With your permission, 
the researchers will contact your treating neurologist or GP to confirm the type of 
MS that you have. We will also ask you whether you would be happy for the 
researchers to contact you in the future to see whether you did start a family or 
not. 
 
After you have completed the questionnaires, you will be randomly assigned (like 
the toss of a coin) to one of two groups. One group will be given a copy of the 
Motherhood Decision Aid to read through. If you are allocated to this group, you 
will receive a telephone call from Martine Sponiar to talk through that information 
and clarify anything that is unclear. This telephone conversation would take no 
more than half an hour. The other group will not receive the decision aid, but will 
be asked to complete the questionnaires. All information collected during this 
study is confidential, except as is required by law. The information will not be 
stored with your name, but will be stored against a number. Only the 
investigators for this project will have access to this information.  
 
We hope that you will agree to take part in this study, but you do not have to. 
Your participation is completely voluntary. If you do agree to take part, but later 
change your mind you may withdraw at any time. Whatever you decide about the 
study, your decision will not in any way affect you or your future treatment at the 
MS Society, which will continue exactly as before. We will provide you with a 
copy of this information sheet if you agree to take part. 
 
If you have any questions about the study, please do not hesitate to ask Ms. 
Martine Sponiar, the intern clinical psychologist collecting information from 
participants. She can be contacted on (02) 9351 5952. For further information, 
you can contact Dr. Louise Sharpe on (02) 9351 4558 who is the chief 
investigator for this project.  
 
If you have any concerns or complaints about your involvement in the 
study, please contact the Manager of the Human Research Ethics 
Committee, University of Sydney on (02) 9351 4811. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Psychology 
The University of Sydney, N.S.W. 2006 
  
 
CONSENT FORM 
 
“The Motherhood Decision: Developing a Decision Aid for Women with MS” 
 
I, ……………………………………………………, have been told about this study and 
have been allowed the opportunity to ask questions about it. I understand what is 
involved in taking part and I agree to do so. 
 
Signed: ……………………………………………  Date:        /      / 
 Name: …………………………………………… 
 
Witness: …………………………………………  Date:      /      / 
Name: ……………………………………………   
I give permission for the researchers to contact my treating physician to confirm my MS-
type and medications prescribed for its management. 
 
Signed: ……………………………………………  Date:        /      / 
 Name: …………………………………………… 
 
Witness: ………………………………………….  Date:      /      / 
Name: ………………………………………   
Name of Physician: … … … … … … … … … … … 
Address: … … … … … … … … … … … … …  
… … … … … … … … … … … … … … … … 
… … … … … … … … … … … … … … … …  
Phone: … … … … … … … 
 
I would be happy for the researchers to contact me after the end of the study to find out 
whether or not I decided to start a family:   YES / NO 
 
  
 
 
 
 
 
APPENDIX B: 
RECRUITMENT MAIL-OUT 
 
Department of Psychology 
The University of Sydney, N.S.W. 2006 
 
 
Motherhood Choice: Developing a Decision Aid for Women with MS 
The University of Sydney, in conjunction with MS Society, is recruiting women into a 
study to evaluate a decision aid to help women with MS make decisions about whether 
to become a parent 
 
We have mailed all women, who have agreed to take part in research, and are between 
the ages of 20-40 to invite them to take part.  
 
Even if you would prefer not to take part in the study, we would be really interested to 
know which of these situations best describes your current situation with regard to your 
decision about motherhood. If you would be happy to provide this information (either 
anonymously or with your name), simply tick the statement below that best describes 
your current situation, answer the few questions below and return this sheet in the reply-
paid envelope.  
 
 I am currently unsure about whether I want to start a family but am considering 
these issues at the moment. 
 I am currently unsure about whether I want to start a family at some time in the 
future, but am not ready to think about that now. 
 I already have a child (or children), but am not sure whether I will have another 
child and am thinking about this at the moment. 
 I already have a child (or children), but am not sure whether I will have another 
child, but am not ready to think about that now. 
 I already have children and do not want to have any more. 
 I do not have children and have decided not to have any. 
 
Age:     __________________________________ 
How long have you had MS:  __________________________________ 
Type of MS (if known):  __________________________________ 
Age of any children:   __________________________________ 
         
If you are interested in participating in this study to evaluate a decision aid for the 
motherhood decision for women with MS, please complete your details below and we 
will contact you. 
 
Name:   __________________________________ 
Address:   __________________________________ 
   __________________________________ 
   __________________________________ 
Phone No:   __________________________________ 
Mobile:   __________________________________ 
Email (if available):  __________________________________ 
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APPENDIX D: QUESTIONNAIRE & FEEDBACK ON 
DECISION AID FROM WOMEN IN FOCUS 
GROUPS 
Acceptability Questionnaire 
 
My thoughts on the decision-aid for the motherhood choice after an MS diagnosis 
 
We would like to know what you think about the decision-aid you have just reviewed. 
 
1. Please rate each section, by circling ‘poor’, ‘fair’, ‘good’, or ‘excellent’ to show 
what you think about the way the information was presented on: 
 
Impact of MS Poor Fair Good Excellent 
 
Medication Poor Fair Good Excellent 
 
Types of MS Poor Fair Good Excellent 
 
Pregnancy Poor Fair Good Excellent 
 
Postnatal period Poor Fair Good Excellent 
 
Breastfeeding 
 
Poor Fair Good Excellent 
Disability Poor Fair Good Excellent 
 
Concerns of women with MS Poor Fair Good Excellent 
 
Stories about other women 
 
Poor Fair Good Excellent 
Values clarification 
 
Poor Fair Good Excellent 
Decision making steps 
 
Poor Fair Good Excellent 
 
2. The length of the booklet was (tick one) 
ß Too short 
ß Too long 
ß Just right 
 
3. The amount of information was (tick one) 
ß Too much information 
ß Too little information 
ß Just right 
 
4. I found the information 
ß Slanted towards having children 
ß Slanted towards not having children 
ß Balanced 
5. Would you have found this decision aid useful when you were making the 
motherhood choice? 
ß Yes 
ß No 
Comments: 
 
 
6. Did you find the values-clarification exercise made options: 
ß Easier to contemplate 
ß More difficult to contemplate 
Comments: 
 
 
7. Did the decision-making steps make your decision: 
ß Easier 
ß More difficult 
Comments: 
 
 
8. Do you think we included enough information to help a woman make this 
decision? 
ß Yes 
ß No 
Comments: 
 
 
9. What did you like about the decision aid and worksheet? 
 
 
 
 
 
10. What suggestions do you have to improve the decision aid or worksheet? 
 
 
 
Table 7.1 
Mean ratings of the way the information was presented in the decision aid 
Item Mean Descriptor 
Impact of MS 3.1 Good 
Medication 3.25 Good 
Types of MS 3.15 Good 
Pregnancy 3.1 Good 
Postnatal 3.2 Good 
Breastfeeding 3.3 Good 
Disability 3.1 Good 
Concerns 3.2 Good 
Values 2.6 Good 
Decision steps 2.7 Good 
Length 1.7 Just right 
Amount 2.25 Just right 
Slant 2.05 Balanced 
Useful 1 Yes 
Values 1.55 EasierÆ unchanged 
Decision steps 1.45 Easier Æ unchanged 
Enough information 1.25 Yes 
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APPENDIX F: 
MEASURES USED IN RANDOMISED 
CONTROLLED TRIAL 
ID # …………. 
 
Demographic Questionnaire 
 
 
1. Age:  
 
2. How old were you when you were diagnosed with MS? 
 
3. What type (course) of MS have you been diagnosed with? 
à Relapse-remitting 
à Secondary-progressive 
à Primary-progressive 
à Progressive-relapsing 
à Benign 
à Other ………………………………………. 
 
4. Please list any medication you are currently taking to manage your MS: 
 
 
 
5. Do you already have children? 
à Yes, 1 child 
à Yes, more than 1 child 
à No 
 
6. Before you were diagnosed with MS, did you want to have children? 
à Yes 
à No 
à Unsure 
 
7. Did your MS diagnosis complicate your previous decision of whether or not to 
have children? 
à Yes 
à No 
 
8. When was your last relapse/exacerbation? 
 
 
 
9. Please circle where you see yourself on the following continuum: 
 
-5 -4 -3 -2 -1 0 1 2 3 4 5 
Definitely will 
not have children 
now or in the future 
Unsure              Definitely will 
have children 
now or in the 
future 
 
KNOWLEDGE QUESTIONNAIRE 
 
1. The majority of studies on pregnancy in MS have been carried out on women with which 
course of MS: 
ß Benign MS  
ß Relapse-Remitting MS 
ß Secondary-Progressive MS 
ß Primary-Progressive MS 
ß Progressive-Relapsing MS 
 
2. The risk of passing on MS when one of the parents has it is: 
ß 20% 
ß 0.1% 
ß 50% 
ß 3-5% 
ß 10-12% 
 
3. When trying to become pregnant, how early should a woman stop taking their 
Immunotherapy medication? 
ß 1 month before trying to conceive 
ß 3 months before trying to conceive 
ß 2 weeks before trying to conceive 
ß Once pregnancy is confirmed 
ß After the first trimester 
 
4. Which childbirth aesthetic procedure is not advised for women with MS? 
ß Spinal anaesthesia 
ß General anaesthesia 
ß Epidural 
ß All of the above 
ß None. All are considered safe. 
 
5. Which of the following statements is true? 
ß Pregnancy accelerates a woman’s course of MS 
ß There is a higher risk of stillbirth in women with MS 
ß Pregnancy does not affect the course of MS 
ß MS symptoms remain unchanged during the pregnancy period 
ß There is a lower risk of stillbirth in women with MS 
 
 
6. Which are the most reliable predictors of relapse during the postpartum period? 
ß A higher number of previous pregnancies, increase disability at pregnancy onset 
& an increased relapse rate during pregnancy 
ß An earlier age at MS onset, lower number of previous pregnancies & an 
increased relapse rate during pregnancy 
ß Breastfeeding, a progressive-relapsing course of MS & a decreased relapse 
during pregnancy 
ß A progressive-relapsing course of MS, higher number of previous pregnancies & 
a later age at MS onset 
ß An increased relapse rate in the pre-pregnancy year, an increase relapse rate 
during pregnancy & increased disability at pregnancy onset 
 
7. Which of the following statements is true? 
ß Breastfeeding is not recommended for women with MS 
ß Relapse rates generally decrease during pregnancy 
ß Becoming pregnancy increases relapse rates in the long term 
ß MS can be passed on to a baby through breast milk 
ß Managing relapse rates with medication is vital during pregnancy 
 
8. Which of the following statements is not true? 
ß MS can result in sexual dysfunction 
ß There is an 80% risk of increased relapses in the postpartum period 
ß Fatigue is worse in the postpartum months 
ß MS medication can reduce the effectiveness of oral contraceptives 
ß Parenting may be impractical for some women with MS 
 
9. How might engaging in physical affection with your child be affected by your MS? 
ß Fatigue 
ß Sensory problems 
ß Motor problems 
ß A & C only 
ß All of the above 
 
10. Women with MS commonly express concern about not being able to perform tasks to the 
social standard expected of a mother. These worries can become worse when a mother 
perceives social doubt of her ability to parent her children, and can increase the risk of 
depression. What factor significantly mediates the negative effects of these concerns? 
ß Less obvious disability 
ß A longer period of time since diagnosis, thus there is a higher chance that the 
woman will have come to terms with her illness. 
ß Being on effective medication 
ß Social support 
ß Having a well behaved child 
Decisional Conflict 
 
My difficulty making this choice 
 
Please look at the following comments made by people when making decisions. 
 
Please show how strongly you agree or disagree with these statements by 
circling the number from 1 (strongly agree) to 5 (strongly disagree), which best 
shows how you feel about the choice you will be making. 
 
1. This decision is easy for me 
to make 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
2. I am sure what to do in this 
decision 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
3. It is clear what choice is best 
for me 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
4. I am aware of the options I 
have in this decision 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
5. I feel I know pros of each 
option 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
6. I feel I know cons of each 
option 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
7. I know how important the pros 
are to me in this decision 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
8. I know how important the 
cons are to me in this 
1 
Strongly 
2  
Agree 
3 
Neither 
4 
Disagree 
5 
Strongly 
decision Agree Agree 
Nor 
Disagree 
Disagree 
9. I know which is more 
important to me (the pros or 
the cons) 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
10. I am making this choice    
without any pressure from 
others 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
11. I have the right amount of 
support from others in making 
this choice 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
12. I have enough advice about 
the options 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
13. I feel I will make an informed 
choice 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
14. My decision will show what 
is important to me 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
15. I expect to stick with my 
decision (when I make it) 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
16. I think I will be satisfied with 
my decision (when I make it) 
1 
Strongly 
Agree 
2  
Agree 
3 
Neither 
Agree 
Nor 
Disagree 
 
4 
Disagree 
5 
Strongly 
Disagree 
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Decision Self-Efficacy 
 
My confidence in making an informed choice 
 
Below are listed some things involved in making an informed choice. Please 
show how confident you feel in doing these things by circling the number from 0 
(not at all confident) to 4 (very confident) for each item listed below. 
 
I feel confident that I can: 
 
1. Get the facts about the 
medication choices available to 
me 
 
Not at all 
confident
0 1 2 3 4 Very 
confident
2. Get the facts about the benefits 
of each choice 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
3. Get the facts about the risks and 
consequences of each choice 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
4. Understand the information 
enough to be able to make a 
choice 
Not at all 
confident
0 1 2 3 4 Very 
confident
5. Ask questions without feeling 
dumb 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
6. Express my concerns about each 
choice 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
7. Ask for advice Not at all 
confident
 
0 1 2 3 4 Very 
confident
8. Figure out the choice that best 
suits me 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
9. Handle unwanted pressure from 
others in making my choice 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
10. Let my partner/family know 
what is best for me 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
11. Delay my decision if I feel I 
need more time 
Not at all 
confident
 
0 1 2 3 4 Very 
confident
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CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CESD) 
Name:______________________  Date:____/_____/_____ 
                (day/month/year) 
 
CES-D      Instructions:  Below is a list of the ways you might have felt or behaved.  
Please tell me how often you have felt this way during the past week. 
 
Responses:  A. Rarely or none of the time (less than 1 day) 
   B. Some or a little of the time (1-2days) 
   C. Occasionally or a moderate amount of time (3-4 days) 
   D. Most or all of the time (5-7 days) 
     
 A B C D  
1. I was bothered by things that usually don’t bother me.  ڤ ڤ ڤ ڤ 
2. I did not feel like eating, my appetite was poor.  ڤ ڤ ڤ ڤ 
3. I felt that I could not shake off the blues even with the 
       help of my family or  friends.  ڤ ڤ ڤ ڤ        
4. I felt that I was just as good as other people.  ڤ ڤ ڤ ڤ 
5. I had trouble keeping my mind on what I was doing.  ڤ ڤ ڤ ڤ        
6. I felt depressed.  ڤ ڤ ڤ ڤ    
7. I felt that everything I did was an effort.  ڤ ڤ ڤ ڤ 
8. I felt hopeful about the future.  ڤ ڤ ڤ ڤ 
9. I thought my life had been a failure.  ڤ ڤ ڤ ڤ 
10. I felt fearful.  ڤ ڤ ڤ ڤ 
11. My sleep was restless.  ڤ ڤ ڤ ڤ 
12. I was happy.  ڤ ڤ ڤ ڤ 
13. I talked less than usual.  ڤ ڤ ڤ ڤ 
14. I felt lonely.  ڤ ڤ ڤ ڤ 
15. People were unfriendly.  ڤ ڤ ڤ ڤ 
16. I enjoyed life.  ڤ ڤ ڤ ڤ    
17. I had crying spells.  ڤ ڤ ڤ ڤ 
18. I felt sad.  ڤ ڤ ڤ ڤ 
19. I felt that people dislike me.  ڤ ڤ ڤ ڤ 
20. I could not “get going”. ڤ ڤ ڤ ڤ    
 
Radloff, L.S. (1977) 
STATE-TRAIT ANXIETY INVENTORY FOR ADULTS 
 
SELF-EVALUATION QUESTIONNAIRE - Part 1 
 
Please read each statement below and then place a cross over the 
appropriate number to the right of the statement to indicate how you 
feel right now, that is, at this very moment. There are no right or 
wrong answers. Do not spend too much time on any one statement 
but give the answer that seems to describe your feelings best. 
 
 
  Not at 
all 
Some-
what 
Moder-
ately so 
Very 
much 
so 
  1.   I feel calm 1 2 3 4 
  2.   I feel secure 1 2 3 4 
  3.   I am tense 1 2 3 4 
  4.   I feel strained 1 2 3 4 
  5.   I feel at ease 1 2 3 4 
  6.   I feel upset 1 2 3 4 
  7.   I am presently worrying 
over possible misfortunes 
1 2 3 4 
  8.   I feel satisfied 1 2 3 4 
  9.   I feel frightened 1 2 3 4 
10.   I feel comfortable 1 2 3 4 
11.   I feel self-confident 1 2 3 4 
12.   I feel nervous 1 2 3 4 
13.   I am jittery 1 2 3 4 
14.   I feel indecisive 1 2 3 4 
15.   I am relaxed 1 2 3 4 
16.   I feel content 1 2 3 4 
17.   I am worried 1 2 3 4 
18.   I feel confused 1 2 3 4 
19.   I feel steady 1 2 3 4 
20.   I feel pleasant 1 2 3 4 
 
Spielberger, C. D. (1983) 
 
  
 
 
 
ADDPENDIX G: 
STATISTICAL ANALYES FOR RANDOMISED 
CONTROLLED TRIAL 
Table 7.2 
T-test baseline differences pre-intervention 
 t Df Sig. 
Age -1.093 149 0.276 
Depression  -0.088 147 0.930 
Anxiety -0.194 147 0.846 
Self-Efficacy 1.809 149 0.072 
Decisional Conflict -1.684 148 0.094 
Knowledge 0.380 148 0.704 
Certainty 0.895 148 0.372 
MS Type -0.677 149 0.498 
Whether subjects 
wanted kids before 
their diagnosis 
 
-0.604 
 
149 
 
0.546 
Whether diagnosis 
complicated 
decision of children 
 
-1.998 
 
149 
 
0.046 
 
Table 7.3 
Correlations of outcome measures 
 Balance Depression Anxiety Self-
Efficacy
Decisional 
Conflict 
Knowledge Certainty 
Balance - -0.128 -0.062 0.069 -0.152 0.063 0.454** 
Depression  - 0.658** -0.299** 0.127 -0.245** -0.067 
Anxiety   - -0.283** 0.250** -0.256** -0.159 
Self-
Efficacy 
   - -0.278** 0.012 0.038 
Decisional 
Conflict 
    - -0.007 -0.352** 
Knowledge      - 0.103 
Certainty       - 
** Correlation is significant at the 0.01 level (2-tailed) 
* Correlation is significant at the 0.05 level (2-tailed) 
 
Table 7.4 
ANOVA Table 
Measure Source df Mean 
Square 
F sig Partial Eta 
Squared 
Certainty Time 
Group 
Time x group 
135 
135 
135 
10.135 
2.859 
3.310 
8.739 
0.493 
2.854 
0.004 
0.484 
0.047 
0.061 
0.004 
0.021 
Balance Time 
Group 
Time x group 
135 
135 
135 
2.496 
41.167 
0.228 
0.863 
2.513 
0.079 
0.355 
0.115 
0.779 
0.006 
0.018 
0.001 
Self-
Efficacy 
Time 
Group 
Time x group 
135 
135 
135 
295.580 
2.605 
995.818 
2.486 
0.006 
8.375 
0.117 
0.936 
0.002 
0.018 
0.001 
0.058 
Decisional 
Conflict 
Time 
Group 
Time x group 
133 
133 
133 
1.902 
0.692 
1.715 
11.997 
1.211 
10.820 
0.001 
0.273 
0.001 
0.083 
0.009 
0.075 
Knowledge Time 
Group 
Time x group 
133 
133 
133 
19.402 
35.884 
46.961 
8.215 
6.774 
19.883 
0.005 
0.010 
0.001 
0.058 
0.048 
0.130 
Depression Time 
Group 
Time x group 
133 
133 
133 
81.654 
0.566 
0.052 
1.744 
0.003 
0.001 
0.189 
0.954 
0.973 
0.013 
0.001 
0.001 
Anxiety Time 
Group 
Time x group 
133 
133 
133 
17.477 
4.049 
59.988 
0.291 
0019 
0.001 
0.590 
0.890 
0.991 
0.002 
0.001 
0.001 
 
Table 7.5 
Chi-square table of clinical significance 
Measure Chi-Square Df sig. 
Self-Efficacy 4.475 2 0.107 
Decisional Conflict 6.467 2 0.018 
Pre-intervention 
Knowledge 
0.123 2 0.940 
Post-intervention 
Knowledge 
11.147 1 0.001 
 
 Table 7.6 
Clinical significance cross-tabulation 
Measure Clinical significance Total 
 Worse Same Better  
Self-Efficacy 
Control 
DA Intervention 
 
4 
1 
 
53 
66 
 
4 
11 
 
61 
78 
Decisional Conflict 
Control 
DA Intervention 
 
4 
0 
 
52 
68 
 
4 
10 
 
60 
78 
  
Below 7/10 
 
7/10 or Above 
 
Total 
Pre-Intervention 
Knowledge 
Control 
DA Intervention 
 
 
61 
75 
 
 
6 
8 
 
 
67 
83 
Post-Intervention 
Knowledge 
Control 
DA Intervention 
 
 
48 
41 
 
 
12 
37 
 
 
60 
78 
  
 
 
 
 
 
APPENDIX H: 
STATISTICAL ANALYSES FOR FOLLOW-UP 
Table 7.7 
ANOVA table comparing those who completed the study with those who did not 
Variable Df Mean 
square 
F Sig 
Group            Between groups 
                         Within groups 
1 
192 
0.144 
0.250 
0.575 
 
0.449 
Age                Between groups 
                         Within groups 
1 
159 
5.012 
16.860 
0.297 0.586 
Time since     Between groups  
Diagnosis         Within groups 
1 
150 
33.080 
14.514 
2.279 0.133 
MS Type       Between groups 
                         Within groups 
1 
150 
1.898 
0.627 
3.025 0.084 
Whether they wanted kids 
before their diagnosis 
                      Between groups 
                         Within groups 
 
 
1 
150 
 
 
0.070 
0.283 
 
 
0.248 
 
 
0.619 
Whether diagnosis 
complicated their motherhood 
decision 
                      Between groups 
                        Within groups 
 
 
 
1 
149 
 
 
 
0.229 
0.210 
 
 
 
1.090 
 
 
 
0.298 
 
 
Table 7.8 
ANOVA table  
Measure Source Df Mean 
square 
F Sig. Partial Eta 
squared 
Certainty Time 
Group 
Time x group 
1 
1 
102 
21.604 
2.532 
2.844 
6.464 
1.041 
0.851 
0.013 
0.310 
0.358 
0.060 
0.010 
0.008 
Balance Time 
Group 
Time x group 
1 
1 
102 
43.270 
12.984 
0.091 
4.101 
1.483 
0.009 
0.045 
0.226 
0.926 
0.039 
0.014 
0.001 
       
       
 
  
 
 
APPENDIX I: 
PUBLISHED PAPERS 
 
